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CHAPTER I     
 
INTRODUCTION 
 
 Lymphedema is an accumulation of lymphatic fluid and proteins in the interstitial 
spaces (Rockson, 2001). Lymphedema may be either primary or secondary. Primary 
lymphedema is a rare, inherited condition in which lymph nodes and lymph vessels are 
abnormal or absent (National Cancer Institute [NCI], 2007a). Secondary lymphedema is 
usually the consequence of cancer treatment, of blocking the lymphatic pathways by 
tumors (Foldi, Foldi, Strobenreuther, & Kubik, 2006), trauma, large or circumferential 
wounds, or burns (Hettrick, Nof, Ward, & Echernach, 2004; Rockson & Rivera, 2008). 
Secondary lymphedema is the most common form of lymphedema in developed countries 
(Foldi et al., 2006). The most common cause of secondary lymphedema in the United 
States is cancer therapy (Dos, Gorska-Dos, & Szuba, 2005; Lymphoedema Framework, 
2006).  As a result of lymph node dissection, radiation, and chemotherapy, many cancer 
patients develop secondary lymphedema after their cancer treatment, such as those with 
breast, ovarian, melanoma, and head and neck cancer (Foldi et al., 2006; Ridner, 2008). 
Once an individual develops either primary or secondary lymphedema, they face 
burdensome life-long self-care and often experience physical, psychological, and social 
difficulties. For example, they may have to change their vocations, and family income 
may suffer (Lewis & Morgan, 2008; Radina & Armer, 2001). Their families or 
significant others may also be impacted by the changes lymphedema causes in the 
affected person (Lymphoedema Framework, 2006; Rockson & Rivera, 2008; Sneddon & 
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Lewis, 2007). Thus, lymphedema is a significant societal issue for patients, their families, 
and society.  
 
Statement of Problem 
 The problem of interest is secondary lymphedema related to head and neck cancer 
treatment. European literature provides evidence that head and neck cancer patients may 
have a higher risk and a higher prevalence of secondary lymphedema from surgery, 
radiotherapy, and chemoradiation therapy than other cancer patients (Micke et al., 2003). 
However, limited research studies exist regarding secondary lymphedema related to 
treatment of head and neck cancer patients, especially its symptoms, signs 
(measurement), affects on body functions, influences on quality of life, and possible risk 
factors. There is a need (1) to examine the significance of the problem of interest to 
society, healthcare, and science of nursing; (2) to determine the state of science; and (3) 
to conduct a research study that will further our knowledge and fill in gaps in the current 
literature (e.g., symptoms, functional status, and quality of life related to secondary 
lymphedema in head and neck cancer patients).  
 
Significance of the Issue and the Study 
 
Significance to Society 
Incidence of Head and Neck Cancer and Related Secondary Lymphedema  
 In the United States, although the overall incidence of head and neck cancer has 
slightly decreased in the past two decades, the incidence of tongue and tonsillar cancer 
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has increased, especially in young adults (Argiris, Karamouzis, Raben, & Ferris, 2008). It 
was estimated that 48,010 Americans developed head and neck cancer and 11,260 deaths 
from oral cavity, pharynx, and larynx cancer occurred in 2009 (American Cancer Society, 
[ACS], 2009). Early detection and multi-modality therapy have led to improvement in 
survival rates, leaving many head and neck cancer patients at risk for experiencing 
secondary complications from their cancer treatment (Bentzen et al., 2003; ONS 
Research Agenda, 2009-2013), such as secondary lymphedema. In the European 
literature, the prevalence of secondary lymphedema after head and neck cancer, whether 
with combined or single treatment, varies between 12% and 54% (Buntzel, Glatzel, 
Mucke, Micke, & Bruns, 2007; Dietz et al., 1998; Schiefke et al., 2009; Wolff et al., 
2009). The prevalence and the incidence of secondary lymphedema related to head and 
neck cancer treatment in the United States are unknown and unpublished at this time. The 
data from a observation study the PI conducted over 7 clinic days at the Vanderbilt-
Ingram Cancer Center, Tennessee, USA, show that approximately 25% (11/43) head and 
neck cancer patients greater than 3 months post-treatment have secondary external 
lymphedema. There are more than a half million head and neck cancer survivors in the 
United States (Head and Neck Cancer, 2008; Jemal et al., 2007; Oishi, 2007). If head and 
neck cancer patients in the United States experience lymphedema at rates similar to their 
European counterparts, 60,000 to 270,000 of them could have lymphedema. 
Risk Factors for Head and Neck Cancer and Related Secondary Lymphedema  
Behaviors common to many members of society appear to place individuals 
directly at risk for developing head and neck cancer and indirectly at risk for developing 
secondary lymphedema. Specifically, smoking and alcohol use are identified as 
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independent risk factors (Hashibe et al., 2007; Itano & Taoka, 2005; NCI, 2007b). 
Several studies report that the combined consumption of cigarette smoke and alcohol 
increases risk of head and neck cancer by over 30-fold (ACS, 2008). Although the 
prevalence of cigarette smoking among adults 18 and older has decreased over the last 30 
years, 20.8% of adults and 23% of high school students continue to smoke (ACS, 2008). 
In fact, smoking rates are higher in southern states than the rest of the nation, such as 
26% of Tennessee adults and 27% of Kentucky adults smoke compared to 20.8% 
nationally. The trend is also present among two states’ youth: 27.6% Tennessee high 
school students and 28% Kentucky high school students smoke compared to 23% 
nationally (ACS, 2008). 
Compared to quitting completely, some of these smokers switched to using 
smokeless tobacco, which they assume to be a risk-free alternative, but this does not 
reduce the risk of head and neck cancer (American Academic of Otolaryngology-Head 
and Neck Surgery [AAO-HNS], 2008). A sexually transmitted virus, the human 
papillomavirus (HPV), also places certain individuals at risk for developing head and 
neck cancer (Mouth Cancer Foundation [MCF], 2008; NCI, 2007b). Currently, 5-year 
survival rate for head and neck cancer is between 59.8% and 63.6% (NCI, 2007c). Head 
and neck cancer is curable if detected early (AAO-HNS, 2008; Werner & Davis, 2004). 
Significant societal changes in smoking and alcohol use or abuse and sexual behavioral 
may be needed to reduce the incidence of head and neck cancer in the United States. 
Risk factors for development of secondary lymphedema related to head and neck 
cancer are unclear as the exact mechanism for development of secondary lymphedema in 
head and neck cancer patients has not been clarified. This lack of knowledge makes it 
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difficult to develop risk reduction strategies or prevention regimens for these patients. 
Some pathophysiological processes related to cancer treatment may precipitate 
lymphedema. Head and neck cancer treatment (i.e., surgery, radiation, and/or 
chemotherapy) disrupts lymphatic structures (e.g., surgical lymphadenectomy and injury 
of lymphatic vessels), and leads to an increased accumulation of lymphatic fluid in 
interstitial space. The retention of lymphatic fluid activates inflammatory/immune 
responses and results in skin tissue fibrosis and adipose deposition (Tabibiazar et al., 
2006). Skin tissue fibrosis further aggravates lymphatic function. Thus, lymphatic 
damage renders the lymphatic system unable to transport normal amounts of fluid and 
protein from the normal capillary filtration, which is the primary reason that lymphedema 
occurs after cancer treatment (Foldi et al., 2006). Because of this pathophysiological 
process, head and neck cancer patients are at high risk for developing secondary 
lymphedema (Dennert & Horneber, 2007; Dos et al., 2005; Lymphoedema Framework, 
2006; Murphy, Gilbert, & Ridner, 2007a; Ridner, 2008).  
Cost to Patients and Society 
 Financial costs. Secondary lymphedema may result in added healthcare costs to 
patients, including treatment costs (such as rehabilitation treatment and compression 
bandages) and financial loss related to lymphedema influences on their ability to do their 
jobs. One cohort study demonstrated significantly higher costs among the women in the 
breast-cancer-related lymphedema group compared with the breast cancer group without 
lymphedema; and the estimated difference in the two-year medical costs ranged from 
$14,877-$23,167 based on insurance data (Shih et al., 2009). Currently, secondary 
lymphedema is most commonly associated with breast cancer treatment. Insurance 
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companies do not fully cover lymphedema treatment in breast cancer patients; therefore, 
these data may underestimate the cost of lymphedema in breast cancer patients. That is, 
the insurance reimbursement is still an issue for some breast cancer patients with 
secondary lymphedema. Lymphedema is a less well-known phenomenon in head and 
neck cancer, and therefore the reimbursement issues are likely greater. Some head and 
neck cancer patients pay for their lymphedema treatment and compression garment fees 
themselves.   
 Head and neck cancer patients need to be referred for lymphedema treatment and 
rehabilitation in order to relieve the symptoms and improve compromised body functions 
related to secondary lymphedema (Foldi et al., 2006).  In general, this therapy includes 
education of postural techniques, head/neck massage, head/neck exercise, and application 
of compression mask/garment/bandages on the head/neck (Foldi et al., 2006; 
Lymphoedema Framework, 2006). No actual data regarding the cost of head and neck 
lymphedema treatment are available in the literature. The data from one rehabilitation 
center located in Middle Tennessee, USA, show a reasonable estimate of the cost for 
initial treatment. The initial treatment includes the first evaluation fee, daily treatment fee 
(about 14 days), weekly treatment fee (about one to two months), and cost of material for 
treatment. Thus, the cost of the initial treatment for one head and neck cancer patient with 
secondary lymphedema is estimated from $ 7,676 to $ 9,284 (see Table 1) (A.M. Flores, 
personal communication, September 16, 2008).  
 This estimate does not include the custom garment fee. These garments vary in 
price. Over-the-counter and customized lymphedema garments range from approximately 
$50 to $300 (About Lymphedema Sleeves/Garments, 2008). Additionally, the cost of 
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materials for self-management for one head and neck cancer patient with secondary 
lymphedema after the initial treatment is approximately $220 per year (A.M. Flores, 
personal communication, September 16, 2008).   
 
Table 1  
An Estimate of the Cost for Initial Treatment for One Head and Neck Cancer Patient with 
Secondary Lymphedema 
      Initial Treatment                                         Cost ($) 
       1ST Evaluation                                                 350 
       Daily Treatment × 14 Days                          5,628 (402×14 Days) 
         Weekly Treatment × 1-2 Months                 1,608 (402×4, for 1 Month), 3216 (402×8, for 2 Months) 
         Cost of Materials for Treatment                        90 
       Total Cost for Initial Treatment                   7,676-9,284 
  
   
 In addition to the direct costs incurred from treatment, we could hypothesize that 
secondary lymphedema in head and neck cancer patients causes moderate or severe 
alterations in cervical range of motion, swallowing, and speaking functions. Such 
changes may affect work ability/efficiency for some individuals and family income could 
be reduced. One study estimated the number of days a patient’s usual daily activities 
were interrupted by either hospitalization or office visits and found a significant 
difference between the breast cancer patients with lymphedema and breast cancer patients 
without lymphedema (58.7 days vs. 46.5 days, p< .001) (Shih et al., 2009). Furthermore, 
some patients have to pay out of pocket for medications they take for their pain and 
muscle spasm related to moderate or severe head and neck lymphedema. Thus, the issues 
of potential loss of income and additional costs related to secondary lymphedema in head 
and neck cancer patients need to be examined. 
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 Other costs. The treatment of lymphedema not only costs patients money, but also 
takes up their time and energy, exacting a high psychological expense. Head and neck 
cancer patients with secondary lymphedema are often instructed to do self-massage daily 
until their lymphedema is controlled or relieved. They may also have to wear highly 
visible face and neck compression garments that cause them to avoid many social 
situations. Thus, they may also lose needed social support systems.  
Summary 
 Addressing secondary lymphedema related to head and neck cancer is important 
to society for several reasons. First, approximately 12%-54% of the head and neck cancer 
population after their cancer treatment may have the condition. Second, this may be a 
preventable/controllable health problem if risk factors are identified and made known to 
the general public, as has been done with cigarette smoking and lung cancer. Third, 
secondary lymphedema related to head and neck cancer creates financial and 
psychological burdens to both individuals and society. Therefore, research into secondary 
lymphedema related to head and neck cancer will provide society with evidence-based 
information to develop better strategies to reduce lymphedema occurrence, manage 
lymphedema, and decrease expenses related to this condition.  
 
Significance to Healthcare  
Continuum of Care Required 
  Patients with locally advanced head and neck cancer are treated with radical neck 
dissection, large area radiation therapy, and/or concurrent chemoradiation (CCR) (Vokes 
et al., 2000). These treatments often lead to a damaged lymphatic system and leave 
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individuals at risk for developing secondary lymphedema (Foldi et al., 2006; 
Lymphoedema Framework, 2006). Head and neck lymphedema not only alters the 
appearance of patients’ most visible body areas (Hammond, 2007; Zimmermann et al., 
2005), but also may cause functional impairment, such as speaking, breathing, and 
swallowing (Bruns et al., 2004; Micke et al., 2003). Severe lymphedema may be life-
threatening (Murphy et al., 2007a).  For instance, severe interstitial mucosal swelling of 
the supraglottic region may cause inspiratory stridor and dyspnea, and require 
tracheotomy (Micke et al., 2003). Depending upon the severity and location of the 
swelling, patients may require either outpatient treatment from a lymphedema therapist or 
hospital treatment from a skilled surgeon. 
Treatment Issues 
Secondary lymphedema is often treated by physical decongestive therapy, such as 
manual lymphatic drainage and wearing a compression garment (Piso et al., 2001). Such 
treatment should be provided by certified lymphedema therapists (National Lymphedema 
Network [NLN], 2005a). The therapists can be from a variety of healthcare professions; 
however, typically physical therapists and advanced practice nurses are eligible for 
reimbursement under Medicare guidelines (NLN, 2005b). Head and neck lymphedema 
treatment is likely to be more complex and difficult than breast cancer-related arm 
lymphedema based on the following reasons. First, head and neck lymphedema includes 
not only external but also internal lymphedema. External lymphedema is treated through 
compression devices and manual lymphatic drainage (Piso et al., 2001). Due to the 
contour and location of the head and neck lymphedema, a general compression bandage 
is not appropriate for all patients (Coopee, 2008). Many individuals may require 
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customized compression garments. Some patients find it difficult to tolerate compression 
garments on their face and neck. This is also risk for obstructing blood flow to the brain if 
the garments are too tight. Sometimes they could only wear the compression garments for 
two hours at a time as compared to breast cancer patients with arm lymphedema who can 
continue to wear compression sleeves over several hours. This intermittent use of the 
compression garment might affect the effectiveness of lymphedema treatment. Moreover, 
literature is lacking about how to manage internal lymphedema. It is also unknown if 
external lymphedema treatment (e.g., manual lymphatic drainage and compression 
garment) reduces internal lymphedema.  
In addition, some head and neck cancer patients with lymphedema, such as those 
with hypersensitive carotid sinus and cardiac arrhythmias (Foldi et al., 2006), are not 
eligible for physical decongestive therapy. If unable to undergo early physical 
decongestive therapy, head and neck cancer patients with secondary lymphedema are at 
risk for development of chronic lymphedema and even late fibrosis, such as skin 
stiffness, tightness, and limited neck range of motion, similar to breast cancer-related arm 
lymphedema (Davis et al., 2003). Once fibrosis develops, it is much more difficult to 
treat lymphedema. Secondary lymphedema, as a chronic process, may be refractory to 
therapy, and requires extensive management of co-morbid conditions such as impaired 
swallowing and voice alterations (Lymphoedema Framework, 2006). Therefore, 
secondary lymphedema, especially late-effect lymphedema (occurring 3 to 6 months after 
cancer treatment), remains a unique treatment challenge when caring for head and neck 
cancer patients. This challenge warrants future studies to address the issue of 
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lymphedema treatment and decrease patients’ physical and psychological symptom 
burden and functional loss. 
Access to Knowledgeable Professionals 
Although lymphedema is a progressive chronic condition and a lifelong side- 
effect of cancer and cancer therapy, it may be ameliorated by proper management by 
healthcare professionals (Lymphoedema Framework, 2006). Access to healthcare 
professionals with lymphatic system and diseases knowledge is critical to manage 
lymphedema. These trained professionals can be aware of the potential risk factors for 
lymphedema, identify the patients at risk of lymphedema, assess patients’ lymphedema 
symptoms, document the risks of lymphedema to alert other healthcare professionals, and 
refer lymphedema patients for appropriate and timely treatment (Lymphoedema 
Framework, 2006). However, studies have found that breast cancer-related lymphedema 
patients had a limited access to trained professionals. For example, some breast cancer 
patients do not have access to qualified professionals who understand lymphedema 
(Hadamitzky & Pabst, 2008; Ridner, 2005). Lack of understanding of lymphedema by 
healthcare professionals and poor information provided to patients affect health-related 
quality of life in breast cancer patients with lymphedema (Coward, 1999; Morgan, 
Franks, & Moffatt, 2005). Breast cancer-related lymphedema is a much more well-known 
phenomenon than head and neck lymphedema; thus access to educated healthcare 
professionals may be even a larger issue in head and neck cancer patients with 
lymphedema.  
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Summary  
 Managing head and neck lymphedema is a significant issue to healthcare. First, 
management of secondary lymphedema in head and neck cancer patients requires a 
multidisciplinary approach and runs the full continuum of services from outpatient clinics 
to intensive care units. Second, early detection and appropriate treatment may minimize 
certain patients’ secondary lymphedema and associated symptoms; if disregarded, 
lymphedema can progress and become difficult to handle (Lymphoedema Framework, 
2006; Marrs, 2007). Third, access to well-informed healthcare professionals may be a key 
aspect to address various challenges in treating and managing head and neck 
lymphedema. Consistent with one of the goals of Healthy People 2010 (i.e., improving 
the quality of life and years of healthy living) (Healthy People 2010, 2000), healthcare 
professionals need to play an active role in lymphedema treatment and management. 
Well-informed healthcare professionals have knowledge of the patients at risk of 
lymphedema, relieve their lymphedema associated symptom burden and functional loss, 
and improve their quality of life.  
 
Significance to Science of Nursing 
 Nurses have collaborated with other healthcare professionals to provide patients 
with the best care since the time of Florence Nightingale (Miracle, 2008). They have 
participated in directly collecting patients’ symptoms and complaints, evaluating their 
signs and compromised functions, and communicating with and educating patients how 
to maintain a good quality of life. As the American Nurses Association (ANA) states, 
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“The nurse determines the appropriate delegation of tasks consistent with the nurse’s 
obligation to provide optimum patient care” (Code of Ethics for Nurses, 2008). 
 The National Lymphedema Network (NLN) indicates nurses are key members for 
helping patients manage lymphedema (NLN, 2005b). As a member of the 
interdisciplinary healthcare team, a large amount of information has shown that nurses 
have taken a critical and unique role in managing breast cancer-related secondary 
lymphedema in clinical settings. Nurses engage in not only assessing secondary 
lymphedema, but also in educating and guiding breast cancer patients on how to conduct 
self-monitoring, detect early secondary lymphedema, take appropriate actions to reduce 
risk factors, and implement management strategies to alleviate the impact of lymphedema 
(Lymphoedema Framework, 2006; Marrs, 2007). 
 Besides caring for patients with lymphedema in clinical settings, nurses have 
engaged in numerous significant studies in the role of principal investigator. Nurses have 
conducted a great number of studies related to secondary complications of cancer 
treatment, such as breast cancer-related lymphedema. Their studies have covered a 
variety of domains, such as symptoms and symptoms cluster, measurements, quality of 
life, and possible risk factors (Armer & Whitman, 2002; Coward, 1999; Ridner, 2005). 
The studies have contributed to clearly describing secondary lymphedema related to 
breast cancer treatment.  
 Although studies have examined breast cancer-related lymphedema, little concern 
has been given to exploring other cancer-related lymphedema, such as head and neck 
lymphedema. Critical information about how nurses should educate and manage head and 
neck cancer patients at risk for or with secondary lymphedema is absent at this time. 
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Many gaps related to head and neck lymphedema need to be addressed, such as 
symptoms and symptom burden, functional loss, compromised quality of life, possible 
risk factors, incidence, and prevalence. These unanswered domains affect nurses and 
other healthcare professionals who care for head and neck cancer patients with secondary 
lymphedema, that is, clinical care related to head and neck lymphedema is still an under-
addressed issue in current clinical settings. Nurses and other healthcare professionals are 
poorly equipped with knowledge and skills about caring for secondary lymphedema 
related to head and neck cancer treatment. Therefore, research into head and neck 
lymphedema is not only critical to nursing research but also significant to clinical nursing 
care. 
 Based on their pathophysiological similarity, we assume that a fair amount of 
overlap exists between breast cancer-related lymphedema and head/neck cancer-related 
lymphedema. It may be possible to select and adapt the instruments used in breast cancer-
related lymphedema to gauge the experiences of head and neck cancer patients with 
lymphedema. Nevertheless, head and neck lymphedema is most likely to have different 
symptom burden, functional status, quality of life, and possible risk factors from breast 
cancer-related lymphedema due to their different anatomical sites, treatment regimens, 
and different cancer types. There is a need to examine and identify the similarities and 
differences between breast cancer-related lymphedema and head and neck cancer-related 
lymphedema. The Oncology Nursing Society (ONS) stated the research priorities of 
oncology nursing during 2009-2013, including research that considered cancer treatment-
related side-effects and late-effects (ONS Research Agenda, 2009-2013). Thus, 
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examining secondary lymphedema related to head and neck cancer treatment is consistent 
with the research priorities of the ONS. 
Summary  
Identified gaps in the literature regarding head and neck cancer patients with 
secondary lymphedema include lack of evidence on risk factors, deficiency in its 
symptoms and symptom burden, and poor understanding of its influence on functional 
loss and quality of life. These gaps not only influence how nurses and other healthcare 
professionals detect and assess head and neck cancer patients at risk of secondary 
lymphedema but also affect how they educate and guide patients about how to manage, 
alleviate, and control symptom burden related to secondary lymphedema.  
 The study focused on the gaps in the literature and clinical care. It will also 
provide nurses and other healthcare professionals with empirical evidence to manage 
secondary lymphedema after cancer treatment. The study will advance the development 
of oncology nursing, increase the knowledge base of secondary lymphedema for 
oncology nursing and other healthcare providers’ practice, and help oncology nurses 
recognize and better care for patients with secondary lymphedema after head and neck 
cancer treatment. Quality oncology nursing care may make a remarkable impact on 
patient outcomes. Armed with an essential knowledge of secondary lymphedema, nurses 
and other healthcare providers can be hands-on in patient education, monitor for the 
occurrence of secondary lymphedema, and become involved in reducing the extent of 
secondary lymphedema and its negative impact on patients, healthcare, and society 
(Marrs, 2007).   
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Purpose of the Study 
 The purpose of the study was to examine the association among the severity of 
lymphedema, symptoms, functional status, and quality of life in head and neck cancer 
patients. This study also examined the possible factors contributing to the presence of 
secondary lymphedema in head and neck cancer patients. The specific aims for the study 
included:  
1. To determine the prevalence of secondary lymphedema in head and neck cancer 
patients (Aim 1); 
2. To examine the associations between the severity of lymphedema in head and neck 
cancer patients and (a) symptoms; (b) functional status; and (c) quality of life (Aim 2);       
3. To examine the possible risk factors contributing to the presence of secondary 
lymphedema after head and neck cancer treatment by comparing patients with and 
without secondary lymphedema (e.g., demographic information and head and neck 
cancer disease information) (Aim 3).    
         
Research Questions 
1. What is the prevalence of external lymphedema, internal lymphedema and combined 
lymphedema in head and neck cancer patients? 
2. What are the associations between severity of lymphedema in head and neck cancer 
patients and (a) symptoms; (b) functional status; and (c) quality of life? 
3. What are the possible factors contributing to the presence of secondary lymphedema in 
head and neck cancer patients? 
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CHAPTER II   
   
LITERATURE REVIEW 
 
 The section reviews the problem of interest from the perspectives of its origin and 
history, theoretical frameworks, and methodological approaches used in the literature. 
Based on the extensive literature review, syntheses of knowledge and research 
hypotheses are proposed. The key concepts and the theoretical framework for the study 
are developed. 
 
History of the Problem of Interest 
 There are differing historical perspectives about the origin and history of 
lymphedema. The Merriam-Webster Dictionary (2007) cites the etymology of 
lymphedema as being from New Latin in 1889 and its definition as edema due to faulty 
lymphatic drainage. However, Foldi (2001) states that an Italian anatomist, Paulo 
Mascagni, in the 18th century, had a correct, deep insight into the etiology of 
lymphedema. Mascagni thought that edema was caused by the obstruction of the lymph 
nodes, and dilatation of the lymph vessels led to the valves being inadequate to prevent 
the retrograde flow of lymph (Foldi, 2001). Nevertheless, his views were dismissed at the 
turn of the 19th century and replaced by a vague concept that lymphedema was related to 
a defect of the nervous system (Foldi, 2001). It was not until the third decade of the 20th 
century that the accurate physiological view of lymphedema was reinstated. Drinker and 
Field, in 1933, correctly explicated and demonstrated that blockage of the lymphatic 
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system of an experimental animal led to lymphedema. They established that lymphedema 
occurs as a consequence of the inability of the lymph system to drain away the lymphatic 
fluid overload (Foldi, 2001; Mayerson, 1969). 
 Cancer therapy, as the most common cause of secondary lymphedema in 
developed countries, might be related to the origin of secondary lymphedema. Although 
there is lack of clear documentation of the historical origin of secondary lymphedema in 
head and neck cancer patients, it probably arises with emergence of treatment modalities 
of head and neck cancer (e.g., surgery and/or radiation therapy). The history of surgical 
treatment of cervical lymph node metastases began in the 19th century (Ferlito et al., 
2007). According to Werner and Davis (2004), in 1880 a Swiss surgeon, Theodor 
Kocher, advocated lymph node dissection of the submandibular triangle when performing 
a transcervical approach for the surgical removal of tongue cancer. An American 
Surgeon, George Washington Crile, performed radical neck dissection in 1906, which 
was a decisive progress in the treatment of metastatically affected cervical lymph nodes 
(Werner & Davis, 2004). Because of lymphatic system damage, radical neck dissection 
may be associated with development of secondary lymphedema.   
 Although the first radical neck dissection surgery was done in 1906 and the first 
article available regarding secondary lymphedema was published in 1936 (Reichent & 
Mathes, 1936), the exact mechanism leading to secondary lymphedema has not been 
totally clarified, and there is a lack of a curative therapy available for secondary 
lymphedema (Lymphoedema Framework, 2006). Research has centered on mechanisms 
that result in secondary lymphedema. However, some aspects of secondary lymphedema 
in head and neck cancer patients have been neglected. The incidence and prevalence of 
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secondary lymphedema related to head and neck cancer treatment, its effect on symptom 
burden, functional loss, risk factors, and effects on quality of life have been unexplored. 
Therefore, secondary lymphedema related to head and neck cancer treatment is an 
understudied disease.  
 
Theoretical Literature Review 
 Throughout the literature review, four conceptual models/theories have been used 
to understand secondary lymphedema after cancer treatment: the Biomedical Conceptual 
Approach (Uzarski et al., 2008), the Structural Model of Post-breast Cancer 
Lymphedema (Armer, Radina, Porock, & Culbertson, 2003), the Biopsychosocial 
Conceptual Approach (Jager, Doller, & Roth, 2006; Passik, Newman, Brennan, & 
Tunkel, 1995), and the Theory of Unpleasant Symptoms (Lenz, Pugh, Milligan, Gift, & 
Suppe, 1997). The following table (see Table 2) summarizes the characteristics, 
strengths, and limitations of the four conceptual models/theories.  
 Through the above analysis, it is clear that the Biomedical Conceptual Approach 
has contributed significantly to further our understanding of the pathological reasons that 
lymphedema occurs and supports various treatment modalities. Specifically, this model 
has supported lymphedema as a progressive pathologic condition of the lymphatic system 
with an abnormal accumulation of protein-rich fluid in the interstitial space (Cheville et 
al., 2003). The lymph accumulation in the interstitial space triggers subsequent 
inflammation, adipose tissue hypertrophy, and fibrosis. The swelling and later induration 
of the affected area can lead to disfigurement, as well as decreased function and mobility 
(Cheville et al., 2003; Warren, Brorson, Borud, & Slavin, 2007).  
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Table 2  
Conceptual Models & Theories Related to the Problem of Interest 
Conceptual 
Models/ 
Theories 
Characteristics  Strengths Limitations 
Biomedical 
Conceptual 
Model 
The Biomedical 
Conceptual Model 
focuses on the 
physical process of 
lymphedema (e.g., 
physiology and 
pathology).  
The Biomedical Conceptual 
Model has been extremely 
useful throughout history by 
establishing the pathological 
reasons that lymphedema 
occurs, and exploring and 
developing different 
treatment regimens. 
It does not take into 
account the role of 
psychological or social 
factors, individual 
differences, and individual 
subjectivity. It does not 
explain how lymphedema 
affects patients’ daily life, 
mood, other distressful 
symptoms, and ignores the 
nursing perspectives. 
Structural 
Model of Post-
breast Cancer 
Lymphedema  
The Structural Model 
proposes the inter-
relationships among 
lymphedema, coping 
effectiveness, 
psychosocial 
adjustment, functional 
health status, and 
protective 
mechanisms.  
The Structural Model views 
lymphedema from a global 
perspective through depicting 
multiple dimensions of post-
breast cancer lymphedema. 
The goal of the model is to 
identify variables that 
influence lymphedema 
progression, its impact  on 
psychosocial outcomes, and 
functional health status, 
which then can enlighten 
subsequent interventions.  
The Structural Model was 
used in one study, which 
did not examine the entire 
relationships among its 
multiple variables (Armer 
et al., 2003). The model 
needs to be further tested 
on the propositions among 
its variables through more 
studies. Another issue is 
that the model does not 
cover the component of 
possible risk factors of 
leading to lymphedema 
occurrence. 
 Biopsycho- 
social 
Conceptual 
Model 
The Biopsychosocial 
Conceptual Model 
implies management 
of disease processes 
(e.g., secondary 
lymphedema) requires 
the healthcare team to 
address biological, 
psychological, and 
social influences upon 
a patient's functioning.  
The Biopsychosocial 
Conceptual Model can be a 
general framework to 
understand the problem of 
interest and has potential to 
guide this study. That is to 
say, secondary lymphedema 
may not only affect head and 
neck cancer patients’ 
physical functions but also 
influence their psychosocial 
well-being and quality of life. 
The Biopsychosocial 
Conceptual Model is broad 
and does not provide a 
straightforward, testable 
model to explain the 
interactions or causal 
influences among different 
variables. 
Theory of 
Unpleasant 
Symptoms 
(Lenz et al., 
1997) 
 
The Theory of 
Unpleasant Symptoms 
has three major 
components: the 
symptoms, the 
influencing factors, 
and the consequences 
of the symptom 
experience.  
In comparison to the other 
models, the Theory of 
Unpleasant Symptoms views 
lymphedema from a more 
clearly defined perspective, 
including the symptoms, the 
influencing factors, and 
performance. The theory has 
been applied to various 
symptom studies.   
The Theory of Unpleasant 
Symptoms lacks the 
component of symptom 
management strategies.  
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 However, it does not focus on individual subjective experience (i.e., symptoms) 
related to the impact of secondary lymphedema, does not consider individual differences, 
and ignores the influence of the psychological and social factors. In some circumstances, 
the Biomedical Conceptual Approach limits understanding and examination of secondary 
lymphedema related issues from a holistic viewpoint (Wade & Halligan, 2004). For 
example, the Biomedical Conceptual Approach comprehends and manages secondary 
lymphedema from the viewpoint of physical factors and neglects the roles of both 
situational factors (e.g., working environment) and psychological factors (e.g., distressed 
mood) related to experiencing secondary lymphedema associated symptoms.   
 The Structural Model of Post-breast Cancer Lymphedema is a conceptual 
framework proposed in 2002 (Armer & Whitman, 2002). The model was developed 
based on the biobehavioral model of cancer, stress, and disease progression (as cited in 
Armer et al., 2003) and the model of stress and coping (as cited in Armer et al., 2003). 
The model has three components: the indicators of lymphedema, protective mechanisms, 
and post-breast cancer psychosocial adjustment and functional health status. 
Lymphedema is conceptualized as consisting of both objective (e.g., circumferential 
measurement) and subjective (e.g., coping effectiveness) indicators. The objective 
assessment reflects the physical aspects of lymphedema, and subjective assessments 
describe the cognitive /emotional components related to coping with lymphedema. The 
protective mechanism includes problem solving and social support, which could reduce 
the progression of lymphedema. Finally, both of the protective mechanisms and the 
indicators of lymphedema are related to post-breast cancer psychosocial adjustment and 
functional health status (Armer et al., 2003). Only one study examined one of the three 
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components, that is, objective and subjective indicators of lymphedema (Armer et al., 
2003). The other components and entire propositions of the model have not been tested or 
clarified at the current time, which affects its usefulness in research.  
 The Biopsychosocial Conceptual Approach developed by George Engel may be 
appropriate to understand the problem of interest, as it indicates that management of 
disease processes (such as lymphedema) requires addressing biological, psychological, 
and social domains. This model emphasizes the interaction relationship among the three 
domains and their contribution to the comprehension and management of a disease. 
However, it is broad and lacks explanatory components by not explaining the domains of 
symptoms and interactions among different variables. Thus, it could not guide a study as 
a concrete theoretical framework. 
 The Theory of Unpleasant Symptoms was published in 1995 (Lenz, Suppe, Gift, 
Pugh, & Milligan, 1995) and updated in 1997 (Lenz et al., 1997). It has three major 
components: the symptoms, the influencing factors, and the consequences of the 
symptom experience. Symptoms are the central focus of the theory. Each symptom can 
be measured separately or in combination with other symptoms (e.g., symptoms cluster). 
Each symptom has four common domains: intensity (strength or severity), timing 
(duration and frequency of occurrence), level of distress perceived (degree of discomfort 
or bothersomeness), and quality. These domains are related to one another. In the Theory 
of Unpleasant Symptoms, three categories of influencing factors are assumed to affect 
symptoms: physiologic factors, psychologic factors, and situational factors. Physiologic 
factors include normal physiological conditions and abnormal pathological status. The 
psychologic factors contain an individual's emotional reaction to a disease/injury and 
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associated knowledge about the symptoms and their possible meaning. Situational factors 
cover a person’s social and physical environment that may affect the individual's 
experiencing, interpreting, and reporting of symptoms. The three categories of 
influencing factors may interact with one another and commonly influence the symptom 
experience. Performance is the final component of the Theory of Unpleasant Symptoms 
and includes the "outcome" or "effect" of the symptom experience. It contains functional 
health status and quality of life related to the symptoms. The performance outcomes can 
have an impact on the symptom experience and the influencing factors.  
            Based on its components of a symptom, the Theory of Unpleasant Symptoms has 
been applied to development of a symptom scale, which measures intensity, distress, 
timing, and quality of the symptom (Fadol et al., 2008). In clinical settings, the Theory of 
Unpleasant Symptoms can be used to explore symptom relief strategies based on its three 
major components (Liehr, 2005). Additionally, the Theory of Unpleasant Symptoms has 
been extensively applied to various symptom experience and management studies. It has 
been used in not only breast cancer patients with lymphedema (Ridner, 2005) but also in 
other disease populations with related symptom management, such as postoperative pain 
(Huth & Broome, 2007), postpartum fatigue (Rychnovsky, 2007), hemodialysis fatigue 
(Liu, 2006), and COPD symptoms (Reishtein, 2005). Compared with other models, the 
Theory of Unpleasant Symptoms may be the best conceptual framework to guide my 
research study.  
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Methodological Literature Review 
In the United States, injury to or removal of regional lymph nodes during surgery 
or radiation therapy, infection, or tumor growth are the most common conditions that lead 
to secondary lymphedema (Holcomb, 2006). As healthcare professionals have become 
aware of the problem of secondary lymphedema related to cancer treatment, more 
concern has been raised about the availability of methodological approaches that are 
reliable and valid for use in research and clinical practice with breast cancer patients. 
Little attention has been given to methodological approaches specific to head and neck 
cancer patients with secondary lymphedema (Foldi et al., 2006; Lymphoedema 
Framework, 2006).    
 The purposes of this section include (1) critically analyzing methodological 
approaches that have been used to study secondary lymphedema related to head and neck 
cancer treatment; (2) discussing advantages and disadvantages of methods used in the 
literature (e.g., efficiency of method, cost of method); and (3) identifying strengths and 
weaknesses of the methodological approaches used to investigate the problem of interest 
(e.g., small sample size, poor reliability/validity of instruments). Through this empirical 
literature review, the state of the science in relation to secondary lymphedema in head 
and neck cancer patients will be integrated and the implications for improving 
methodological approaches in this area will be proposed. Moreover, the integration of 
methodological approaches was used as the knowledge base underpinning the 
methodological design and measurement instruments chosen for the research study.  
 Additionally, to be consistent with the key concepts of the  research study, the 
methodological approaches to secondary lymphedema related to head and neck cancer 
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treatment are reviewed and analyzed from five domains: (1) signs and measurement; (2) 
symptoms and effects on body functions; (3) psychological effects, (4) effects on quality 
of life; and (5) possible risk factors. 
 
Methodological Approaches Used in the Literature 
Signs and Measurement  
 The National Cancer Institute updated and published the Common Terminology 
Criteria for Adverse Events v3.0 (CTCAE v3.0) in 2006 (CTCAE v3.0, 2006). CTACE 
v3.0 is commonly used as a comprehensive, multimodality grading system for reporting 
the acute and late-effects of cancer treatment (Trotti et al., 2003). It provides a grading 
(severity) scale to describe head and neck lymphedema (see Table 3). It also provides a 
scale to evaluate lymphedema-related fibrosis (see Table 4). 
 
Table 3  
NCI Lymphedema of the Head and Neck Grading Scale 
 
 
 
 
Grade                                      Descriptions                                                 
Grade 1          Localized to dependent areas, no disability or functional impairment 
Grade 2          Localized facial or neck edema with functional impairment 
  Grade 3          Generalized facial or neck edema with functional impairment (e.g., difficulty in turning   
                         neck or opening mouth compared to baseline) 
Grade 4          Severe with ulceration or cerebral edema; tracheotomy or feeding tube indicated 
Grade 5          Death 
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Table 4  
NCI Lymphedema-related Fibrosis Scale 
 
Grade                                      Descriptions                                                 
Grade 1           Minimal to moderate redundant soft tissue, unresponsive to elevation or compression,  
                        with moderately firm texture or spongy feel 
Grade 2           Marked increase in density and firmness, with or without tethering 
Grade 3           Very marked density and firmness with tethering affecting ≥ 40% of the edematous area  
 
 
The American Cancer Society also provides a system for grading non-limb 
lymphedema from Stage 0 to Stage III based on the CTACE v3.0 of the National Cancer 
Institute (ACS, 2006; Cheville et al., 2003). The four stages provide a basic method of 
evaluating lymphedema of the head and neck (see Table 5). 
 The above two scales are interchangeable, e.g., Grade 1=Stage 0, Grade 2=Stage 
I, and Grade 3=Stage II. Although the two scales have been developed to assess cancer 
treatment-associated lymphedema, they do not differentiate the measurement of external 
and internal lymphedema, nor do they contain distance and volume measurement of 
lymphedema other than edema or swelling that may be related to head and neck cancer 
patients with lymphedema. In addition, the two scales do not have any skin changes 
related to secondary lymphedema nor whether elevation (or posture changes) reduces the 
swelling.  
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Table 5 
ACS Lymphedema of the Head and Neck Staging Criteria 
 Stage                                      Descriptions                                                 
Stage 0           Swelling is local and does not affect regular functioning 
Stage I            Swelling is local and affects regular functioning 
  Stage II          General swelling in the face or neck affects regular functioning (e.g., it may make  
                         it more difficult for a person to turn his or her head or open and close her mouth) 
Stage III         Swelling is severe and may accompany ulcers on the skin or brain swelling; the  
                       ability to eat is severely affected 
  
  
 Throughout the literature review, no other criteria are available specifically for 
grading secondary lymphedema after head and neck cancer treatment. Some criteria focus 
on general lymphedema from pathophysiological domains, e.g., the Clinical 
Classification of Lymphedema (International Society of Lymphology) (Twycross, Jenns, 
& Todd, 2000) (see Table 6) and the Stages of Lymphedema (Foldi, Foldi, & Kubik, 
2003) (see Table 7). The Stages of Lymphedema was developed by Foldi and his 
colleagues (2003). Although the authors did not state the reliability and validity of the 
scale, they developed the Stages of Lymphedema based on their experience treating over 
100,000 patients suffering from lymphedema. There are three major components in the 
scale: pathology, signs and symptoms, and diagnosis. Thus, the scale illustrates the entire 
picture for general secondary lymphedema. Although these criteria are not specific for 
head and neck lymphedema, they can be used to comprehend the possible pathological 
process and clinical changes, and help diagnose secondary lymphedema after head and 
neck cancer treatment. 
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Table 6  
Clinical Classification of Lymphedema  
Grade                                      Descriptions                                                 
Grade 1       No or minimal fibrosis, i.e., oedema pits on pressure and reduced with limb elevation 
  Grade 2       Substantial fibrosis clinically, i.e., oedema does not pit and does not reduce with limb elevation 
Grade 3       Grade 2 plus elephantine (trophic) changes 
 
 
Table 7  
Stages of Lymphedema  
  Stage             Pathology      Signs and Symptoms      Diagnosis 
    0  
Latency 
 
    I 
Reversible 
 
 
    II 
Spontaneously  
Irreversible 
 
    III 
Elephantiasis 
Focal fibrosclerotic 
tissue alterations 
 
High protein edema; 
focal fibrosclerotic tissue 
alterations 
 
Extensive fibrosclerosis, 
proliferation of adipose 
tissue 
 
Extensive fibrosclerosis, 
proliferation of adipose 
tissue 
None  
 
 
Pitting edema; elevation reduces the 
swelling; possibly “pain of 
congestion” 
 
Brawny, hard swelling that does not 
recede with elevation 
 
 
Like Stage II; invalidism 
Functional isotope 
lymphograpy 
 
Basic diagnostic 
procedures 
 
 
 
Basic diagnostic 
procedures 
 
 
 
Basic diagnostic 
procedures 
 
 
Although there are several criteria available to grade the degree of secondary 
lymphedema, none of them are evidence-based standards for grading secondary 
lymphedema in head and neck cancer population in the current literature review. 
Therefore, it is essential to systematically investigate pathophysiological processes and 
clinical changes of secondary lymphedema related to head and neck cancer, and further 
develop evidence-based staging criteria of secondary lymphedema for head and neck 
cancer population in future research. 
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In addition, certain head and neck cancer patients may develop secondary 
lymphedema externally (e.g., face and submental area) (Hammond, 2007; Zimmermann 
et al., 2005) and internally (e.g., laryngx, pharyngx, and oral cavity) (Bruns et al., 2004; 
Micke et al., 2003). Thus, the signs and measurement of head and neck cancer patients 
with secondary lymphedema may include external lymphedema and internal 
lymphedema. 
 External lymphedema. Current distance and volume lymphedema measurement 
systems do not allow for more detailed evaluation of swelling that occurs in head and 
neck cancer treatment (ACS, 2006; Cheville et al., 2003). This has given rise to an almost 
complete lack of information on lymphedema incidence after the treatment of head and 
neck cancer (Cheville et al., 2003). A review of the literature reveals that the following 
studies explore quantitative measurement for external lymphedema of the head and neck 
by using a measuring tape.  
 One study (Zimmermann et al., 2005) employed a self-designed measurement 
standard to grade 20 head and neck cancer patients’ external lymphedema by using a 
measuring tape. The authors chose four anatomical sites (including tragus, nostrils, corner 
of the mouth, and tip of the chin) to measure and compare the treatment effects of sodium 
selenite on postoperative lymphedema. The authors stated that the circumferential 
distance from the tragus to the tip of the chin best represents the lymphedema. In order to 
ensure the validity of the lymphedema measurement, they considered the influence of 
facial size. That is to say, the absolute distance between tragus and tip of the chin was 
subtracted from the circumferential measurement in each case. Although the authors 
mentioned the same PI completed all measurements and used the measuring tape in a 
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straight line to ensure reproducibility, they did not clearly report intra-rater reliability and 
if the measurement tool was used in other studies.  
 In another study (Piso et al., 2001), a clinical evaluation of lymphedema was 
performed to grade 11 head and neck cancer patients’ external lymphedema by distance 
measurements. The authors measured the distances among seven well-defined anatomic 
marks (including tragus, mental protuberance, mouth angle, mandibular angle, nasal 
wing, internal eye corner, and external eye corner). Meanwhile, they also used 
sonographic assessment of soft-tissue width at the face and neck. They found that 
although tape measurement seemed to best gauge the degree of lymphedema, 
sonographic assessment was necessary especially in patients with severe swelling and 
difficultly detecting the well-defined anatomic marks. Their study indicated good validity 
of the measurement methods using both types of measurements, but the authors did not 
clearly describe the reliability of the measurement tool in the article (i.e., intra-rater or 
inter-rater) or whether the measurement method was employed in other research studies. 
Piso, Eckardt, Liebermann, and Gehrke (2002) found that sonographic soft tissue width at 
defined sites of the head and neck was highly reproducible in 21 healthy adults without 
marking the measurement sites. They suggested that sonographic soft tissue width could 
be used to measure and quantify the effectiveness of manual lymphatic drainage for head 
and neck lymphedema by monitoring the course of the skin-to-bone distance. Their study 
reflected a good reliability and validity for assessing lymphedema. 
 In addition, a scoring system modified after Foldi and Foldi et al., Micke et al., 
and Miller et al. was used to measure external lymphedema in two studies (Bruns et al., 
2004; Micke et al., 2003). In their study, they indicated content validity based on the 
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experts’ review but did not report reliability of the scoring system (i.e., neither intra-rater 
nor inter-rater reliability). Throughout the literature review, volume-based or distance-
based technologies measuring external lymphedema of the head and neck have been 
explored in some studies, but they have not been validated as an evidence-based 
measurement method to guide clinical assessment due to the small sample sizes of the 
studies and limited psychometrically validated information of the instruments. Future 
work is needed to establish validity and reliability regarding volume-based or distance-
based measurement of head and neck lymphedema.  
 Internal lymphedema. It has been recognized that edema may involve 
mucosal/soft tissue structures visible only on endoscopic examination. The following 
studies explored internal lymphedema in head and neck cancer patients. Patterson et al. 
(2007) thought available instruments lack sensitivity to record internal edema that occurs 
after radiotherapy in specific laryngo-pharyngeal structures. They conducted an 
exploratory study to develop a rating scale to measure edema in the larynx and pharynx 
for irradiated head and neck cancer patients. Eleven structures (e.g., posterior pharyngeal 
wall and epiglottis) and two spaces (i.e., valleculare and pyriform sinus) were identified 
as the areas sensitive to the development of edema. They viewed 25 
nasendolaryngoscopic images using the scale. The interrater reliability for scoring the 
edema rating scale was noted by the investigator as moderate (weighted kappa, 0.54). The 
intra-rater reliability was very good (weighted kappa=0.84). The edema rating scale can 
be scored with very good test-retest reproducibility and moderate levels of agreement 
between clinicians. Based on the experts’ suggestions, the scale was developed with a 
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good content validity. The authors suggested that modifications to the method were 
needed to increase inter-rater reliability of the rating scale.  
 In two other studies (Bruns et al., 2004; Micke et al., 2003), interstitial 
endolaryngeal edema was graded using a scoring system modified after the late-effects of 
normal tissue and somatic objective management analytic (LENT-SOMA) system. In one 
study, the late radiation morbidity scoring scheme of Toxicity Criteria of the Radiation 
Therapy Oncology Group (RTOG)/the European Organization for Research and 
Treatment for Cancer (EORTC) was used to diagnose the grade of laryngeal lymphedema 
(Rudat et al., 1999). The LENT-SOMA and RTOG/EORTC scoring systems were 
developed based on the experts’ views, and both had content validity but lacked reported 
reliability data.  
 Although some studies have researched and developed some instruments for 
measuring external and internal lymphedema, these instruments’ psychometric 
characteristics need to be further examined. Due to limited quantitative measurement 
components, the applications of these instruments are restricted which affects accurate 
collection of patients’ data and examination of the overall incidence of lymphedema in 
head and neck cancer patients. Thus, investigators need to be involved in exploring and 
addressing lymphedema measurement issues through developing validated and reliable 
rating scales.  
Symptoms and Effects on Body Functions 
 Head and neck cancer-related lymphedema studies. Six studies (Bruns et al., 
2004; Eisbruch et al., 2004; Machtay et al., 2004; Micke et al., 2003; Piso et al., 2001; 
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Rudat et al., 1999) discussed lymphedema-induced symptoms and function loss in head 
and neck cancer patients; two studies reported co-existing fibrosis (see Table 8). 
 
Table 8  
 
Symptom and Functional Impairment Studies 
 
  Study    Description  Cancer 
Treatment 
Modality 
Follow-up 
Period  
Symptom/Functional 
Status Assessment 
Methods/Instruments 
Results      
(Symptoms/ 
Functional 
Impairments) 
Piso et 
al. 2001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bruns et 
al. 2004 
 
 
 
 
 
 
 
 
Micke et 
al. 2003 
 
 
 
 
To evaluate  
manual lymphatic 
drainage and 
compression 
garments  for 
postoperative 
head-neck 
lymphedema after 
curative surgery 
for orofacial 
tumors (N=11) 
 
 
 
 
 
 
To investigate the 
impact of selenium 
in the treatment of 
lymphedema of the 
head and neck 
region after cancer 
treatment (N=36) 
 
 
 
To investigate the 
influence of 
selenium in the 
treatment of 
lymphedema of the 
head and 
 Surgery alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Radiation 
alone or  in 
combination 
with surgery  
 
 
 
 
 
 
Radiation 
alone or by 
irradiation 
after surgery 
 
 
Up to 
postoperative 
   30 days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The median 
interval was 4 
months after 
the end of 
head and neck 
cancer 
treatment 
(range: 2-12 
months) 
 
The median 
interval was 4 
months after 
the end of 
cancer 
treatment 
Self-reported intensity of 
tension/pain caused by the 
swelling (visual analog 
scale of 0–10).  
Self-reported disability 
with swallowing and 
speaking (score, 0–6 
points). Impaired 
swallowing and speaking 
were quantified as follows: 
0=no difficulties; 
1=minimal difficulties; 
2=moderate difficulties; 
and 3= severe difficulties. 
 
 
 
A scoring system modified 
after the LENT-SOMA 
criteria for endolaryngeal 
lymphedema (i.e., 
subjective parameters 
assessing breathing from 
Grade 0 to Grade 4) 
 
 
 
A scoring system modified 
after the LENT-SOMA 
criteria (i.e., subjective 
domain evaluating 
breathing from Grade 0 to 
Grade 4) 
Feeling of tension in 
the face and/or neck, 
pain in the 
submandibular region;  
Impaired swallowing 
and speaking   
 
 
 
 
 
 
 
 
 
 
 
Interstitial 
endolaryngeal 
lymphedema 
associated with stridor 
and dyspnea symptoms 
 
 
 
 
 
Laryngeal lymphedema 
associated with stridor 
and dyspnea  
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Rudat et 
al. 1999 
 
 
 
 
 
 
 
 
 
Machtay 
et al. 
2004 
 
 
 
 
 
 
 
 
 
 
 
 
Eisbruch 
et al. 
2004 
 neck region after 
cancer treatment 
(N=36) 
 
 
To detect the 
associations 
between acute and 
late radiation 
effects, tumour 
control and in vitro 
radiosensitivity  
of primary normal 
tissue fibroblasts 
(N=68) 
 
To determine the 
feasibility, 
toxicity, and 
preliminary 
efficacy of a 
regimen of 
postoperative 
reirradiation, 
chemotherapy and 
the radioprotector 
amifostine after 
salvage head-and-
neck surgery 
(N=16) 
 
To identify the 
anatomic 
structures whose 
damage or 
malfunction cause 
late dysphagia and 
aspiration after 
intensive 
chemotherapy and 
radiotherapy (RT) 
for head-and-neck 
cancer (N=26) 
 
 
 
 
 
Simultaneous 
concomitant 
boost 
radiochemo-
therapy with  
carboplatin 
 
 
 
 
 
Multi-
modality 
cancer 
treatment  
 
 
 
 
 
 
 
 
 
 
 
Chemotherapy 
and 
radiotherapy 
(range: 2-12 
months) 
 
 
 
The median 
follow-up 
was 21 
months 
(range: 2.5-81 
months) 
 
 
 
 
 
The median 
follow-up 
was 35 
months 
(range:12–52 
months) 
 
 
 
 
 
 
 
 
 
The early (1–
3 months) and 
late  
(6–12 
months) after 
cancer 
therapy 
completion 
 
 
 
 
 
The author stated that a 
tracheotomy had to be 
performed in five of 68 
patients (7%) because of 
the  
radiation-induced chronic 
larynx lymphedema.  
 
 
 
 
The Radiation Therapy 
Oncology Group/European 
Organization for Research 
and Treatment of Cancer 
late effects criteria 
(RTOG/EORTC) (i.e., 
subjective domain 
evaluating 
pharynx/dysphagia)  
 
 
 
 
 
 
Evaluation of swallowing 
with 
videofluoroscopy and 
direct endoscopy 
 
 
 
 
 
Impaired breathing 
function 
 
 
 
 
 
 
 
 
 
Co-existing fibrosis 
with swallowing 
and voice dysfunction 
 
 
 
 
 
 
 
 
 
 
 
 
Co-existing fibrosis 
with impaired 
aspiration and 
swallowing; Stiffness 
of laryngeal and 
epiglottic walls due to 
lymphedema and 
fibrosis; Mucosal and 
submucosal fibrosis at 
base of tongue or at its 
attachment to 
pharyngeal 
musculature 
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 Bruns and colleagues (2004) investigated the impact of selenium in the treatment 
of lymphedema of the head and neck region. Their results suggested a short positive 
effect of sodium selenite on secondary head and neck lymphedema caused by 
radiotherapy alone or in combination with surgery. They recruited 36 head and neck 
cancer patients with persistent, extensive, or progressive lymphedema of the head and 
neck region, including 20 patients with interstitial endolaryngeal lymphedema and 16 
patients with other lymphedemas of the head and neck area. They determined their 
subjects actually had lymphedema through the following modified clinical grading 
systems: (1) interstitial endolaryngeal lymphedema was clinically graded using a score 
adopted from the LENT-SOMA system (as cited in Bruns et al., 2004); (2) the extent of 
other lymphedemas of the head and neck area was graded using the modified scoring 
systems of Foldi and Foldi et al. and of Millere et al. (as cited in Bruns et al., 2004). In 
their study, they reported that 20 head and neck cancer patients with interstitial 
endolaryngeal lymphedema had stridor and dyspnea symptoms. 
 Micke and colleagues (2003) also evaluated the impact of selenium in the 
treatment of lymphedema after radiotherapy. Their results suggested that sodium selenite 
had a positive on secondary-developing lymphedema caused by radiation therapy alone 
or by irradiation after surgery. They determined their subjects actually had lymphedema 
of the head and neck area using the scoring system modified after Foldi and Foldi et al. 
and Micke et al., and Miller et al. (as cited in Micke et al., 2003). Interstitial 
endolaryngeal edema was graded using a scoring system modified after the LENT-
SOMA criteria (as cited in Micke et al., 2003). Indeed, they used several grading systems 
that might be similar to Bruns’ (2004). In their study, they found that 20 patients had 
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subjective breathing difficulty symptoms related to interstitial endolaryngeal 
lymphedema. 
 A study aimed at the detection of associations between acute and late radiation 
effects in head and neck cancer patients found that 29 of 68 (43%) head and neck cancer 
patients developed chronic laryngeal lymphedema within 12 months of radiation therapy 
and that it impeded their breathing function (Rudat et al., 1999). The authors stated that 
laryngeal lymphedema was caused by an impaired lymphatic system due to radiation 
therapy. In their study, laryngoscopy and CT were employed to examine laryngeal 
lymphedema and the late radiation morbidity scoring scheme of Toxicity Criteria of the 
RTOG/EORTC was used to diagnose the grade of lymphedema.  
 Thus, there are the several common characteristics across the head and neck 
cancer-related lymphedema studies. (1) Lymphedema was identified after surgery alone, 
radiotherapy alone, or combined surgery and radiation. (2) The studies examined 
treatment-associated early and late-effect lymphedema, that is, time spans from less than 
30 days to within 12 months after cancer treatment. (3) The studies found head and neck 
cancer-associated lymphedema caused patients to have unpleasant symptoms (i.e., 
tension, pain, stridor, dyspnea, and sensory deprivation) and functional impairments (i.e., 
swallowing, speaking, and breathing).    
 Fibrosis and lymphedema. If a patient has injury to vital anatomy in the head and 
neck, fibrosis can often coexistent with local or regional lymphedema, which may also 
contribute to soft-tissue induration and functional consequences (O’Sullivan & Levin, 
2003). Two studies (Eisbruch et al., 2004; Machtay et al., 2004) identified that 
lymphedema coexists with fibrosis in head and neck cancer patients. The exact 
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mechanism or relationship between lymphedema and tissue fibrosis has not been 
clarified, but lymphedema patients often develop tissue fibrosis over time (Foldi et al., 
2006). The fibrosis might cause head and neck cancer patients with secondary 
lymphedema to have specific symptoms, such as tightness, stiffness, and limited neck 
range of motion. For example, stiffness of laryngeal walls caused by lymphedema and 
fibrosis has been reported to negatively affect both phonation and swallowing (Eisbruch 
et al., 2004). However, other possible symptoms (e.g., tightness and problems driving) 
related to fibrosis in head and neck cancer patients with secondary lymphedema have not 
been examined or reported in the current literature. 
Experts’ viewpoints. Based on experts’ knowledge and clinical experience, the 
following review articles explicate the possible symptoms that may be experienced by 
head and neck cancer patients with secondary lymphedema. Hammond (2007) stated that 
symptoms of head and neck lymphedema not only include external swelling or puffing 
around the head, face, or neck, but might also include many invisible symptoms patients 
also experience, such as trouble swallowing and pain when moving the neck and head 
into certain positions. Murphy et al. (2007a) noted that lymphedema can impair 
breathing, eating, swallowing and speech, and that the swelling alters the appearance of a 
patient. Matorin (1994) noted that oral cavity and laryngeal involvement lymphedema 
could produce dyspnea and feeding difficulties.    
 Based on the literature review, the relationship between fibrosis and lymphedema, 
and experts’ viewpoints, secondary lymphedema may be associated with numerous 
symptom issues and functional impairment. However, limited research studies are 
available that address symptom burden and functional loss related to secondary 
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lymphedema in head and neck cancer patients. It is unknown whether secondary 
lymphedema in head and neck cancer is associated with functional impairment, such as 
hearing, mouth range of motion, and neck range of motion. If external or internal 
lymphedema (swelling or fibrosis) affects the anatomical structures of outer or middle 
ear, it is unclear whether patients develop conductive hearing impairment. If internal 
lymphedema (swelling or fibrosis) influences patients’ inner ear or hearing nerve, it is 
unknown whether patients have sensorineural hearing impairment. Similarly, if 
lymphedema (swelling or fibrosis) affects trigeminal nerve or masticatory muscles, 
patients might have trismus. Lymphedema (swelling or fibrosis) might compromise skin, 
muscles, or nerves in the neck and shoulder area, thus patients might have decreased neck 
range of motion and abnormal signs (such as tenderness and postural abnormalities). 
Nonetheless, all these postulations need to be clarified. Therefore, there is a need to 
systematically explore and examine symptoms, symptom burden, and functional 
difficulties in head and neck cancer patients with secondary lymphedema.  
 Breast cancer-related lymphedema studies. Although limited studies examined 
symptoms and functional difficulties related to secondary lymphedema in head and neck 
cancer patients, research conducted with breast cancer patients provides insight into how 
lymphedema can result in physical and psychological symptoms and symptom burden. In 
a cross-sectional, mixed-methods design that included 64 breast cancer survivors with 
lymphedema and 64 breast cancer survivors without lymphedema, Ridner (2005) found 
that breast cancer survivors with lymphedema reported a symptom cluster that included 
alteration in limb sensation, loss of confidence in body, decreased physical activity, 
fatigue, and psychological distress. In a cross-sectional descriptive study (Armer & 
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Whitman, 2002), symptoms experienced most commonly among breast cancer survivors 
(n=102) with lymphedema were swelling (63%), heaviness (60%), tenderness (45%), and 
numbness (38%). Other symptoms associated with post-breast cancer lymphedema 
included fatigue, pain and other sensation changes, and limitations in arm range of 
motion. 
 Furthermore, Kosir et al. (2001) stated that sensation changes (such as numbness, 
aching, and tingling) may be the earliest indicator of increasing interstitial pressure 
changes associated with lymphedema in breast cancer patients, even before observable 
changes or measurable volume changes. Armer et al. (2003) found that the onset of 
lymphedema was predicted by three symptoms: "heaviness in past year," "swelling now," 
and "numbness in past year." Their findings suggested that changes in sensations may be 
indicators of early lymphedema and need to be assessed carefully at each follow-up visit 
and over time. At this time, no specific tests are available to diagnose lymphedema; 
typically, clinicians rely on patients’ presentation and history to make a diagnosis. 
Lymphedema usually is not detectable clinically until the interstitial volume is about 30% 
above normal (Holcomb, 2006); that is, patients with lymphedema often feel symptoms 
before clinical manifestations are detected. Therefore, it is important to assess patients’ 
symptoms early.  
Psychological Effects 
 Psychological effects refer to cognitive and emotional responses. Psychological 
distress is a broad term that encompasses various psychological responses, such as 
depression and anxiety (NCI, 2008a; Ridner, 2004; Stein, Syrjala, & Andrykowski, 
2008). Depression and anxiety are the two global indicators of emotional status often 
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measured in cancer survivors (Deimling, Bowman, Sterns, Wagner, & Kahana, 2006). 
Besides depression and anxiety, other psychological phenomena reported in cancer 
survivors include mood disturbance (NCI, 2008b), adjustment disorders (i.e., a depressed 
or anxious mood or a mixture of both) (Casey et al., 2006), post-traumatic stress disorder 
(PTSD) (Kangas, Henry, & Bryant, 2002; Kangas, Henry, & Bryant, 2005), and body 
image (Cash & Pruzinsky, 2002; Hopwood, Fletcher, Lee, & Ghazal, 2001; Hormes et 
al., 2008). The following table lists the common instruments used to assess psychological 
effects in cancer patients in the reviewed literature (see Table 9).  
 
Table 9  
Common Instruments Used to Measure Psychological Effects in Cancer Survivors 
Psychological Effects                                         Instruments                                        
Distress                                Distress Thermometer, Brief Symptom Inventory 
Anxiety                                Hospital Anxiety and Depression Scale (HADS), Beck Anxiety Inventory 
Depressive Symptoms         HADS, Center for Epidemiological Studies-Depression Scale (CES-D) 
Mood Disturbance               Profile of Mood States (POMS), POMS-SF 
Adjustment Disorder           Schedule Clinical Assessment in Neuropsychiatry 
PTSD                                   PTSD Checklist Civilian Version, Structured Clinical Interview for DSM-IV 
Body Image                         Body Image Survey, Body Image Scale  
  
  
 Two relatively early studies reported that head and neck cancer survivors appear 
to be particularly vulnerable to depression or they may experience depressive symptoms 
(Derogatis et al., 1983; Morton, Davis, Baker, Baker, & Stell, 1984). In addition, research 
has demonstrated some positive psychological impacts reported in cancer survivors, such 
as opportunity for personal growth and increasing social connectivity (Coreil, Wilke, & 
Pintado, 2004; Kinney, Rodgers, Nash, & Bray, 2003).  
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 Throughout the literature review, none of the studies report and assess 
psychological effects of secondary lymphedema in head and neck cancer patients. 
Nevertheless, head and neck lymphedema influences patients’ most visible areas of their 
body (e.g., face and neck). Patients with head and neck lymphedema may have to wear 
highly visible face and neck compression garments that may cause them to avoid many 
social situations. Thus, the extent to which they experience body image issues needs to be 
examined. Moreover, the experts suggest that secondary lymphedema may affect head 
and neck cancer patients’ psychological distress level (Murphy et al., 2007a) and they 
may experience a substantial degree of psychological morbidity (Dennert & Horneber, 
2007). Furthermore, the studies conducted with breast cancer patients provide 
information regarding psychological effects of secondary lymphedema. For instance, 
breast cancer patients with lymphedema experience psychological distress and loss of 
confidence in their body (Ridner, 2005). In addition to a negative body image (Morgan et 
al., 2005), they feel shock, fear, annoyance, frustration, less sexually attractive, and view 
lymphedema as a constant reminder of cancer (Carter, 1997). They often experience a 
negative emotional state (Jung & Cho, 2006) and are more likely to develop anxiety and 
depression than the general population (Morgan et al., 2005).  
Quality of Life Effects  
 Quality of life in head and neck cancer patients is a major concern throughout the 
treatment and survival trajectory, thus numerous studies have focused on treatment-
related quality of life. However, recent quality of life studies suggest that the type of head 
and neck cancer treatment alone may not be the major contributing factor to poorer 
quality of life, and the symptoms and secondary complications may impact on quality of 
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life (Donatelli-Lassig et al., 2008; El-Deiry, Futran, McDowell, Weymuller, & Yueh, 
2009; Langendijk et al., 2008). Throughout the literature review, only two studies, each 
of which having a similar small sample size, (Bruns et al., 2004; Micke et al., 2003) are 
available in relation to secondary lymphedema affecting head and neck cancer patients’ 
quality of life. Bruns and colleagues (2004) explored the impact of selenium in the 
treatment of lymphedema of the head and neck region after radiotherapy alone or in 
combination with surgery. In their study, they also evaluated head and neck cancer 
patients’ overall quality of life related to secondary lymphedema. They used a single item 
visual analogue scale (VAS) to assess 36 head and neck cancer patients’ quality of life.  
 Micke et al. (2003) investigated the impact of selenium in the treatment of 
lymphedema after radiotherapy. In their study, they also assessed 36 head and neck 
cancer patients’ overall quality of life related to secondary lymphedema using a VAS. 
They stated that the VAS is a validated tool for estimation of the patients’ general health 
condition by the physician or the patient himself or herself. The investigators did not 
report detailed information about the quality of life assessment scale, such as the 
development process of the tool or if it was used in other studies.  
 In general, secondary lymphedema is viewed as a side-effect of cancer treatment. 
From this perspective, the instruments that assess head and neck cancer treatment-
specific quality of life might be used as the tools to evaluate secondary lymphedema-
related quality of life. Upon reviewing the literature, there are many measurement 
instruments available to assess treatment-specific quality of life in head and neck cancer 
patients. The following table lists the instruments for assessing head and neck treatment-
specific quality of life (see Table 10), including Functional Assessment of Cancer 
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Therapy Scale-Head & Neck (FACT-H&N) (D’Antonio, Zimmerman, Cella, & Long, 
1996), the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire- Head and Neck (EORTC H&N 35) (Bjordal et al., 1999), the University 
of Michigan Head and Neck Quality-of-life Questionnaire (HNQOL) (Terrell et al., 
1997), Head and Neck Cancer Inventory (HNCI) (Funk, Karnell, Christensen, Moran, & 
Ricks, 2003),  and the University of Washington Quality-of-life Instrument (UWQOL) 
(Hassan, & Weymuller, 1993). Although different instruments measure quality of life 
from different domains, there are overlaps among them. In terms of the measurement 
domains and the number of items in the instruments, comparing studies in the literature 
revealed that FACT-H&N and EORTC H&N35 are more frequently used instruments in 
the literature to measure treatment-related quality of life in head and neck cancer patients 
at this time (Murphy, Ridner, Wells, & Dietrich, 2007b; Pusic et al., 2007).    
 
Table 10  
Common Quality of Life Instruments for Head and Neck Cancer 
Instruments                 Descriptions                                    Validity                                Reliability                                       
FACT-H&N               39-item, five major domains             Convergent validity        Cronbach’s alpha: .59-.79           
EORTC H&N 35       35-item, seven major domains          Convergent validity         Cronbach’s alpha > .70                     
HNQOL                     20-item, four major domains             Construct validity            Cronbach’s alpha: .79-.93           
HNCI                         30-item, five domains                        Convergent validity         Cronbach’s alpha: .87-.94           
UWQOL                    12 domains                                         Convergent validity         Cronbach’s alpha: .74-.83                 
  
  
 Overall, there are few instruments that address quality of life related to 
lymphedema. For example, breast cancer related lymphedema is the most commonly 
studied type of secondary lymphedema, but only two quality of life instruments exist. 
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The Upper Limb Lymphedema-27 (ULL-27) was developed to measure breast cancer 
patients’ quality of life related to secondary lymphedema (Launois, Mègnigbêto, Pocquet, 
& Alliot, 2002). The reliability and validity has been examined in two studies (Launois et 
al., 2002; Ridner, 2005). The Freiburg Life Quality Assessment Lymphedema 
questionnaire (FLQA-l) was a novel quality of life questionnaire developed specifically 
for use in lymphedema based on the previously validated FLQA vein questionnaire 
(Augustin, Bross, Foldi, Vanscheidt, & Zschocke, 2005). The FLQA-l is a disease-
specific quality of life questionnaire for patients with lymphedema. The validity and 
reliability of the FLQA-l was examined in only one study (Augustin et al., 2005). No 
instruments are available in the current literature to measure secondary lymphedema-
related quality of life after head and neck cancer treatment.  
Possible Risk Factors 
 Head and neck cancer-associated lymphedema studies. The following studies 
reported that possible risk factors contribute to occurrence of secondary lymphedema in 
head and neck area. In a cross-sectional study, Warren and Slavin (2007) reported on 11 
patients with scar lymphedema from a history of trauma or prior reconstructive, 
excisional, or esthetic surgical procedures. The development of swelling around a scar 
has been attributed to lymphatic channels damaged by traumatic laceration or surgical 
incision, thus causing lymphatic dysfunction and trapping lymphatic fluid within a 
curvilinear scar. Sanguineti et al. (2007) examined the correlation between laryngeal 
edema and dosimetric parameters through a retrospective study design in 66 head and 
neck cancer patients. They found that the risk of laryngeal edema was strictly correlated 
with various dosimetric parameters. To minimize the risk of edema, the mean laryngeal 
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radiation dose should be kept as low as possible. They stated edema of the larynx was 
attributed to the inflammatory process during irradiation along with disruption of 
lymphatic channels resulting in a common complication of head-and-neck radiotherapy. 
Lymphedema results from an imbalance in capillary filtration and lymph drainage 
(Lymphoedema Framework, 2006), which leads to collection of fluid and protein in the 
extravascular and interstitial spaces of the affected head and neck region. For head and 
neck cancer patients with lymphedema, it seems that lymph node dissection, radiation 
therapy, and surgery may be the main contributing and pathological risk factors 
(Lymphoedema Framework, 2006). However, other possible risk factors have not been 
examined and reported at this time (Lymphoedema Framework, 2006). For example, 
factors damaging head and neck cancer patients’ lymph vessel function and leading to 
lymphatic pathological status might include tumor characteristics, hypertension, and 
diabetes. Likewise, other behavioral and situational factors related to secondary 
lymphedema in head and neck cancer patients have not been examined, including how 
head and neck cancer patients’ smoking and alcohol drinking behaviors might influence 
patients’ lymph drainage functions via compromised lymph nodes and lymph vessels. For 
another example, head and neck cancer patients’ area of residence (rural vs. urban) might 
influence patients’ access to healthcare resources related to the lymphedema treatment 
and management.  
Breast cancer-associated lymphedema studies. Although limited literature is 
available on possible risk factors related to occurrence of secondary lymphedema in head 
and neck cancer patients, many studies have examined the possible risk factors for 
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secondary lymphedema in breast cancer patients. These risk factors may also apply to 
head and neck cancer patients with lymphedema, as the pathophysiology is similar. 
The studies reviewed mainly focused on examining physiological and situational 
risk factors related to the occurrence of secondary lymphedema in breast cancer patients. 
The studies conducted in the United States found the following physiological factors 
associated with an increased risk of developing secondary lymphedema in breast cancer 
patients.  
In a prospective study (McLaughlin et al., 2008), 936 breast cancer patients, 
including 600 women undergoing sentinel lymph node biopsy alone and 336 women 
undergoing sentinel lymph nodes biopsy and axillary lymph node dissection, were 
followed up five years after surgery. They found higher body mass index (BMI), and 
infection or injury were significant risk factors for developing lymphedema. Sentinel 
lymph node biopsy alone significantly lowered the patients’ lymphedema odds. In 
another prospective study (Meeske et al., 2008), 494 breast cancer patients were followed 
up 50 months after diagnosis. Arm lymphedema was statistically associated with younger 
age at diagnosis, positive history of hypertension, obesity (or BMI >30), and having 
surgery where 10 or more lymph nodes were excised. The risk of arm lymphedema did 
not differ significantly for African American and Caucasian women. The two other 
prospective studies (Geller, Vacek, O’Brien, & Secker-Walker, 2003; Paskett, Naughton, 
McCoy, Case, & Abbott, 2007) found receiving chemotherapy related to increasing risk 
of developing secondary lymphedema in breast cancer patients.  
Several retrospective studies with larger sample sizes also contribute to 
exploration of the possible risk factors related to the occurrence of secondary 
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lymphedema in breast cancer patients. A retrospective study analyzed 727 breast cancer 
patients and reported nodal irradiation was the only significant risk factor for arm 
lymphedema in patients receiving breast conservative therapy for early-stage breast 
cancer (Powell, Taghian, Kachnic, Coen, & Assaad, 2003). Another retrospective study 
systematically examined the association of nonradiation and radiation variables with 
lymphedema (Hinrichs et al., 2004). They examined by the chart review method 105 
patients who received postmastectomy radiation (PMRT) and found 27% developed 
lymphedema after PMRT. Total dose, posterior axillary boost, and overlapping radiation 
fields were significantly related with lymphedema. One case-control study identified 
TNM stage, number of dissected nodes, number of positive nodes, tumor size, infection, 
allergy, diabetes mellitus, hypertension, hypothyroidism, chronic obstructive pulmonary 
disease, and BMI as risk factors of breast cancer-related lymphedema (Soran et al., 
2006).  
The studies conducted in other countries also found similar risk factors to those 
found in the United States. One prospective study conducted in the UK discovered 
hospital skin puncture, mastectomy, and BMI > 26 to increase risk of developing 
lymphedema (Clark, Sitzia, & Harlow, 2005). In one prospective study conducted in 
Australia (Hayes, Janda, Cornish, Battistutta, & Newman, 2008), 33% of the patients 
were diagnosed as having lymphedema from six to 18 months after surgery. In their 
study, older age, more extensive surgery or axillary node dissection, and experiencing 
one or more treatment-related complications or symptoms (e.g., poor range, numbness, 
weakness) were associated with increased odds of lymphedema. Another prospective 
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study conducted in Australia found that the number of positive nodes was significant to 
patient-reported lymphedema (Graham, 2002). 
The three prospective studies separately completed in Italy, Korea, and India also 
reported similar findings about the risk factors related to developing secondary 
lymphedema in breast cancer patients (Deo et al., 2004; Herd-Smith, Russo, Muraca, 
Turco, & Cardona, 2001; Park, Lee, & Chung, 2008). They also identified higher stage of 
the disease, a pathologic T2 classification, and presence of co-morbid conditions 
contributing to occurrence of breast cancer lymphedema. Research found that a 
combination of axillary dissection and axillary radiation should be avoided whenever 
feasible to avoid lymphedema (Deo et al., 2004). 
Additionally, the studies reported some situational factors related to a risk of 
secondary lymphedema occurring in breast cancer patients. The situational factors 
include aspects of the social and physical environment that may affect the person’s 
experience and reporting of symptoms (Lenz et al., 1997). Situational factors may include 
individual’s vocation, lifestyle behaviors (such as diet and exercise), and area of 
residence. These studies found that the situational factors related to occurrence of arm 
lymphedema include working outside the home (Geller et al., 2003), occupation/hobby 
(hand use) (Soran et al., 2006), air travel, exposure to extreme temperature (cold/heat), 
strenuous exercise and activity (Nielsen, Gordon, & Selby, 2008).  
There is paucity of research regarding possible risk factors related to head and 
neck cancer-related lymphedema at this time. Based upon the similarity of 
pathophysiological process between breast cancer-related lymphedema and head and 
neck cancer-related lymphedema, researcher can examine whether the risk factors for 
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development of lymphedema in breast cancer patients lead to occurrence of secondary 
lymphedema in head and neck cancer patients. It is significant to examine and identify 
whether these factors are the same risk factors for developing secondary lymphedema 
after head and neck cancer treatment. Once nurses and other healthcare professionals 
recognize and are aware of the possible risk factors, they will be able to provide head and 
neck cancer patients with evidence-based assessment, informed education, and, perhaps, 
decrease patients’ symptom burden related to secondary lymphedema. Thus, it is 
important to research and examine the possible risk factors of secondary lymphedema in 
head and neck cancer patients. 
 
Advantages and Disadvantages of Methods  
Signs and Measurement  
 Signs are objective evidences of disease and can be seen by healthcare 
professionals. In the literature, head and neck cancer patients’ lymphedema signs and/or 
lymphedema measurement are primarily assessed by healthcare clinicians using scales 
and proper equipment (e.g., laryngoscope). Scales to measure external lymphedema 
(ACS, 2006; CTCAE v3.0, 2006) in head and neck cancer have been developed and used 
in clinical settings. However, due to lack of validity and reliability testing, the scales to 
measure external lymphedema need to be improved in future studies. Moreover, the 
scales used to measure internal lymphedema in head and neck cancer patients have not 
obtained consensus and need to be validated for their reliability and validity. That is, head 
and neck lymphedema measurement is still a difficult issue in clinical settings, especially 
for internal lymphedema.  
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 Currently, a laryngoscope is a common medical instrument for examining internal 
structures (e.g., the larynx) in head and neck cancer patients. Thus, direct visualization 
via endoscopy may be an option available to collect internal lymphedema data (Patterson 
et al. (2007). However, using only equipment (i.e., laryngoscope) does not ensure the 
accuracy of assessment for patients’ signs of secondary lymphedema. In some 
circumstances, clinicians are limited by their understanding of secondary lymphedema 
and they do not make it common practice to examine patients' early signs of secondary 
lymphedema. Moreover, limited validated scales are available in clinical and research 
settings, which affect accurate description of patients’ lymphedema. In addition, 
clinicians employ different scales to evaluate patients’ signs related to secondary 
lymphedema. Thus, the measurement of signs for secondary lymphedema in head and 
neck cancer patients need to be improved in both research and clinical settings.  
Symptoms/Effects on Body Function/Quality of life 
 Six articles were available that investigated symptoms, effects on body function, 
and quality of life in head and neck cancer patients with secondary lymphedema (Bruns 
et al., 2004; Eisbruch et al., 2004; Machtay et al., 2004; Micke et al., 2003; Piso et al., 
2001; Rudat et al., 1999). Three of them were the intervention studies exploring the 
treatment methods for secondary lymphedema in head and neck cancer patients. They 
used pretest-posttest, pre-experimental designs without control groups. The major 
advantages of one-group pretest-posttest designs are that they are practical and 
economical with small sample sizes. The rest of them were the descriptive studies using a 
cross-sectional design. The main advantages of cross-sectional designs are that they are 
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time saving and relatively economical but not appropriate for examining causational 
relationship (Polit & Beck, 2004). 
 In addition, the method of patients’ self-reports is often used to research 
symptoms, effects on body function, and quality of life related to secondary lymphedema 
in head and neck cancer patients (Micke et al., 2003; Piso et al., 2001; Rudat et al., 1999). 
Traditionally, patients’ symptom data are collected by clinicians interviewing patients, 
eliciting, and interpreting patients’ complaints (Trotti, Colevas, Setser, & Basch, 2007). 
Clinicians’ individual differences may influence the accuracy of the symptom data. Thus, 
the subjective domain of patients’ data can be associated with poor inter-rater reliability 
regarding grading consistency and completeness of capture (Trotti et al., 2007). For 
example, symptom research has documented systematic underreporting of symptoms (in 
number, severity, and time of onset/resolution) by clinicians compared with patients 
(Bruner, Carr, Curren, & Chamberlain, 1998; Varricchio & Sloan, 2002). A study 
compared the reporting of symptom severity by patients and clinicians (Basch et al., 
2006). The study found that agreement was higher for symptoms that could be observed 
directly, such as vomiting and diarrhea, than for more subjective symptoms, such as 
fatigue and dyspnea. They suggested that patient reporting of symptoms could add to the 
current approach to symptom monitoring in cancer treatment and cancer symptom 
management. Compared with healthcare clinicians’ interpretation, patients’ self-report 
would be the most appropriate method to collect the severity of their symptoms 
(subjective experiences for diseases and treatments) (Trotti et al., 2007). As for the cost 
of the self-report method, it saves time and is low-cost.  
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 However, the self-report method requires that validated and reliable 
questionnaires be available to ensure accuracy and completeness of data using self-report. 
Although a fair amount of overlap may exist between arm lymphedema and head/neck 
lymphedema symptoms, the instruments used to measure arm lymphedema symptoms 
cannot fully describe/cover head/neck lymphedema symptoms because of the different 
anatomical sites, different functional impairments, and treatment methods involved. 
Thus, there is a need to examine symptoms and develop evidence-based symptom 
questionnaires for nurses and other healthcare professionals to evaluate and manage head 
and neck cancer-related secondary lymphedema in clinical settings.  
Possible Risk Factors  
 Two studies reviewed in the literature examined the possible risk factors related to 
head and neck lymphedema. One study (Sanguineti et al., 2007) used a retrospective 
design to collect the data related to the possible risk factors leading to occurrence of 
secondary lymphedema over time. The major advantage of a retrospective design is an 
efficient, low-cost and convenient method to find the possible risk factors. The other 
study used a cross-sectional design and examined the possible risk factors related to head 
and neck lymphedema (Warren & Slavin, 2007). The major advantages of cross-sectional 
designs are that they have low cost and are practical. However, the studies reviewed 
mainly examined the possible risk factors from some of the physiological factors. Based 
on the literature on risk factors for secondary lymphedema in breast cancer patients, 
lymphedema symptoms are also closely related to a variety of physiological and 
situational factors (e.g., air travel and lifting/carrying heavy luggage) (Air Travel & 
Lymphedema, 2008). Thus, examining possible multidimensional risk factors related to 
 53 
 
secondary lymphedema in head and neck cancer patients is needed and has the  potential 
to optimize symptom management.   
 
Strengths and Weaknesses of Methods 
 The strengths and weaknesses of the methodological approaches will be discussed 
based on the following components in the literature: design, sample, instruments options, 
and knowledge integration.  
Strengths of the Methods 
 The strengths of the methodological approaches used to investigate the problem 
of interest are as follows. (1) Design: In terms of different research objectives, the studies 
reviewed used a variety of research designs, including one-group pretest-posttest pre-
experimental, longitudinal, and cross-sectional designs. The strengths of one-group pre-
experimental designs are that the studies used more conveniently collected data without a 
control group and randomization (Trochim, 2001). The strengths of longitudinal designs 
are appropriate to examine causation and possible risk factors of leading to a given 
outcome. By measuring the risk factors prior to the certain outcome, the longitudinal 
design makes it possible to identify the relationship between risk factors exposure and the 
specified result. The strengths of cross-sectional designs are that research data can be 
completely collected at one time thus minimizing attrition. When the research question 
does not involve continuity and change, a cross-sectional design is a proper method to 
collect data in descriptive studies (such as collecting descriptive data related to patients’ 
symptoms, functions, and quality of life). In a cross-sectional design, there is no 
pretest/posttest effect and test-retest bias and subjects’ burden is decreased. (2) Sample: 
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Three of the studies clearly described the participant recruitment, the sampling procedure 
(i.e., eligibility, settings, locations, etc.), types of participants, and drop-out rates and the 
causes of the drop-outs (Bruns et al., 2004; Micke et al., 2003; Piso et al., 2001). (3) 
Instruments: In two of the studies, reliability and validity of the measurement instruments 
were reported in detail and each instrument measured the concept it was intended to 
measure (Patterson et al., 2007; Piso et al., 2002). (4) Knowledge integration: In two of 
the studies, the investigators reiterated the main findings and further compared them with 
previous research. They also offered hypotheses regarding the part of findings that were 
at odds with previous work. They articulated generalizibility of the study findings and 
described general interpretation of the results in the current evidence. The meaningful 
point was that some authors described clinical implications for future similar 
settings/participants (Micke et al., 2003; Patterson et al., 2007).  
Weaknesses of the Methods 
 The weaknesses of the methodological approaches used to investigate the problem 
of interest include as follows. (1) Design: Three of the studies used a one-group pretest-
posttest pre-experimental design (Bruns et al., 2004; Micke et al., 2003; Piso et al., 2001). 
Because there is no control group, the design is at risk to most of the threats to internal 
validity (e.g., environmental and maturation threat). Several studies used a cross-sectional 
design, which is appropriate for describing symptoms, effects on body function, and 
quality of life but is not appropriate for exploring causation and timing (Polit & Beck, 
2004). (2) Sample: There are several concerns about the samples in some of the articles. 
First, the authors (Piso et al., 2001; Zimmermann et al., 2005) did not state how the 
sample sizes were determined and did not address statistical power analysis. They did not 
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describe if the samples are homogeneous or heterogeneous. Some studies (Piso et al., 
2001; Zimmermann et al., 2005) had small sample sizes (e.g., 11 and 20 subjects, 
respectively). The small sample sizes influence the internal and external validity of the 
studies. Second, the authors did not describe clearly the inclusion and exclusion criteria 
(Micke et al., 2003); (3) Instruments: Some of the studies did not report the reliability of 
instruments and how the instruments were developed (Bruns et al., 2004; Piso et al., 
2001). Limited instruments are available to evaluate lymphedema-associated symptoms 
in head and neck cancer patients; (4) Knowledge integration: Some of the authors did not 
compare the research results with previous studies and did not discuss generalizability of 
their research findings. They did not suggest implications for future studies and did not 
include any limitations of their studies (Zimmermann et al., 2005).  
 
Synthesis of Knowledge 
 Although early detection and multimodality treatments have decreased the 
mortality of cancer patients, the secondary complications from cancer and its treatment 
affect patients’ quality of life. In approximately the past 10 years, healthcare 
professionals have realized the early effects and late-effects from cancer treatment and 
provided patients with evidence-based symptom management. However, certain head and 
neck cancer patients still suffer some unpleasant and distressful symptoms that are not 
explained and hard to control by current symptom management strategies. Secondary 
lymphedema is one of the refractory complications that disrupt patients’ body functions 
and affect their quality of life.  
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 Although some investigators have reported and examined secondary lymphedema 
after head and neck cancer treatment, lack of systematic research that focuses on patients’ 
physical and psychological symptoms, effects on body function, effects on quality of life, 
and possible risk factors. The data on physical symptoms and effects on body functions 
related to secondary lymphedema in head and neck cancer patients are obtained from 
studies with small sample sizes and experts’ individual viewpoints. Some measurement 
instruments used in the literature lacked proper information about validity and reliability. 
There is lack of specific and unique measurement tools to assess head and neck cancer 
patients’ symptoms associated with secondary lymphedema. Limited studies have 
examined possible risk factors of leading to occurrence of head and neck lymphedema. 
Currently, the incidence and prevalence of secondary lymphedema in head and neck 
cancer patients is unpublished in the United States. Financial costs and insurance 
coverage for treatment of secondary lymphedema in this population are not reported. It is 
needed to develop treatment and management strategies of secondary lymphedema in 
head and neck cancer patients. Therefore, these gaps indicate more research needed in 
this area. The research methodological limitations in the reviewed literature also warrant 
systematic methodological approaches to examine lymphedema-associated symptoms, 
effects on body function, effects on quality of life, and possible risk factors.  
 Through the literature review, the following implications are proposed regarding 
studying secondary lymphedema related to head and neck cancer treatment.  
1. There is a need to systematically research and recognize the phenomenon of secondary 
lymphedema (e.g., incidence, prevalence, and financial burden) in head and neck cancer 
populations.  
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2. There is a need to conduct studies to clearly describe all types of symptoms, effects on 
body function, and effects on quality of life related to secondary lymphedema in the head 
and neck cancer population.  
3. There is a need to conduct the research with appropriate sample sizes based on 
statistical power analysis to improve statistical and external validity of the studies.  
4. There is a need to develop sensitive instruments to measure lymphedema-related 
symptoms in head and neck cancer patients.  
5. There is a need to examine the possible risk factors to guide nurses and other 
healthcare professionals to identify and manage lymphedema and improve patients’ 
awareness of self-monitoring and self-care.  
6. There is a need to explore effective treatment and management strategies of secondary 
lymphedema in head and neck cancer patients. 
 In summary, secondary lymphedema of head and neck patients is an important 
concept and needs to be investigated from theory, research, and evidence-based clinical 
intervention viewpoints.  
 
Research Hypotheses 
 The research reviewed does not provide ample evidence from which to develop 
hypotheses. A descriptive and correlational design is indicated as a first step in 
developing an evidence base from which to develop hypotheses for future studies.  
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Key Concepts  
The key concepts related to the research study include lymphedema, symptoms, 
function, signs, quality of life, and risk factors. The key concepts are stated as follows.  
Lymphedema  
 Lymphedema is the general term for a set of pathologic conditions in which there 
is excessive, regional interstitial accumulation of protein-rich fluid. It can be either a 
primary or a secondary (acquired) condition (Rockson, 2001). The most common cause 
of secondary lymphedema in developed countries is cancer treatment (Dos et al., 2005; 
Lymphoedema Framework, 2006). The lymphedema related to the problem of interest 
includes two key points of (1) secondary lymphedema related to head and neck cancer 
treatment and (2) late-effect lymphedema that occurs or has not healed by three months 
after the end of head and neck cancer treatment (Bentzen et al., 2003; ONS Research 
Agenda, 2009-2013). For the purposes of this study, lymphedema refers to secondary 
lymphedema developing three or more months after the completion of head and neck 
cancer treatment.  
Signs 
 Signs are physical manifestations of illness that are noted by a doctor, nurse, or 
other healthcare professional on physical exam (ACS, 2007) rather than by the patient or 
lay observer (Merriam-Webster’s Medical Dictionary, 2008). Signs are objective 
evidences of disease. The signs related to the problem of interest specify the objective 
manifestations of external and internal lymphedema (e.g., submental edema and laryngeal 
edema), which will be used to determine if a patient actually has lymphedema. 
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Symptom 
 Symptoms are indications of disease, illness, injury, or something that is not right 
in the body. Symptoms are felt or noticed by a person, but may not easily be noticed by 
anyone else (ACS, 2007). Symptoms are a subjective experience, appraised by the patient 
(Liehr, 2005). Symptoms are often dichotomized as either physical symptoms or 
psychological symptoms (Kroenke, 2003). The symptoms related to the problem of 
interest may include physical symptoms (e.g., dysphagia, hoarseness, and swallowing 
difficulty) and psychological symptoms (e.g., distress). 
Function 
 Function is the special, normal, or proper physiologic (or physical) activity of an 
organ or part (Biology-online, 2008). The functions related to the problem of interest 
specify the concrete physiological actions of the head and neck region, such as 
swallowing, hearing, and neck range of motion. 
Quality of Life (QOL) 
 QOL is an individual's overall sense of well-being. In medical studies, QOL is a 
multidimensional variable and measured using various standardized questionnaires to rate 
such factors as pain, treatment side-effects, mood, energy level, family and social 
interactions, sexual function, ability to work, and ability to keep up with routine daily 
activities (National Anemia Action Council [NAAC], 2007). The QOL related to the 
problem of interest specifies the global QOL from the patients’ perspective. Symptom 
burden can affect a patient’s perceived QOL. 
Risk Factors 
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 Risk factors are variables that may increase the chance of developing a disease or 
injury. Risk factors are correlational and not necessarily causal (NCI, 2008c). The 
possible risk factors related to the problem of interest may include physiological, 
psychological, and situational factors, such as tumor stage, emotional reaction to a 
disease, and vocation. 
 
Theoretical Framework for the Study  
 Given the lack of published descriptive data about the problem of interest, 
lymphedema will be examined according to patients’ subjective experiences (symptoms) 
and objective manifestations (signs). Additionally, as lymphedema also disturbs physical 
functions and quality of life for affected individuals, these components were also 
addressed. Therefore, the theoretical basis for the study should address these components. 
Based on the theoretical literature review, the key research variables (i.e., the symptoms, 
possible risk factors, and the effects of lymphedema on body functions and quality of 
life) related to the problem of interest best fit the three key components (i.e., the 
symptoms, the influencing factors, and the performances) in the Theory of Unpleasant 
Symptoms (Lenz et al., 1997) (see Figure 1). Thus, the Theory of Unpleasant Symptoms 
was chosen as the theoretical framework to direct the research study. The following 
operational definitions are offered to provide clarification. 
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Figure 1. The Theory of Unpleasant Symptoms (Lenz et al., 1997) 
 
1. Symptoms 
 In the study, symptoms (subjective experience) was a key variable to be assessed 
based on the Theory of Unpleasant Symptoms. According to the Theory of Unpleasant 
Symptoms, four dimensions are common across symptoms: intensity, timing, level of 
distress perceived, and quality. Thus, given those dimensions, symptoms related to 
secondary lymphedema can be assessed and described using a symptom scale, which 
measures intensity of the symptom, the level of distress perceived, timing, and quality. A 
second component related to symptoms in the Theory of Unpleasant Symptoms suggests 
patients seldom experience only one symptom at a time. More often, they may experience 
multiple symptoms or a cluster of symptoms, such as swallowing difficulties and 
tightness. The multiple symptoms lead to patients’ symptom burden.   
2. Influencing factors (possible risk factors) 
 In terms of the Theory of Unpleasant Symptoms, patients’ symptoms can be 
driven by multidimensional influencing factors, including physiological, psychological, 
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and situational factors. These three types of factors interact with one another and 
commonly have an impact on the symptom experience (Lenz et al., 1997). The 
multidimensional influencing factors in the Theory of Unpleasant Symptoms facilitate 
examination of possible risk factors leading to occurrence of secondary lymphedema. For 
example, the doses of radiation might be correlated to lymphedema development in the 
head and neck cancer population.  
3. Performance (functional status and quality of life) 
 In the Theory of Unpleasant Symptoms, Lenz et al. interpreted that performance 
means the outcome or effect of symptom experience (Lenz et al., 1997). In the study, 
functional status and quality of life were examined as the effects of lymphedema.   
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CHAPTER III 
 
 METHODOLOGY 
 
 The purpose of this section is to describe the methodology used in the research 
study of secondary lymphedema related to head and neck cancer treatment. This section 
will include research design and assumptions, research setting, sample and sampling plan, 
data collection methods, and data analysis procedures.  
 
Research Design and Assumptions 
A descriptive, correlational, cross-sectional design was used in the study. The 
lymphedema diagnosis and stage was established by the Staging/Grading criteria and 
basic diagnostic procedures (i.e., by taking the medical history, and by inspection and 
palpation) (Foldi et al., 2003). External lymphedema was identified using the following 
three scales: 1) the Stages of Lymphedema (Foldi et al., 2003), 2) Lymphedema of the 
Head and neck Grading Scale (CTCAE v3.0, 2006), and 3) Lymphedema of the Head and 
Neck Staging Criteria (ACI, 2006). Internal lymphedema was identified using Patterson’s 
Scale for Edema in Larynx and Pharynx (Patterson et al., 2007). The associations of the 
severity of lymphedema with symptoms, functional status, and quality of life in head and 
neck cancer patients were examined. Furthermore, possible factors contributing to the 
presence of secondary lymphedema in head and neck cancer patients were explored. 
Three assumptions were proposed based on the comprehensive literature review 
and the theoretical framework of this study. 1) Patients may develop external 
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lymphedema, internal lymphedema, and combined lymphedema after head and neck 
cancer treatment. 2) The severity of lymphedema may be associated with symptoms, 
functional status, and quality of life. 3) Some demographic and cancer disease and 
treatment factors may be related to the presence of secondary lymphedema in head and 
neck cancer patients.   
 
Research Setting 
 The study was conducted at the Vanderbilt-Ingram Cancer Center, Tennessee, 
U.S.A. There are about 4,000 new cancer patients each year and more than 65,000 
outpatient visits annually in the comprehensive cancer center. Study participants were 
identified from the cancer center.  
 
Sample and Sampling Plan 
 
Nature and Size of Sample 
 A convenience sample consisting of 103 adult head and neck cancer patients after 
their cancer treatment was obtained. This was a descriptive, preliminary study of 
lymphedema in patients who have been treated for head and neck cancer; there are no 
preliminary data available to guide statistical powering other than rates that have been 
observed in patients treated for breast cancer. This study investigated the associations 
between the severity of lymphedema and symptom, functional, and quality of life self-
reports. Given that this was a preliminary study and many measures of associations were 
generated, it was important to detect the largest and most clinically relevant effects or 
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associations. Therefore, it was decided that any correlations smaller than an observed 
beta coefficient ± 0.30 (representing 9% shared variance) would not be considered 
clinically relevant at this time. Because of the large number of associations assessed in 
this preliminary study, it was determined also that an alpha level of .010 would be used 
for determining statistical significance. A sample size of 103 achieves 80% power to 
meet the criteria for clinical (associations of ± 0.30) and statistical significance (p < 
.010).   
 
Criteria for Sample Selection 
 The participants recruited into the study met the following inclusion criteria: (1) 
18 and over years of age; (2) ≥ 3 months after completion of their cancer treatment; and 
(3) no current evidence of cancer. Individuals were excluded if they met the following the 
exclusion criteria: (1) actively undergoing chemotherapy or radiation therapy; (2) having 
metastatic cancer or any other active cancer; and (3) unable to understand the informed 
consent as evidenced by incorrectly describing the study when asked. 
 The underlying principles for the exclusion criteria are as follows. (1) Patients 
actively undergoing chemotherapy or radiation therapy may have cancer treatment-
related acute edema (NCI, 2007a). The patients may experience symptom burden and 
functional impairments related to the acute edema. The study focuses on secondary 
lymphedema rather than acute edema. In order to control for the influence of acute 
edema, the study excluded patients actively undergoing chemotherapy or radiation 
therapy and recruited patients who had completed their cancer treatment greater than 
three months ago. (2) Patients with metastatic cancer or any other active cancer may 
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experience different cancer treatment strategies, and have different physical and 
emotional responses from patients without metastatic cancer or any other active cancer; 
the responses are likely to be potential confounding variables in the research study. (3) 
Patients who were unable to understand the informed consent as evidenced by incorrectly 
describing the study when asked were excluded to avoid any confounding effects on the 
self-reported subjective symptoms in the research study.  
 
Participant Recruitment 
The participants were identified in the study by the PI screening the potential 
participants at the Vanderbilt-Ingram Cancer Center. The following specific steps were 
used. (1) The PI visited head and neck cancer oncologists (i.e., medical, surgical, and 
radiation oncologists) at the Vanderbilt-Ingram Cancer Center and told them about the 
purpose and procedure of the study. (2) The head and neck cancer oncologists helped tell 
the potential participants about the study. (3) The PI screened and recruited the persons 
expressing interest in the study using the screening form. 
 
Human Subjects Protection 
 Prior to recruiting the participants, approval was obtained from the Vanderbilt 
University Institutional Review Board (IRB) and the Scientific Review Committee (SRC) 
at the Vanderbilt-Ingram Cancer Center. Study participation was open to all patients with 
head and neck cancer. No one was excluded based on gender, race, or ethnicity. The 
following specific steps were used to obtain the informed consent from all the 
participants. (1) The PI explained the study to potential participants. (2) The participants 
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were provided one copy of the informed consent to read and review. (3) The PI asked the 
potential participants if they had any questions during and after their reading/reviewing 
the informed consent. (4) The PI answered all the questions the potential participants 
asked. (5) The potential participants agreed to be in the study and signed on the informed 
consent as the PI witnessed. This process took place in a private location at the cancer 
center to ensure confidentiality. There was no anticipated potential risk to participants for 
participating in the study. The study only posed some time inconvenience to the 
participants. Participants were free to withdraw from the study at any time, for any reason 
simply by telling the PI that they wished to withdraw.                     
 Compliance with study procedures was assured by the PI and the PI’s advisor, Dr. 
Sheila Ridner, through regular meetings. Participants’ data were randomly examined 
during this regular meeting. The PI reported any issues related to the study procedures to 
her advisor, e.g., participants’ recruitment, data collection, and data entry. All files were 
saved in both hard copies and one password protected safe electronic database. All hard 
copies were placed in a locked file cabinet. All data were coded and filed without any 
name or other identifiable information. Dr. Ridner, Dr. Mary Dietrich (a member of the 
dissertation committee who served as the statistical consultant), and the PI had access to 
the electronic database. Only Dr. Ridner and the PI had access to the hard copy file 
cabinet. All the hard copy research data were stored at the Vanderbilt University School 
of Nursing. The PI’s advisor and the PI stored the electronic database in password-
protected electronic files.  
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Data Collection Methods 
 
Procedures 
The PI contacted the head and neck cancer oncologists by using a script (see 
Appendix A) and told them about the study. Then the PI contacted and screened the 
possible participants who expressed interest in the study by using the patient’s contact 
script (Appendix B) and the screening form (Appendix C). Once an exclusion criterion 
was met, no other information was gathered. If they were eligible, the participants were 
provided an informed consent form. After informed consent was obtained, the PI 
evaluated the participants’ external lymphedema, neck range of motion, mouth range of 
motion, and hearing, and collected their demographic and lymphedema treatment 
information. Participants’ cancer disease and treatment information were gathered from 
their medical records via chart review by the PI. The skilled head and neck surgical 
oncologists (i.e., ENTs) and radiation oncologists evaluated internal lymphedema of the 
participants based on Patterson’s Scale for Edema in Larynx and Pharynx. The 
participants completed the self-report instruments designed and/or chosen for the study. 
All data collected from participants were locked in a safe place.      
 
Instruments 
 The instruments used in the study are listed below in terms of the following 
domains: (1) sample characteristics; (2) prevalence of lymphedema [Aim 1]; (3) 
symptoms, functional status, and quality of life [Aim 2]; and (4) possible risk factors 
[Aim 3]. The instruments in each domain are described based on their content and 
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previous use in the literature, and information about reliability and validity.  
Sample Characteristics 
 Demographic and Background Information Form (Appendix D). The 
demographic and health behavior characteristics form included questions about age, 
gender, race, education, marital status, employment status, area of residence, presence of 
any co-morbid conditions, medical history, alcohol use, smoking assumption, dietary 
habits, etc. The information was obtained through interviewing the participants. 
 Head and Neck Cancer Disease & Treatment Information Form (Appendix E).  
The head and neck disease and treatment information form included questions about date 
of diagnosis of head and neck cancer, location, stage of tumor TNM (T: the extent of the 
tumor; N: the extent of spread to the lymph nodes; and M: the presence of metastasis), 
type and dates of treatment, and complications. The information was collected by the PI 
via medical records and chart review.  
Aim 1: Prevalence of Lymphedema  
External lymphedema. Four staging/grading scales (see below) were used to 
assess external lymphedema after head and neck cancer treatment in the study.   
Stages of Lymphedema (abbreviation: Foldi’s LE scale). The Stages of 
Lymphedema scale was developed by Foldi and his colleagues and was introduced in 
their Textbook of Lymphology (2003). Although the authors did not state the reliability 
and validity of their scale, they developed the Stages of Lymphedema based on their 
experience treating over 100,000 patients with lymphedema, thus content validity can be 
assumed. There are three major components in the Foldi et al. scale, i.e., pathology, signs 
and symptoms, and diagnosis. Therefore, the scale illustrates the entire picture of 
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secondary lymphedema.  
Lymphedema of the Head and Neck Grading Scale (abbreviation: NCI LE scale). 
The National Cancer Institute developed the Lymphedema of the Head and Neck Grading 
Scale (CTCAE v3.0, 2006). The five grades provide a basic method of evaluating external 
lymphedema after treatment of the head and neck cancer. The content validity of the 
scale was supported by the expert panel during development of the CTCAE v3.0. The 
reliability of the scale has not been reported.  
Lymphedema-related Fibrosis Scale (abbreviation: NCI Fibrosis scale).  The 
National Cancer Institute developed the Lymphedema-related Fibrosis Scale (CTCAE 
v3.0, 2006). The three grades provide a fundamental method of evaluating lymphedema-
related skin fibrosis after cancer treatment. The content validity of the scale was 
supported by the expert panel during development of the CTCAE v3.0. The reliability of 
the scale has not been reported.      
Lymphedema of the Head and Neck Staging Criteria (abbreviation: ACS LE 
scale). Based on the Lymphedema of the Head and Neck Grading Scale of the National 
Cancer Institute, the American Cancer Society provides the staging criteria for grading 
head and neck lymphedema from normal to severe (ACS, 2006; Cheville et al., 2003). 
The four stages are described to assess external lymphedema of the head and neck. The 
content validity of the criteria was supported by the expert panel during development of 
the staging criteria. The reliability of the scale has not been published.  
Internal Lymphedema. One scale (see below) was used in this research study to 
assess internal lymphedema after head and neck cancer treatment.   
Patterson’s Scale for Edema in Larynx and Pharynx (abbreviation: Patterson 
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scale) (Appendix F). Patterson’s Scale was used to assess internal lymphedema in the 
larynx and pharynx (Patterson et al., 2007). The scale has good intra-rater reliability 
(weighted kappa, 0.84) and moderate inter-rater reliability (weighted kappa, 0.54) 
(Patterson et al., 2007). Based on the experts’ suggestions, the rating scale was developed 
with good content validity. Following Patterson et al. (2007), direct visualization via 
endoscopy was used to collect internal lymphedema data. Head and neck surgical or 
radiation oncologists used the scale to collect internal lymphedema data by routinely 
performing the procedure of endoscopy. 
In summary, the severity of lymphedema in this study as an independent variable 
was classified into three sub-variables, i.e., severity of external lymphedema, severity of 
internal lymphedema, and severity of combined lymphedema. The severity of combined 
lymphedema was evaluated using two different methods. Method one included NCI LE 
scale (for external swelling), NCI Fibrosis scale (for external fibrosis), and Patterson’s 
scale (for internal lymphedema). Method two included Foldi’s LE scale (swelling and 
fibrosis) and Patterson’s Scale (for internal lymphedema).  
Lymphedema Disease & Treatment Information Form (Appendix G).  This form 
included date of diagnosis of lymphedema, location of lymphedema, treatment history 
and current treatment of lymphedema. The information was collected through 
interviewing participants and was double-checked with the participants’ medical records.   
Aim 2:  Symptoms, Functional Status, and Quality of Life 
Symptoms  
 Vanderbilt Head and Neck Symptom Survey (VHNSS) (Appendix H).  The 
VHNSS was developed to assess physical symptom burden related to head and neck 
 72 
 
cancer and its treatment. The 27 items are rated by respondents on a 0 to 10 numeric 
rating scale according to the intensity of symptoms from none to a lot. Higher scores 
reflect greater symptom intensity. The VHNSS was tested in over 300 patients with head 
and neck cancer and can be completed by patients in less than five minutes. Previous 
research (Murphy et al., 2004) has reported good internal consistency for the total 
VHNSS scale (alpha=.94) and the 12 item VHNSS swallow subscale (alpha=.91). The 
convergent validity of the VHNSS was supported by the correlation between the VHNSS 
total score and the EORTC HN-35 subscales and the PSS-HN swallow subscale (Murphy 
et al., 2004). Construct validity of the VHNSS swallow subscale was supported by 
correlation with an objective measure of swallowing function (Murphy et al., 2010). 
  Two instruments (see below) were used to assess psychological symptoms after 
head and neck cancer treatment in the research study.   
 Hospital Anxiety and Depression Scale (HADS) (Appendix I). The HADS was 
developed by Zigmond and Snaith (1983) to provide an efficient assessment tool to 
measure symptoms of anxiety and depression among the non-psychiatric hospitalized 
population. The HADS is a self-report questionnaire and only takes two to five minutes 
to complete (Snaith, 2003). The HADS contains 14 items that generate separate scores 
for depressive (7 items) and anxious (7 items) symptoms. Items are rated on a 4-point 
scale; to score the HADS, the 7 items on each subscale (anxiety and depression) are 
summed separately. Scores on each of the subscales can range from 0 to 21. Good 
internal consistency has been reported in the literature (alpha for HADS-anxiety from .68 
to .93 and for HADS-depression from .67 to .90) (Bjelland, Dahl, Haug, & Neckelmann, 
2002). Construct validity has been supported through correlation between the HAD 
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subscales and psychiatric diagnostic interview (Razavi et al., 1992; Zigmond & Snaith, 
1983) and factor analysis (Moorey et al., 1991). Factor analyses demonstrated that the 
HADS is a two-factor instrument with the independent subscales for anxiety (HADS-A) 
and depression (HADS-D). Correlation coefficient (Pearson’s) between the HADS 
scale’s anxiety and depression sub-scales is reported to be 0.49 - 0.63 (Savard, Laberge, 
Gauthier, Ivers, & Bergeron, 1998). 
 Body Image Scale (BIS) (Appendix J). The BIS was developed by Hopwood and 
colleagues to examine oncology patients’ self-assessment of body image related to cancer 
and cancer treatment (Cash & Pruzinsky, 2002). The 10 items are rated by respondents 
from 0 (not at all) to 3 (very much). The overall summary score for each respondent 
ranges from 0 to 30, and higher scores represent increasing symptoms/distress of body 
image. The scale was tested in a heterogeneous sample of 276 cancer patients and 682 
patients with breast cancer. The scale has demonstrated high reliability in previous 
research (alpha= .93) and good discriminant validity (Hopwood et al., 2001).  
Functional Status 
 Hearing. Two tests (i.e., the whispered voice test and the tuning fork test) were 
used to assess hearing impairment after head and neck cancer treatment in the study.   
Whispered Voice Test (Appendix K). Hearing was evaluated using the whispered 
voice test (Pirozzo, Papinczak, & Glasziou, 2003). The whispered voice test is a simple 
and accurate test for detecting hearing impairment. The literature reported that the 
whispered voice test has a sensitivity of 87%-96% and a specificity of 70%-90% (Pirozzo 
et al., 2003). It is one test recommended by the United Kingdom and Australia as the 
national health guidelines to screen for hearing impairment in the elderly population. The 
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test was conducted by the PI using a standard procedure.  
Tuning Fork Test.  The tuning fork test (Fix, 2002) was used to distinguish 
between conduction hearing impairment and nerve hearing impairment. The Weber test 
and Rinne test was performed by the PI using a standard procedure. The test results were 
analyzed based on the following rationale (see Table 11).  
 
 
Table 11  
 
Tuning Fork Test Results (Fix, 2002) 
 
Otologic Finding Weber Test           Rinne Test 
Conduction deafness (left ear) 
Conduction deafness (right ear) 
Nerve deafness (left ear) 
Nerve deafness (right ear) 
Normal ears  
Lateralizes to left ear 
Lateralizes to right ear 
Lateralizes to right ear 
Lateralizes to left ear 
No lateralization 
BC>AC on left   AC>BC on right 
BC>AC on right   AC>BC on left 
AC>BC, both ears 
AC>BC, both ears 
AC>BC, both ears 
Conduction deafness=middle ear deafness (e.g., otosclerosis, otitis media); nerve deafness=sensorineural 
deafness (e.g., presbycusis); AC=air conduction; BC=bone conduction.  
 
Trismus Grading Criteria (Appendix L). Trismus was evaluated using the three 
fingers test and graded using the CTCAE v3.0 trismus subscales (CTCAE v3.0, 2006). 
The three grades provide a basic method of evaluating trismus of the head and neck 
cancer patients in the  study. The content validity of the Trismus Grading Criteria was 
supported by the expert panel during development of the CTCAE v3.0. Trismus was 
measured by the PI.    
 Cervical Range of Motion (CROM) Device (Appendix M). The CROM device 
was used to measure whether an individual has a reduced CROM. This instrument has 
been used to examine neck range of motion the literature. The normal CROM are as 
follows: forward flexion 0-45 degrees, extension 0-45 degrees, left lateral flexion 0-45 
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degrees, right lateral flexion 0-45 degrees, left lateral rotation 0-80 degrees, and right 
lateral rotation 0-80 degrees (De Koning, van den Heuvel, Staal, Smits-Engelsman, & 
Herdriks, 2008).  In addition, presence or absence of elicited pain, tenderness, postural 
abnormalities and fixed deformity (ankylosis) of cervical spine musculature were 
documented (De Koning et al., 2008). The CROM measurement was performed by the PI 
using a standard procedure. 
Quality of Life 
 Two instruments (see below) were used to assess quality of life after head and 
neck cancer treatment in the study.    
 Functional Assessment Cancer Therapy-Head & Neck (FACT-H&N) (Appendix 
N). The FACT-H&N was used to measure quality of life in head and neck cancer patients 
related to cancer treatment. The 39-item FACT-H&N measures concerns associated with 
head and neck cancer and was tested in 151 head and neck cancer patients being treated 
at two facilities in Chicago (List et al., 1996). Consistent with the FACT-G, a 5-point 
response format is used for concerns experienced during the past 7 days. There are 5 
subscales on the FACT-H&N, including physical well-being (7 items), social/family 
well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and 
head and neck cancer subscale (12 items). Scores on each of the subscales can range from 
0 to 28 for the physical well-being, 0 to 28 for the social/family well-being, 0 to 24 for 
the emotional well-being, 0 to 28 for the functional well-being, and 0 to 48 for head and 
neck cancer subscale. After reverse scoring the negative items in the scale, higher scores 
on the subscales indicate better quality of life. In past studies, the internal consistency of 
the subscales have been shown to be adequate (alpha= .59 -.79) (List et al., 1996). The 
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FACT-H&N has been used in head and neck cancer trials, and has demonstrated 
sensitivity to change in disease status (Murphy et al., 2007b).  
Quality of Life Scale (Linear Analog Self Assessment, LASA) (Appendix O). The 
5-item linear analog scale assessment of quality of life was published by Locke et al. in 
2007. The literature supported that the LASA is a psychometrically validated brief 
measure of quality of life. In previous reports, the scale has showed good reliability 
(alpha= .83 - .88) and good concurrent/construct validity (Locke et al., 2007). Despite its 
brevity, it provides an overall estimate and covers four major subcomponents of quality 
of life (i.e., physical, emotional, spiritual, and intellectual). Therefore, the LASA gives a 
global, comprehensive view of a patient’s quality of life.  
Aim 3: Possible Risk Factors 
 The possible risk factors contributing to the presence of lymphedema in head and 
neck cancer patients were examined based on data from two forms, Demographic and 
Background Information Form and Head and Neck Cancer Disease & Treatment 
Information Form, which were described above in the sample characteristics section (see 
page 68).  
The following list summarizes the coding of key factors for purposes of the 
analyses conducted in this study.  
(1) Location of head and neck cancer was recoded into paranasal sinuses, oral 
cavity, nasopharynx/oropharynx, hypopharynx, larynx, and other. The ‘other category’ 
included participants with salivary gland tumors and others.  
(2) Histological type of tumor was coded as squamous cell carcinoma (SCC) and 
non-SCC. The later included acinic cell carcinoma, clear cell mucoepidermoid, 
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embryonal rhabdomyosarcoma, hemangiopericytoma, and small cell carcinoma.  
(3) Dosage of radiation therapy was coded as low dose (≤ 6000  cGy) and high 
dose (> 6000 cGy).  
(4) Type of chemotherapy was collapsed into taxol/carboplatin group and non-
taxol/carboplatin group.  
(5) Total treatment received for head and neck cancer was coded as one modality 
of cancer treatment (i.e., surgery only or radiation only), two modalities of cancer 
treatment (i.e., surgery with radiation, or concurrent chemotherapy and radiotherapy), 
three modalities of cancer treatment (i.e., surgery and concurrent chemotherapy and 
radiotherapy; chemo-induction and concurrent chemotherapy and radiotherapy), and four 
modalities of cancer treatment (i.e., surgery, chemo-induction, and concurrent 
chemotherapy and radiotherapy). 
 
Summary 
             The following table (see Table 12) lists the data resources and data collection 
methods used in the study.  
 
Table 12  
Data Resources and Data Collection Methods     
Domains/ 
Concepts 
Measured 
Measurement 
Variables 
Measurement 
Instruments 
Data Collection 
Methods 
Sample 
Characteristics 
Demographic data 
health behavior data 
 
Demographic and Background 
Information Form The PI Interview 
Head and neck cancer 
disease and treatment 
data 
Head and Neck Cancer Disease & 
Treatment Information Form 
The PI Chart 
Review 
Aim 1: 
Prevalence of 
Lymphedema 
External lymphedema 
NCI LE scale  
The PI Interview/ 
Examination Foldi’s LE scale 
NCI Fibrosis scale 
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ACS LE scale 
Internal lymphedema Patterson’s scale MDs/the PI 
Aim 2: Symptoms 
Physical symptoms VHNSS 
Participant Self-
report Psychological 
symptoms 
HADS 
BIS 
Aim 2: Functional 
Status 
Hearing 
Whispered Voice Test 
The PI Examination 
Tuning Fork Test 
Mouth range of motion 
Three Fingers Test 
Trismus Grading Criteria 
Neck range of motion Cervical Range of Motion 
Aim 2: Quality of 
Life Quality of life 
FACT-H&N Participant Self-
report LASA 
Aim 3: Possible 
Risk Factors 
Demographic data Demographic and Background Information Form The PI Interview 
Cancer treatment data Head and Neck Cancer Disease & Treatment Information Form 
The PI Chart 
Review 
 
 
Credibility, Rigor, and Validity 
The study ensured rigor through the following aspects.   
Internal validity 
The study used a cross-sectional design and limited its explanation about causal 
relationships between research variables due to lack of a time dimension. However, the 
cross-sectional design was a most appropriate and ideal design based on the current state 
of science of the phenomenon of interest. Throughout the literature review, limited 
literature is available related to secondary lymphedema in head and neck cancer patients 
and thus it is critical to conduct descriptive studies delineating this understudied 
phenomenon. Thus, this dissertation focused on describing the prevalence of secondary 
lymphedema, its associations with symptomatology, functional status, quality of life, and 
the possible risk factors.  
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External validity 
Due to a cross-sectional design, the study had a particularly low missing data and 
most instances of missing data were random. Moreover, no participants were excluded 
based on gender, race, or ethnicity. The study sample characteristics were similar to most 
of literature reports. The study result can be generalized to adult head and neck cancer 
populations after their cancer treatment > 3 months.  Thus, the study had a good external 
validity. 
Reliability  
The study used the validated instruments to collect patients’ self-reported data. 
These instruments had been tested with good reliability and validity parameters. This 
study used Cronbach’s alpha coefficients to assess internal consistency of the instruments 
and the alpha values for each instrument were similar to literature reports. This further 
demonstrated that there was good internal consistency of all the instruments. Moreover, 
the physical examinations across the study were accurate and consistent. The PI was a 
licensed-nurse and trained by a physical therapist regarding how to measure CROM 
before all data collection activity. The two skilled oncologists who conducted endoscopic 
examinations were trained on use of the Patterson’s scale by the PI. All the physical 
measurements were performed using the standard procedures. Thus, the study had a good 
reliability and ensured the quality of data in this study. 
Objectivity  
The study not only collected subjective (self-reported) data but also objective data 
(physical examination), which engendered confidence in the truth of the data. The 
univariate and multivariate statistical methodologies were employed to clearly analyze 
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and demonstrate the study findings. As a preliminary study to describe an understudied 
phenomenon, the study focused on detecting rather large effects or associations and used 
a minimal significant level (p < .010) to interpret the study findings. This method of 
interpreting the findings minimized the type I and type II errors.  
 
Data Analysis 
 Data were double entered by the PI into the statistical software package SPSS 
version 17.0. After data entry, data validation and data cleaning procedure were used to 
check for outliers and internal data consistency (Polit & Beck, 2004). The PI examined 
the distribution and patterning of missing data. Because it was a cross-sectional study, 
most instances of missing data were random, particularly some item responses within the 
self-report measures. Missing responses to items within measures were handled 
according to the protocols specified by the authors of those measures.  
 Descriptive statistics were used to describe the sample and to summarize the 
distributions of the study variables, including demographic information, head and neck 
cancer disease/treatment information, lymphedema disease/treatment information, as well 
the measures of symptom, functional status, and quality of life. Categorical and ordinal 
data (e.g., gender) were summarized using frequency distributions. Ordinal data 
summaries also included median and 25th - 75th inter-quartile ranges. Continuous data 
values were evaluated visually with histograms and measures of skewness for 
determining the appropriate descriptive statistics. If normality could be assumed, the 
distributions were described using means and standard deviations; if not, the distributions 
were described using median and 25th - 75th inter-quartile ranges, minimum, and 
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maximum values.  
 Severity of lymphedema was assessed on an ordinal scale, and self-reports of 
symptom/function were, as expected, highly skewed; therefore data were transformed to 
ranks prior to inclusion in correlation and regression analyses. Data were analyzed based 
on each specific aim in the study.  
Aim1: To examine the prevalence of external lymphedema, internal lymphedema and 
combined lymphedema in head and neck cancer patients. 
 Statistical Analysis Methods: Frequency distributions were used to describe the 
prevalence of lymphedema in this study.  
Aim 2: To examine the associations between severity of lymphedema in head and neck 
cancer patients and (a) the symptom scores; (b) functional status scores; and (c) QOL 
scores.  
(2a) Analyze the associations between severity of lymphedema and symptoms in 
head and neck cancer patients.  
Statistical Analysis Methods: Measures used to assess symptoms in this study 
included the Vanderbilt Head and Neck Symptom Survey (VHNSS), the Hospital 
Anxiety and Depression Scale (HADS) and the Body Image Scale (BIS). Simple linear 
regression of transformed data was used to examine the association between each 
measure of lymphedema severity and symptoms scores. Multiple linear regression of 
transformed data was used to assess the association of both internal and external 
lymphedema severity with symptom self-reports. Given that this was an exploratory 
study and given that a large number of statistical tests were conducted, to control for 
Type I error, an association of at least 0.30 (indicating 9% shared variability) was used 
 82 
 
for making interpretations.  
(2b) Analyze the associations between severity of lymphedema and functional 
status in head and neck cancer patients.  
 Statistical Analysis Methods: Functional status was assessed using Cervical 
Range of Motion (CROM), Whispered Voice Test, Tuning Fork Test, and Trismus 
Grading Criteria. Simple linear regression of the transformed data was used to examine 
the association between severity of lymphedema and the continuous functional status 
scores (CROM and Trismus). Logistic regression analyses were used to examine the 
associations of lymphedema severity with the dichotomous functional status values 
(Whispered Voice Test and Tuning Fork Test). Respective multiple linear and logistic 
regressions were used to assess the associations of both internal and external lymphoma 
severity with functional status values. As with the previous analyses, an association of at 
least 0.30 (indicating 9% shared variability) was used for making interpretations of the 
associations with the continuous variables. A critical alpha of at least .010 (p < .010) was 
used for making interpretations of the associations with the dichotomous variables.  
 (2c) Analyze the associations between severity of lymphedema and quality of life 
in head and neck cancer patients.  
 Statistical Analysis Methods: Quality of life was assessed using Functional 
Assessment Cancer Therapy-Head & Neck (FACT-H&N) and QOL Scale (Linear 
Analog Self Assessment, LASA). As with the previously described analyses, simple 
linear regression of transformed data was used to examine the association of each 
measure of severity of lymphedema with quality of life scores. Multiple linear 
regressions of transformed data were used to assess the associations of both internal and 
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external lymphoma severity with the quality of life values. Again, an association of at 
least 0.30 (indicating 9% shared variability) was used for making interpretations of the 
associations. 
Aim 3: To examine the possible risk factors contributing to the presence of secondary 
lymphedema in head and neck cancer patients.  
Statistical Analysis Methods: Information about possible factors contributing to 
the development of lymphedema was collected via the use of two instruments (the 
Demographic and Background Information Form, and the Head and Neck Cancer Disease 
& Treatment Information Form. Univariate (unadjusted) logistic regressions were used to 
examine the association of each possible factor with the occurrence of secondary 
lymphedema. As with the previous research question, due to the large number of tests 
conducted, a critical alpha of at least .010 (p < .010) was used for making interpretations 
of the associations. 
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CHAPTER IV 
 
FINDINGS 
 
This chapter presents the study findings based on statistical analyses. Two 
primary sections are given. Section one focuses on a description of the study participants. 
Section two presents the results from the study aims. 
 
Sample Characteristics 
Four aspects of the study sample: (1) demographic characteristics, (2) health 
behavior characteristics, (3) head and neck cancer disease and treatment characteristics, 
and (4) internal consistency and sample scores on the instruments will be summarized in 
this section. 
A convenience sample of 103 adult head and neck cancer patients were recruited 
by the PI at the Vanderbilt-Ingram Cancer Center. Data were collected from December 
2009, through May 2010. All the participants were three months or more post-treatment. 
Eighty-one participants (78.6%) also underwent endoscopy examination by their surgical 
oncologists or radiation oncologists during enrollment in the study. Internal lymphedema 
data were collected using the Patterson’s scale on each of those eighty-one participants, 
while the remaining twenty-two participants (21.4%) did not have an endoscopic exam. 
Of those twenty-two participants, half of them (n=11) had no surgical oncologists’ or 
radiation oncologists’ appointments scheduled, while the other half (n= 11) had an 
endoscopy exam scheduled beyond the study data collection period.  
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Demographic Characteristics 
Demographic characteristics are summarized in Table 13. The sample was 68.9% 
male and ranged in age from 33 to 86 years. Most participants were White (89.3%) and at 
least high school graduates (89.3%). The majority of the participants (64.1%) were 
married or living with partner. More than half of the participants were receiving 
government insurance aid (57.3%) and lived in a Metropolitan area (63.1%). Thirty-five 
percent of the participants lived in households with more than $50,000 annual income.  
 Health Behavior Characteristics  
 Few of the participants (12.6%) reported special dietary habits, including eating 
sweet, spicy, and sour food. Sixty-six percent reported a smoking history and 37.9% 
reported drinking alcohol. Summaries of the health behavior characteristics of the study 
sample are presented in Table 14.  
  Head and Neck Cancer Disease and Treatment Characteristics 
 Disease and treatment characteristics of the sample are summarized in Table 15. 
The oropharynx was the most common primary tumor location (43.7%). Advanced stage 
disease (III/IV) was present in 80.6% of all participants. The histological type of most 
participants’ tumors was squamous cell carcinoma (93.2%). Sixteen participants (15.5%) 
with oropharyngeal carcinoma had HPV testing with 50% of them testing positive. One 
out of three participants with nasopharyngeal carcinoma (2.9%) was identified as having 
Epstein Barr Virus infection. Eleven participants (10.7%) had tracheostomy tube due to a 
total laryngectomy. 
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Table 13 
 Demographic Characteristics        
 
Characteristic Frequency (%) (N=103) 
Gender  
Male 71 (68.9) 
Female 32 (31.1) 
Race  
White 92 (89.3) 
Black 11 (10.7) 
Education Level  
<12th grade 11 (10.7) 
12th grade 38 (36.9) 
College 44 (42.7) 
Graduate 10 (9.7) 
Marital Status  
Single 23 (22.3) 
Married/Living with partner 66 (64.1) 
Widowed 11 (10.7) 
Other 3 (2.9) 
Employment Status  
Employed                                52 (50.5) 
Retired 33 (32.0) 
Disabled 10 (9.7) 
Unemployed 8 (7.8) 
Residence Area  
Metropolitan 65 (63.1) 
Rural  38 (36.9) 
Insurance Coverage  
Medicare/ Medicaid/TennCare/TriCare 59 (57.3) 
Private Insurance /HMO 37 (35.9) 
None/other 7 (6.8) 
Yearly Household Income  
<=20,000 19 (18.4) 
$20,001 to $50,000 15 (14.6) 
Over $50, 000 36 (35.0) 
Do not care to respond 33 (32.0) 
Age  (Mean, Median, IQR25-75, Min, Max) 59.80,  60.22,  51.91/66.59,  33.08,  86.65 
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 Table 14 
 
 Health Behavior Characteristics   
 
Characteristics Frequency (%) (N=103) 
Special Dietary Habit  
Yes 13 (12.6) 
None 90 (87.4) 
Smoking  
Current 13 (12.6) 
Past  55 (53.4) 
      None 35 (34.0) 
Drinking Alcohol  
Current 13 (12.6) 
Past  26 (25.3) 
      None 64 (62.1) 
Characteristic      Mean         Median          Min        Max 
     Smoking (years)      27.96          30.00               5           50 
     Numbers of Cigarettes (per day)      29.63          20.00             10           70 
     Drinking Alcohol (years)      23.49          20.00               2           55 
     Times of Drinking Alcohol (per week)        5.44            4.00               2           20 
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Table 15 
Head and Neck Cancer Disease and Treatment Characteristics 
 
 
 
 
Characteristic Frequency (%) (N=103) 
Location  
Paranasal sinuses 5 (4.9) 
Oral cavity 14 (13.6) 
Nasopharynx 3 (2.9) 
Oropharynx 45 (43.7) 
Hypopharynx 4 (3.9) 
Larynx 16 (15.5) 
Salivary gland 2 (1.9) 
Other 14 (13.6) 
Tumor Staging at Diagnosis  
    Stage I 6 (5.8) 
    Stage II 9 (8.7) 
Stage III 16 (15.5) 
Stage IVa 59 (57.3) 
Stage IVb 8 (7.8) 
Could not be staged 5 (4.9) 
Type of Tumor  
Squamous cell carcinoma (SCC) 96 (93.2) 
Non-SCC 7 (6.8) 
Surgery Type  
Radical neck dissection 1 (1.7) 
Modified neck dissection 33 (56.9) 
Selective neck dissection  16 (27.6) 
Other 8 (13.8) 
Chemotherapy Type  
Taxol+Carboplatin 51(71.8) 
Cisplatin/ Taxotere/ Erbitux 10 (14.1) 
Other 10 (14.1) 
Complete Treatment Received  
    Surgery alone 8 (7.8) 
    Radiation alone 2 (1.9) 
    Concurrent Chemo-radiation (CCR) 13 (12.6) 
    Surgery and radiation 10 (9.7) 
Surgery and CCR 30 (29.1) 
    Chemo-induction and CCR 30 (29.1) 
    Surgery, chemo-induction, and CCR 10 (9.7) 
Characteristic Mean Median    IQR (25, 75) Min Max 
Total Dosage of Radiation (cGy) 6576.68 6930.00 6300.00 6930.00 3750.00 7500.00 
Prophylactic Dosage of Radiation (cGy) 5372.36 5400.00 5040.00 5610.00 4500.00 7500.00 
Number of Lymph Nodes Removed     21.19 17.00 7.00 29.25 0.00 81.00 
Number of Positive Lymph Nodes       2.05  0.00 0.00 2.00 0.00 49.00 
Head and Neck Cancer Duration (years)        2.77 2.11 0.96 3.87 0.45 14.58 
Time Since Treatment Ended (months) 27.36 19.91 6.01 39.29 3.09 156.39 
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Internal Consistency and Current Sample’s Scores on the Instruments 
The internal consistency and this sample’s scores on the instruments are 
summarized in Table 16.  
VHNSS. Higher scores are indicative of a higher symptom burden related to head 
and neck cancer and its treatment. Mean scores on each VHNSS subscale can range from 
0 (none) to 10 (a lot). In this study, the VHNSS subscale mean scores of participant 
ranged from 1.65 to 3.69. Due to the skewed nature of these distributions, the median 
values are more descriptive of the typical values. As shown, most medians were in the 
range of 0.00 to 3.00. These data suggest that most of the participants in this study had 
mild symptom burden. 
HADS. In this study actual HADS scores on the two subscales ranged from 0 to 
16 (mean=3.94, median=3.00) for anxiety and 0 to 14 (mean=3.31, median=2.00) for 
depression. The results show that most of the participants in this study had few or 
relatively slight anxiety and depressive symptoms.  
BIS. Actual BIS scores in this study ranged from 0 to 30 (mean=6.03, 
median=3.00). These results indicate most of the participants in this study had quite mild 
body image issues. 
FACT-H&N. In this study, the FACT-H&N subscale scores of participant ranged 
from 2 to 28 for physical well-being subscale (mean=23.35, median=25.00), 7 to 28 for 
social/family well-being subscale (mean=23.18, median=24.00), 1 to 24 for emotional 
well-being subscale (mean=20.26, median=22.00), 0 to 28 for functional well-being 
subscale (mean=21.22, median=22.00), 6 to 59 for head and neck cancer subscale 
(mean=43.08, median=44.50). These data indicate that most of the participants had a 
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moderate to high degree of quality of life.  
LASA. LASA was used to evaluate participants’ general and overall quality of life 
in the study. Scores on the each item of LASA can range from 0 to 10. Higher scores 
indicate a high level of quality of life. Actual mean scores in this study ranged from 7.42 
to 8.70. These results indicate most of participants in this study had a moderate to high 
degree of quality of life.   
 
 
Table 16  
 
Internal Consistency and Sample Scores on the Instruments  
 
Instrument (# items) N Mean Median IQR (25, 75) Min Max Cronbach’s  Alpha 
VHNSS (28)              .94 
Nutrition (5) 98 1.65 1.10 0.00 2.25 0.00 10.00 .69 
Pain (4) 98 1.77 0.00 0.00 3.31 0.00 8.25 .77 
Voice (2) 98 2.42 1.00 0.00 4.50 0.00 10.00 .84 
Swallow (7) 98 2.36 1.29 0.14 4.00 0.00 10.00 .92 
Mucous/Dry Mouth (6) 98 3.69 3.00 1.33 5.71 0.00 10.00 .87 
Dentition (1) 98 1.76 0.00 0.00 1.25 0.00 10.00 -- 
Hearing (1) 98 1.75 0.00 0.00 2.25 0.00 10.00 -- 
HADS         
Anxiety (7)                                        98 3.94 3.00 0.75 6.25 0.00 16.00 .88 
Depression (7)                                  98 3.31 2.00 1.00 4.25 0.00 14.00 .83 
BIS (10)                                                 97 6.03 3.00 0.00 9.50 0.00 30.00 .92 
FACT-H&N (39)         
Physical subscale (7)                       98 23.35 25.00 21.75 27.00 2.00 28.00 .83 
Social subscale (7)                           98 23.18 24.00 21.00 27.00 7.00 28.00 .73 
Emotional subscale (6)                     98 20.26 22.00 18.00 24.00 1.00 24.00 .61 
Functional subscale (7)                    98 21.22 22.00 17.00 26.00 0.00 28.00 .86 
Head/Neck Subscale (12)                98 43.08 44.50 37.00   51.25 6.00 59.00 .79 
LASA (5)                                                                                                                                        .85 
Physical item (1)                               98 7.42 8.00 6.00 10.00 2.00 10.00 -- 
Emotional item (1)                            98 7.99 9.00 6.00 10.00 2.00 10.00 -- 
Spiritual item (1)                               98 8.70 10.00 8.00 10.00 0.00 10.00 -- 
Intellectual item (1)                           98 8.36 9.00 7.00 10.00 2.00 10.00 -- 
Overall item (1)                                 98 8.46 9.00 7.00 10.00 4.00 10.00 -- 
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Findings Related to Study Aims 
 Aim 1: To examine the prevalence of external lymphedema, internal lymphedema and 
combined lymphedema in head and neck cancer patients.  
The prevalence of external lymphedema, internal lymphedema, and combined 
lymphedema are presented in Table 17. Of the participants with an endoscopy 
examination (n=81, 78.6%), 75.3% (n=61) had some form of lymphedema, i.e., internal 
lymphedema only, external lymphedema only, and combined lymphedema.  
 
 
Table 17 
 
Prevalence of Secondary Lymphedema  
 
Type of Lymphedema Frequency (%) 
      No Lymphedema 20 (24.7) 
Some Form of Lymphedema 61 (75.3) 
Total    81 (100.0) 
External Lymphedema Only 6 (9.8) 
Internal Lymphedema Only 24 (39.4) 
Combined Lymphedema 31 (50.8) 
Note: 81 participants completed both endoscopic and skin examination.  
 
The internal lymphedema data are listed in Table 18 and Table 19. Of those 
scoped participants, 67.9% (n=55) had internal lymphedema. As shown in Table 19, in 
the participants with mild internal lymphedema, the most commonly involved anatomical 
sites included the arytenoids, base of tongue, posterior pharyngeal wall, and 
pharyngoepiglottic folds. In the participants with moderate lymphedema, the most 
commonly involved sites were the interarytenoid space, valleculae, and aryepiglottic 
folds. In the participants with severe lymphedema, the most commonly involved sites 
were the pyriform sinus and the interarytenoid space.  
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Table 18 
 
Internal Lymphedema Data 
 
Endoscopic Examination  (N=81) Frequency (%) 
No Internal Lymphedema 26 (32.1) 
Mild Internal Lymphedema  19 (23.5) 
Moderate Internal Lymphedema  25 (30.9) 
Severe Internal Lymphedema 11 (13.6) 
 
 
 
Table 19 
 
Location and Extent of Internal Lymphedema  
 
Location of 
Lymphedema 
Sample 
Sizes 
(N) 
Frequency (%) 
No 
Lymphedema  
Mild  Moderate  Severe  Total  
Base of tongue  80 53 (66.3) 26 (32.5) 1 (1.3) 0 (0.0) 80 (100.00) 
Posterior pharyngeal 
wall 
81 54 (66.7) 26 (32.1) 1 (1.2) 0 (0.0) 81 (100.00) 
Epiglottis 72 35 (48.6) 22 (30.6) 12 (16.7) 3 (4.2) 72 (100.00) 
Pharyngoepiglottic folds 73 36 (49.3) 24 (32.9) 10 (13.7) 3 (4.1) 73 (100.00) 
Aryepiglottic folds 73 34 (46.6) 20 (27.4) 16 (21.9) 3 (4.1) 73 (100.00) 
Interarytenoid space 74 36 (48.6) 16 (21.6) 17 (23.0) 5 (6.8) 74 (100.00) 
Cricopharyngeal 
prominence 
69 51 (73.9) 17 (24.6) 1 (1.4) 0 (0.0) 69 (100.00) 
Arytenoids 74 32 (43.2) 26 (35.1) 14 (18.9) 2 (2.7) 74 (100.00) 
False vocal folds 74 38 (51.4) 21 (28.4) 13 (17.6) 2 (2.7) 74 (100.00) 
True vocal folds 74 58 (78.4) 9 (12.2) 7 (9.5) 0 (0.0) 74 (100.00) 
Anterior commissure 73 62 (84.9) 10 (13.7) 1 (1.4) 0 (0.0) 73 (100.00) 
Valleculae   76 41 (53.9) 17 (22.4) 17 (22.4) 1 (1.3) 76 (100.00) 
Pyriform sinus 75 42 (56.0) 16 (21.3) 10 (13.3) 7 (9.3) 75 (100.00) 
 
 
 
The external lymphedema data are listed in Table 20. In terms of Foldi’s LE scale, 
48 participants were identified to have external lymphedema. In this study, the most 
common sites of external lymphedema were neck (n=17, 35.4%) and submental area 
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(n=12, 25%). Based on the nearly identical NCI LE scale or ACS LE scale, 37 
participants were identified to have external lymphedema. Due to lack of a component of 
fibrosis in these two scales, 11 participants with fibrosis only were not captured and 
graded using the NCI LE and ACS LE scales. Due to the interchangeable degrees 
between NCI LE scale and/or ACS LE scale, the severity of lymphedema based on ACS 
LE scale was removed from further analysis. 
 
Table 20 
 
  External Lymphedema Data 
 
Lymphedema Grade 
Frequency (%) (N=103) 
NCI LE scale Foldi’s LE scale ACS LE scale 
None 66 (64.0) -- 66 (64.0) 
Grade I/Stage O 22 (21.4) 55 (53.4) 22 (21.4) 
Grade II /Stage I 12 (11.7) 21 (20.4) 12 (11.7) 
Grade III/Stage II 3 (2.9) 27 (26.2) 3 (2.9) 
Grade IV/Stage III 0 (0.0) 0 (0.0) 0 (0.0) 
Grade V 0 (0.0) -- -- 
Total 103(100.0) 103(100.0) 103 (100.0) 
NCI Lymphedema-related Fibrosis  
None  80 (77.7) 
Grade I 16 (15.5) 
Grade II 7 (6.8) 
Grade III 0 (0.0) 
Location of External Lymphedema Foldi’s LE scale 
   One site 33 (68.8) 
   Two sites 11 (22.9) 
   Three sites 4 (8.3) 
 
 
Aim 2. To examine the associations between severity of lymphedema in head and neck 
cancer patients and (a) symptoms, (b) functional status, and (c) quality of life.  
 (2a) Analyze the associations between severity of lymphedema and symptoms.  
VHNSS. The associations of the severity of lymphedema and symptom scores on 
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the VHNSS are summarized in Table 21. Statistically significant multivariate and 
univariate associations of the severity of fibrosis with reports of nutrition problems were 
found in this study (see Table 21). The multivariate association of the combined Foldi 
(combines fibrosis with external lymphedema) and Patterson indices with nutrition was 
statistically significant (R = 0.35, p = .008) with most of that association explained by the 
Foldi index (beta = 0.32, p = .007). The univariate associations demonstrated a similar 
pattern. Associations of nutrition problems with severity of internal lymphedema were 
not statistically significant.  
As shown, regardless of which set of measures was used, the combined 
associations of the severity of combined lymphedema were found to be statistically 
significant with swallowing difficulties (NCI scales and Patterson: R = 0.40, p = .011; 
Foldi and Patterson: R = 0.40, p = .001), and with mucous/dry mouth symptoms (NCI 
scales and Patterson: R = 0.40, p = .001; Foldi and Patterson: R = 0.45,  p < .001). These 
findings were consistent with the patterns of univariate associations of each of the 
measures with the different clusters of symptom scores. As severity increased on each of 
the individual measures of internal/external lymphedema and fibrosis, there were 
statistically significant associations with increasing mucous/dry mouth symptoms 
(correlations ranging from 0.32 to 0.35, p < .004). The univariate associations increasing 
severity with increasing reports of swallowing problems were not as consistent as those 
with mucous/dry mouth symptoms. The strongest associations were seen with a measure 
that combines external and fibrotic severity (Foldi: beta = 0.31, p = .002) and with 
severity of internal lymphedema (Patterson: beta = 0.31, p = .006). Nevertheless, while 
not meeting the adjusted alpha level used in this study (i.e., p < .010), the other measures 
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of lymphedema severity showed similar patterns of associations with swallowing burden.  
No statistically significant univariate or multivariate associations of severity of 
lymphedema were seen with the clusterings of pain, voice, dentition, and hearing 
symptom burden reports. The strongest associations not reaching the minimal level used 
in this study were those of the severity of internal lymphedema with reports of pain-
related symptom scores (beta = 0.24, p = .034) and with voice problems (beta = 0.29, p = 
.012).   
Table 21  
Associations between Severity of Lymphedema (LE) and VHNSS Scores 
Severity of LE 
Beta (P-value) 
Sample 
size (n) 
Nutri- 
tion Pain Voice Swallow 
Mucous 
/Dry 
mouth 
Denti- 
tion 
Hear- 
ing 
Severity of   
External LE         
  NCI LE Scale 87 0.23 (.036) 
0.11 
(.328) 
0.06 
(.601) 
0.29 
(.006) 
0.32 
(.002) 
0.05 
(.642) 
0.00 
(.989) 
  Foldi’s LE   
  Scale 98 
0.26 
(.011) 
0.05 
(.596) 
0.10 
(.342) 
0.31 
(.002) 
0.35 
(.000) 
0.13 
(.198) 
-0.05 
(.632) 
  NCI Fibrosis  
  Scale 98 
0.34 
(.001) 
0.08 
(.425) 
0.20 
(.044) 
0.28 
(.005) 
0.33 
(.001) 
0.20 
(.044) 
-0.08 
(.460) 
Severity of 
Internal LE         
 Patterson’s  
 Scale 77 
0.18 
(.126) 
0.24 
(.034) 
0.29 
(.012) 
0.31 
(.006) 
0.34 
(.003) 
0.10 
(.410) 
0.04 
(.748) 
Severity of 
Combined LE         
Multiple R  0.29 (.120) 
0.24 
(.291) 
0.24 
(.291) 
0.40 
(.011) 
0.40 
(.001) 
0.18 
(.538) 
0.11 
(.858) 
  NCI LE Scale 
70 
0.24 
(.086) 
0.11 
(.435) 
0.01 
(.962) 
0.27 
(.046) 
0.29 
(.026) 
-0.09 
(.543) 
-0.01 
(.974) 
  NCI Fibrosis  
  Scale 
0.05 
(.705) 
-0.09 
(.509) 
-0.15 
(.263) 
0.04 
(.785) 
0.02 
(.849) 
0.19 
(.184) 
-0.10 
(.457) 
  Patterson’s  
  Scale 
0.07 
(.582) 
0.20 
(.123) 
0.26 
(.047) 
0.21 
(.093) 
0.18 
(.150) 
0.06 
(.637) 
0.06 
(.663) 
Severity of 
Combined LE         
  Multiple R  0.35 (.008) 
0.24 
(.107) 
0.24 
(.107) 
0.40 
(.001) 
0.45 
(.000) 
0.10 
(.397) 
0.10 
(.682) 
  Foldi’s LE  
  Scale 78 
0.32 
(.007) 
-0.01 
(.959) 
-0.00 
(.971) 
0.28 
(.017) 
0.31 
(.005) 
0.04 
(.734) 
-0.10 
(.417) 
  Patterson’s  
  Scale 
0.07 
(.521) 
0.24 
(.044) 
0.29 
(.017) 
0.22 
(.054) 
0.24 
(.034) 
0.08 
(.505) 
0.07 
(.573) 
          Beta is highlighted if it is ≥ 0.30. 
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A secondary analysis of the patterns in the VHNSS symptom scores revealed two 
distinct clusters of patients. One group (n=62, 62%) had very low levels of any type of 
symptom scores (Low Symptom) while the other group (n=38, 38%) demonstrated 
relatively high levels of nutrition, pain, voice, swallowing and mucous/dry mouth 
symptom scores (High Symptom). Subsequently, a crosstabulation analysis of these two 
groups of patients with the measures of lymphedema and fibrosis revealed that the most 
severe levels of internal/external lymphedema, as well as of fibrosis, were 
disproportionately represented in the cluster (group) of participants with increased burden 
in the multiple symptom areas. Of the participants with at least some external 
lymphedema, 52.1% (n=25 of 48) were in the High Symptom group compared to only 
25.0% (n=13 of 52) of the patients without external lymphedema (χ2 = 7.77, p = .005). 
Within the Low Symptom group of patients, only 8.5% (5 of 59) had either a Grade 2 or 
3 level of external lymphedema using the NCI LE criteria while within the high symptom 
cluster 33.3% (10 of 30) of the patients were graded at those levels (χ2 = 9.09, p = .028). 
There were greater differences between the clusters of patients for the distributions of the 
levels of severity using the Foldi criteria (Low Symptom: 11 of 62, 17.7% Stage II; High 
Symptom: 16 of 38, 42.1% Stage II, χ2 = 9.12, p = .010). Approximately 36.8% (14 of 
38) of the patients in the High Symptom cluster group had Grade 1 or 2 fibrosis, while 
none had Grade 2 and only 14.5% (n=9) had Grade 1 in the Low Symptom group (χ2 = 
13.17, p = .001). Finally, 45.3% of the patients with some level of internal lymphedema 
(n=24 of 53) were clustered in the High Symptom group compared to only 12.0% (n=3 of 
25) of the patients without internal lymphedema (χ2 = 8.31, p = .004). Approximately 
55.6% (15 of 27) of the patients in the High Symptom cluster group had moderate to 
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severe levels of internal lymphedema, while only 37.3% (n=19 of 51) had those levels of 
internal LE severity in the Low Symptom group (χ2 = 9.95, p = .019).  
BIS & HADS. The associations of the severity of lymphedema and symptom 
scores on the BIS/HADS are summarized in Table 22. As shown, the multivariate 
association of the severity of combined lymphedema with body image-related symptoms 
was statistically significant (NCI scales and Patterson: R = 0.37, p = .024) with most of 
that association explained by the NCI Fibrosis index (beta = 0.30, p = .026). No 
statistically significant univariate associations of severity of lymphedema were seen with 
body image-related symptom reports. The strongest associations not reaching the 
minimal level of significance used in this study were those of the severity of external 
lymphedema with body image-related symptoms (NCI LE scale: beta = 0.22, p = .041; 
Foldi’s scale: beta = 0.21, p = .043; NCI Fibrosis scale: beta = 0.23, p = .021). 
Associations of body-image problems with severity of internal lymphedema were not 
statistically significant.  
No statistically significant univariate or multivariate associations of severity of 
lymphedema were seen with the HADS anxiety or depressive symptom reports. The 
strongest associations not reaching the minimal level used in this study was the severity 
of external lymphedema with anxiety subscale scores (NCI LE scale, beta = 0.26, p = 
.013).  
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Table 22 
 
Associations between Severity of Lymphedema (LE) and BIS/HADS Scores 
 
Severity of LE 
HADS- 
Anxiety 
HADS-
Depression BIS 
Sample 
size (n) Beta (P-value) Beta (P-value) 
Sample 
size (n) Beta (P-value) 
Severity of External 
LE      
NCI LE Scale 87 0.26 (.013) 0.18 (.102) 86 0.22 (.041) 
Foldi’s LE Scale 98 0.18 (.083) 0.16 (.112) 97 0.21 (.043) 
NCI Fibrosis Scale 98 0.17 (.091) 0.16 (.124) 97 0.23 (.021) 
Severity of Internal LE      
Patterson’s Scale 77 0.09 (.435) 0.17 (.143) 76 0.20 (.091) 
Severity of Both      
Multiple R  0.25 (.241) 0.25 (.238)  0.37 (.024) 
NCI LE Scale 
70 
0.22 (.126) 0.14 (.316) 
69 
0.11 (.416) 
NCI Fibrosis Scale 0.05 (.708) 0.12 (.400) 0.30 (.026) 
Patterson’s Scale 0.03 (.833) 0.08 (.538) 0.03 (.802) 
Severity of Both      
Multiple R  0.20 (.225) 0.24 (.113)  0.29 (.039) 
Foldi’s LE Scale 
78 
0.19 (.124) 0.18 (.137) 
77 
0.23 (.056) 
Patterson’s Scale 0.03 (.801) 0.11 (.354) 0.12 (.297) 
   Beta is highlighted if it is ≥ 0.30. 
 
(2b) Analyze the associations between severity of lymphedema and functional 
status.  
In this study, functional status was evaluated through hearing tests (tuning fork 
test and whispered voice test), trismus, and cervical range of motion. Functional status of 
the sample is summarized in Table 23.  
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Table 23  
 
Functional Status Data 
 
Characteristic Frequency (%) 
Whispered Voice Test (WVT)  
Pass 89 (86.4) 
Fail 13 (12.6) 
Not applicable 1 (1.0) 
Tuning Fork Test (TFT)  
Normal 73 (70.9) 
Conduction deafness (left ear) 3 (2.9) 
Conduction deafness (right ear) 2 (1.9) 
Nerve deafness (left ear) 13 (12.6) 
Nerve deafness (right ear)  11 (10.7) 
  Trismus  
None 70 (68.0) 
Grade 1 16 (15.5) 
Grade 2 14 (13.6) 
Grade 3 3 (2.9) 
Signs in Neck/Shoulder Area  
Elicited Pain 25 (24.3) 
Tenderness 32 (31.1) 
 Postural abnormalities 13 (12.6) 
     Fixed deformity 4 (3.9) 
Cervical Range of Motion                 Mean  Median  IQR (25, 75)   Min   Max (Degree) 
Forward flexion                  43.53   42.67    33.33  50.33   19.33   70.00 
Extension                  49.17   48.00    38.33  60.83   15.33   88.67 
Left lateral flexion                  32.78   32.00    23.33  41.00   13.33   58.67 
Right lateral flexion                  31.28   31.33    22.50  39.33   11.00   58.00 
Left lateral rotation                  54.64   53.33    45.00  62.67   29.33   80.67 
Right lateral rotation                  53.82   52.00    44.67  64.00   26.00   80.00 
 
 
Hearing. The associations of the severity of lymphedema with hearing test status 
are summarized in Table 24. As shown, no statistically significant univariate or 
multivariate associations of severity of lymphedema were seen with the ratings on the 
hearing tests. The strongest associations not reaching the minimal level used in this study 
were those of the severity of combined lymphedema with tuning fork test status (Foldi 
and Patterson scales: χ2 = 6.25,   p= .044), and with whispered voice test status (NCI 
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scales and Patterson scales: χ2 = 8.45,  p = .038; Foldi and Patterson scales: χ2 = 7.29,  p = 
.026).  No statistically significant univariate associations of severity of internal 
lymphedema were seen with the ratings on the hearing test. 
 
Table 24 
 
Associations of Severity of Lymphedema (LE) with Hearing Test 
 
Type of LE Sample size (n)  
Tuning Fork (Yes/No) Whispered Voice Test (Yes/No) 
O.R. P-value 
95% C.I. for 
O.R. O.R. P-value 
95% C.I. for O.R. 
Lower Upper Lower Upper 
Severity of 
External LE          
  NCI LE Scale 91 1.02 .057 1.00 1.04 0.97 .120 0.94 1.01 
  Foldi’s LE  
  Scale 102 1.01 .139 1.00 1.03 0.98 .105 0.95 1.00 
  NCI Fibrosis  
  Scale 102 1.01 .347 0.99 1.03 0.99 .663 0.97 1.02 
Severity of 
Internal LE          
  Patterson’s  
  Scale 80 1.02 .078 1.00 1.05 1.02 .167 0.99 1.05 
Severity of 
Combined LE          
Chi-square  6.07 .108   8.45 .038   
  NCI LE Scale 
71 
1.02 .106 1.00 1.05 0.96 .108 0.91 1.01 
  NCI Fibrosis  
  Scale 1.01 .755 0.97 1.04 0.69 .999 -- -- 
  Patterson’s  
  Scale 1.01 .362 0.99 1.04 1.03 .072 1.00 1.07 
Severity of 
Combined LE          
Chi-square  6.25 .044   7.29 .026   
  Foldi’s LE  
  Scale 80 
1.02 .089 1.00 1.04 0.97 .044 0.94 1.00 
  Patterson’s  
  Scale 1.02 .219 0.99 1.04 1.03 .060 1.00 1.06 
  
 
Trismus. The associations of the severity of lymphedema and trismus are 
summarized in Table 25. As shown, no statistically significant univariate or multivariate 
associations of severity of lymphedema were seen with the trismus degrees.  
 101 
 
Table 25 
 
Associations of Severity of Lymphedema (LE) with Trismus  
 
Severity of LE Sample size (n) 
Grade of Trismus 
Beta (P-value) 
Severity of External LE   
NCI LE Scale 92 -0.07 (.509) 
Foldi’s LE Scale 103 0.04 (.729) 
NCI Fibrosis Scale 103 0.15 (.130) 
Severity of Internal LE   
Patterson’s Scale 81 0.18 (.116) 
Severity of Both   
Multiple R  0.24 (.272) 
NCI LE Scale 
72 
-0.04 (.795) 
NCI Fibrosis Scale -0.11 (.414) 
Patterson’s Scale 0.23 (.064) 
Severity of Both   
Multiple R  0.18 (.291) 
Foldi’s LE Scale 
81 
0.02 (.898) 
Patterson’s Scale 0.17 (.147) 
 
 
CROM. The associations of the severity of lymphedema and neck range of motion 
degrees on the CROM are summarized in Table 26. As shown, no statistically significant 
univariate or multivariate associations of severity of lymphedema were seen with the 
CROM scores. The strongest associations not reaching the minimal level used in this 
study were those of the severity of external lymphedema with forward flexion degrees 
(NCI LE scale: beta = - 0.22, p = .041), and with left rotation degrees (NCI Fibrosis 
scale: beta = - 0.20, p = .044).   
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Table 26 
 
Associations of Severity of Lymphedema (LE) with CROM 
 
Severity of LE 
Beta (P-value) 
Sample 
size (n) Forward  Extension 
Left 
Lateral 
Right 
Lateral 
Left 
Rotation 
Right 
Rotation 
Severity of External 
LE         
NCI LE Scale 90 -0.22 (.041) 
-0.11 
(.307) 
-0.11 
(.306) 
-0.13 
(.215) 
-0.17 
(.121) 
-0.13 
(.207) 
Foldi’s LE Scale 101 -0.18 (.065) 
-0.10 
(.305) 
-0.08 
(.453) 
-0.12 
(.219) 
-0.15 
(.123) 
-0.15 
(.142) 
NCI fibrosis Scale 101 -0.19 (.058) 
-0.15 
(.126) 
-0.10 
(.318) 
-0.14 
(.172) 
-0.20 
(.044) 
-0.15 
(.135) 
Severity of Internal LE        
Patterson’s Scale 79 -0.18 (.108) 
0.01 
 (.950) 
-0.07 
(.549) 
0.00 
(.997) 
-0.02 
(.886) 
-0.20 
(.084) 
Severity of Combined 
LE         
Multiple R  0.19 (.509) 
0.13 
 (.764) 
0.13 
(.790) 
0.18 
(.552) 
0.20 
(.462) 
0.24 
(.271) 
NCI LE Scale 
72 
-0.07 
(.606) 
-0.13 
(.367) 
-0.12 
(.408) 
-0.20 
(.155) 
-0.15 
(.282) 
-0.20 
(.144) 
NCI fibrosis Scale -0.07 (.601) 
0.04 
 (.788) 
0.08 
(.562) 
0.06 
(.675) 
-0.08 
(.556) 
0.02 
(.905) 
Patterson’s Scale -0.11 (.391) 
0.10 
 (.455) 
-0.05 
(.702) 
0.06 
(.662) 
0.09 
(.456) 
-0.10 
(.451) 
Severity of Combined 
LE        
Multiple R  0.20 (.223) 
0.12 
 (.574) 
0.10 
(.708) 
0.18 
(.274) 
0.16 
(.378) 
0.24 
(.097) 
Foldi’s LE Scale 
80 
-0.08 
(.514) 
-0.13 
(.295) 
-0.07 
(.565) 
-0.19 
(.109) 
-0.17 
(.166) 
-0.15 
(.196) 
Patterson’s Scale -0.16 (.182) 
0.05  
(.706) 
-0.05 
(.693) 
0.06 
(.627) 
0.03 
(.777) 
-0.15 
(.203) 
 
 
Signs (Physical Examination). In this study, signs in the neck and shoulder area 
including elicited pain, tenderness, postural abnormalities, and fixed deformity were 
evaluated. The associations of the severity of lymphedema and signs are summarized in 
Table 27. Statistically significant univariate associations of the severity of external 
lymphedema with elicited pain status were found in this study (NCI LE scale: O.R. = 
1.04, p = .001; Foldi LE scale: O.R. = 1.03, p = .002). The multivariate association of the 
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severity of combined lymphedema with elicited pain status was statistically significant 
(Foldi and Patterson scales: χ2 = 9.36, p = .009) with most of that association explained 
by the Foldi index (O.R. = 1.03, p = .006).  
No statistically significant univariate or multivariate associations of severity of 
lymphedema were seen with tenderness, postural abnormalities, and fixed deformity. The 
strongest associations not reaching the minimal level of significance used in this study 
were those of the severity of external lymphedema with tenderness (NCI LE scale: O.R. = 
1.02, p = .017), with postural abnormalities (NCI LE scale: O.R. = 1.04, p = .015; Foldi’s 
LE scale: O.R. = 1.03, p = .015), and fixed deformity (NCI Fibrosis scale: O.R. = 1.06, p 
= .022); and those of the severity of combined lymphedema with combined lymphedema 
with postural abnormalities (Foldi and Patterson scales: χ2 = 6.47, p = .039), and with 
fixed deformity (Foldi and Patterson scales: χ2 = 8.28, p = .016). 
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Table 27 
Associations between Severity of Lymphedema (LE) and Signs in Neck and Shoulder  
Severity of LE Sample Size (n)  
Elicited Pain (Yes/No) Tenderness (Yes/No) 
O.R. P-value 
95% C.I. for 
O.R. O.R. P-value 
95% C.I. for O.R. 
Lower Upper Lower Upper 
Severity of  
External LE          
  NCI LE Scale 92 1.04 .001 1.01 1.06 1.02 .017 1.00 1.04 
  Foldi’s LE Scale 103 1.03 .002 1.01 1.05 1.01 .088 1.00 1.03 
  NCI fibrosis Scale 103 1.02 .062 1.00 1.04 1.02 .124 1.00 1.03 
Severity of  
Internal LE          
  Patterson’s Scale 81 1.01 .377 0.99 1.03 1.00 .797 0.98 1.03 
Severity of  
Combined LE          
Chi-square  10.13 .017   4.07 .254   
  NCI LE Scale 
72 
1.04 .007 1.01 1.07 1.02 .092 1.00 1.05 
  NCI fibrosis Scale 1.00 .863 0.97 1.04 1.01 .755 0.97 1.04 
  Patterson’s Scale 0.99 .465 0.96 1.02 1.00 .686 0.97 1.02 
Severity of  
Combined LE          
  Chi-square  9.36 .009   3.31 .191   
  Foldi’s LE Scale 
81 
1.03 .006 1.01 1.05 1.02 .076 1.00 1.04 
  Patterson’s Scale 1.00 .929 0.97 1.03 1.00 .746 0.97 1.02 
Severity of LE Sample size (n)  
Postural Abnormalities (Yes/No) Fixed Deformity (Yes/No) 
O.R. P-value 
95% C.I. for 
O.R. O.R. P-value 
95% C.I. for O.R. 
Lower Upper Lower Upper 
Severity of  
External LE          
NCI LE Scale 92 1.04 .015 1.01 1.07 1.10 .091 0.99 1.22 
Foldi’s LE Scale 103 1.03 .015 1.01 1.05 2.03 .995 -- -- 
NCI fibrosis Scale 103 1.02 .070 1.00 1.05 1.06 .022 1.01 1.12 
Severity of  
Internal LE          
Patterson’s Scale 81 1.01 .551 0.98 1.04 1.04 .247 0.98 1.10 
Severity of  
Combined LE          
Chi-square  6.45 .092   4.49 .213   
NCI LE Scale 
72 
1.05 .033 1.00 1.09 1.05 .356 0.95 1.16 
NCI fibrosis Scale 0.67 .999 -- -- 1.03 .369 0.97 1.10 
Patterson’s Scale 0.98 .381 0.93 1.03 1.01 .823 0.93 1.10 
Severity of  
Combined LE          
Chi-square  6.47 .039   8.28 .016   
Foldi’s LE Scale 
81 
1.04 .026 1.00 1.07 2.00 .995 -- -- 
Patterson’s Scale 1.00 .789 0.96 1.03 1.01 .715 0.94 1.09 
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(2b) Analyze the associations between severity of lymphedema and quality of life.  
FACT-H&N. The associations of the severity of lymphedema and quality of life 
scores on the FACT-H&N are summarized in Table 28. Statistically significant 
multivariate associations of the severity of combined lymphedema with functional 
subscale scores (NCI scales and Patterson: R = 0.35, p = .036; Foldi and Patterson scales: 
R = 0.36, p = .006), with head and neck cancer subscale scores (NCI scales and Patterson 
scale: R = 0.41, p = .008; Foldi and Patterson scales: R = 0.41, p = .001), with FACT-G 
subscale scores (NCI scales and Patterson scale: R = 0.35, p = .037; Foldi and Patterson 
scales: R = 0.30, p = .028), and with FACT-H&N total scores (NCI scales and Patterson 
scale: R = 0.42, p = .006; Foldi and Patterson scales: R = 0.39, p = .002). These findings 
were consistent with the patterns of univariate associations of the severity of external 
lymphedema with head and neck cancer subscale scores (NCI LE scale: beta = - 0.33, p = 
.002; Foldi’s LE scale: beta = - 0.30, p = .003) and with FACT-H&N total scores (NCI 
LE scale: beta = - 0.32, p = .002). Moreover, the severity of internal lymphedema was 
statistically significantly associated with head and neck cancer subscale scores (beta =  
- 0.33, p = .004).  
No statistically significant univariate or multivariate associations of severity of 
lymphedema were seen with the physical, social/family, and emotional subscale scores. 
The strongest associations not reaching the minimal level used in this study were those of 
the severity of external lymphedema with the physical subscale scores (NCI Fibrosis 
scale: beta = - 0.24, p = .020) and with emotional subscale scores (NCI LE scale: beta =  
- 0.23, p = .036).  
Moreover, no statistically significant univariate associations of severity of 
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external lymphedema were seen with the functional and FACT-G subscale scores. The 
strongest associations not reaching the minimal level used in this study were those of the 
severity of external lymphedema with functional subscale scores (NCI LE scale: beta =  
-0.28, p = .009; Foldi’s LE scale: beta = - 0.28, p = .005; NCI Fibrosis scale: beta =  
- 0.23, p = .025) and with FACT-G subscale scores (NCI LE scale: beta = - 0.25, p = 
.018; Foldi’s LE scale: beta = - 0.20, p = .050; NCI Fibrosis scale: beta = - 0.21, p = 
.035).  
In addition, no statistically significant univariate associations of severity of 
internal lymphedema were seen with the physical, social/family, emotional, functional, 
FACT-G, and FACT-H&N total scores. The strongest association not reaching the 
minimal level used in this study was the severity of internal lymphedema with the FACT-
H&N total scores (beta = - 0.27, p = .017).  
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Table 28 
 
 Associations of Severity of Lymphedema (LE) and FACT-H&N  
 
Severity of LE 
Beta (P-value) 
Sample 
size (n) 
Physical 
subscale 
Social 
subscale 
Emotional 
subscale 
Function
al 
subscale 
Head 
/Neck 
Cancer 
subscale 
FACT-
G 
FACT-
HN 
Severity of 
External LE         
 NCI LE Scale 87 -0.16 (.151) 
0.04 
(.734) 
-0.23 
 (.036) 
-0.28 
(.009) 
-0.33 
(.002) 
-0.25 
(.018) 
-0.32 
(.002) 
 Foldi’s LE  
 Scale 98 
-0.15 
(.129) 
0.03 
(.782) 
-0.12 
 (.239) 
-0.28 
 (.005) 
-0.30 
(.003) 
-0.20 
(.050) 
-0.28 
(.006) 
  NCI fibrosis   
  Scale  98 
-0.24 
(.020) 
-0.06 
(.584) 
-0.09 
 (.355) 
-0.23 
(.025) 
-0.29 
(.003) 
-0.21 
(.035) 
-0.28 
(.005) 
Severity of   
Internal LE         
       Patterson’s  
       Scale 77 
-0.10 
(.376) 
-0.18 
(.118) 
-0.08 
 (.493) 
-0.21 
(.071) 
-0.33 
(.004) 
-0.22 
(.054) 
-0.27 
(.017) 
Severity of 
Combined LE         
 Multiple R  0.23 (.340) 
0.29 
(.126) 
0.21  
(.398) 
0.35 
(.036) 
0.41 
(.008) 
0.35 
(.037) 
0.42 
(.006) 
 NCI LE Scale 
70 
-0.14 
(.313) 
0.16 
(.245) 
-0.16  
(.268) 
-0.23 
(0.93) 
-0.25 
(.062) 
-0.15 
(.257) 
-0.24 
(.070) 
 NCI fibrosis    
 Scale 
-0.13 
(.339) 
-0.25 
(.069) 
-0.10 
 (.471) 
-0.17 
(.190) 
-0.07 
(.602) 
-0.23 
(.088) 
-0.20 
(.127) 
 Patterson’s  
 Scale 
0.03 
(.845) 
-0.18 
(.168) 
0.03 
 (.832) 
-0.03 
(.807) 
-0.22 
(.073) 
-0.07 
(.580) 
-0.11 
(.358) 
Severity of 
Combined LE         
 Multiple R  0.21 (.176) 
0.19 
(.260) 
0.15 
 (.427) 
0.36 
(.006) 
0.41 
 (.001) 
0.30 
(.028) 
0.39 
(.002) 
Foldi’s LE  
 Scale 78 
-0.20 
(.101) 
0.06 
(.611) 
-0.14 
 (.268) 
-0.31 
(.008) 
-0.26 
 (.021) 
-0.22 
(.065) 
-0.29 
(.010) 
 Patterson’s  
  Scale 
-0.04 
(.748) 
-0.20 
(.102) 
-0.04 
 (.768) 
-0.11 
(.352) 
-0.24 
(.033) 
-0.15 
(.201) 
-0.18 
(.120) 
   Beta is highlighted if it is ≥ 0.30. 
 
LASA. The associations of the severity of lymphedema and quality of life scores 
on the LASA are summarized in Table 29. Statistically significant multivariate 
associations of the severity of combined lymphedema with the overall well-being scores 
were found in this study (NCI scales and Patterson scale: R = 0.40, p = .010; Foldi and 
Patterson scales: R = 0.31, p = .027). The univariate association demonstrated that the 
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severity of external fibrosis was statistically significantly associated with the physical 
well-being scores (NCI fibrosis scale: beta = - 0.31, p = .002).  
No statistically significant univariate or multivariate associations of severity of 
lymphedema were seen with the emotional well-being, spiritual well-being, and 
intellectual well-being scores. The associations of each domain score of LASA with 
severity of internal lymphedema were not statistically significant.  
 
Table 29 
 
 Associations between Severity of Lymphedema (LE) and LASA  
Beta is highlighted if it is ≥ 0.30. 
 
Severity of 
LE 
Beta (P-value) 
Sample 
size (n) 
Physical  
well-being 
Emotional  
well-being 
Spiritual  
well-being 
Intellectual 
well-being  
Overall  
well-being 
Severity of  
External LE       
  NCI LE     
  Scale 87 -0.16 (.148) -0.14 (.200) -0.17 (.114) -0.12 (.279) -0.25 (.021) 
  Foldi’s LE  
  Scale 98 -0.18 (.071) -0.08 (.430) -0.17 (.091) -0.08 (.435) -0.19 (.056) 
  NCI fibrosis  
  Scale 98 -0.31 (.002) -0.13 (.198) -0.18 (.084) -0.07 (.525) -0.21 (.042) 
Severity of  
Internal LE       
   Patterson’s  
  Scale 77 -0.12 (.294) -0.08 (.508) -0.08 (.458) -0.04 (.760) -0.18 (.116) 
Severity of 
Combined LE       
Multiple R  0.33 (.055) 0.18 (.561) 0.12 (.818) 0.17 (.602) 0.40 (.010) 
   NCI LE   
   Scale 
70 
-0.06 (.652) -0.07 (.633) -0.04 (.761) -0.16 (.250) -0.21 (.114) 
   NCI fibrosis  
   Scale -0.28 (.038) -0.13 (.355) -0.07 (.632) 0.15 (.275) -0.20 (.125) 
   Patterson’s  
   Scale -0.07 (.602) -0.02 (.860) -0.05 (.697) -0.01 (.936) -0.12 (.315) 
Severity of 
Combined LE       
Multiple R  0.27 (.064) 0.13 (.510) 0.16 (.368) 0.10 (.710) 0.31 (.027) 
  Foldi’s LE  
   Scale 78 
-0.25 (.036) -0.12 (.341) -0.15 (.220) -0.09 (.443) -0.26 (.029) 
  Patterson’s 
   Scale -0.04 (.734) -0.04 (.747) -0.03 (.787) -0.01 (.966) -0.10 (.408) 
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Aim 3. To examine the possible factors contributing to the development of secondary 
lymphedema in head and neck cancer patients.  
In this study, the type of lymphedema included any lymphedema (yes/no) and 
combined lymphedema (yes/no). Thus, factors were examined to identify whether or not 
they were associated with presence of any lymphedema or combined lymphedema.  
 (a) Factors Associated with Any Lymphedema 
Associations of possible risk factors included in this study with the occurrence of 
lymphedema are summarized in Table 30. Factors with statistically significant 
associations with whether or not individuals had any lymphedema included whether or 
not the patient had radiotherapy (O.R. = 38.23, p = .001), had CCR therapy (O.R. = 5.07, 
p = .004), and the total amount of head and neck cancer treatment received (O.R. = 1.03, 
p = .006).  
No other factors included in this study were identified to be statistically 
significantly associated with the occurrence of any lymphedema. The strongest 
associations not reaching the minimal level used in this study were gender (O.R. = 2.86, p 
= .048), area of residence (O.R. = 3.20, p =.026), location of tumor (O.R. = 1.03, p = 
.013), surgery therapy (O.R. = 0.30, p = .045), and chemo-induction therapy (O.R = 4.29, 
p = .030).  
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Table 30 
Logistic Regression of Possible Factors on Any Lymphedema  
 
 
 
 
Factors 
Sample 
size  
(N) 
O.R. P-value 
95% C.I. for O.R. 
Lower Upper 
Age 92 0.99 .260 0.97 1.01 
Gender  92 2.86 .048 1.01 8.11 
Race  92 -- .999 -- -- 
Education 92 1.00 .805 0.99 1.02 
Marital status 89 0.75 .627 0.24 2.36 
Employment Status 92 0.63 .370 0.23 1.73 
Residence Area 92 3.20 .026 1.15 8.89 
Smoking (Yes/No) 92 1.42 .501 0.51 3.95 
Drinking Alcohol (Yes/No) 92 1.49 .451 0.53 4.16 
Dietary Habit 92 0.57 .399 0.16 2.10 
Inflammatory Disease 92 0.53 .483 0.09 3.12 
Hypertension 92 0.60 .316 0.22 1.63 
Diabetes Mellitus 92 2.38 .428 0.28 20.21 
BMI 82 1.02 .126 1.00 1.04 
Stages of Tumor 88 1.02 .074 1.00 1.04 
Locations of Tumor 92 1.03 .013 1.01 1.05 
Squamous Cell Carcinoma 
(Yes/No) 92 2.56 .324 0.40 16.46 
Radiation (Yes/No) 92 38.23 .001 4.33 337.23 
Surgery (Yes/No) 92 0.30 .045 0.09 0.97 
CCR (Yes/No) 92 5.07 .004 1.68 15.32 
Chemo-Induction (Yes/No) 92 4.29 .030 1.15 15.93 
Total Treatment Received 92 1.03 .006 1.01 1.05 
Total Dosage of Radiation 
(Low/High) 66 3.35 .107 0.77 14.55 
Days of Radiation 76 1.01 .309 0.99 1.04 
Neck Dissection 
(Unilateral/Bilateral) 55 1.48 .405 0.59 3.74 
Number of Lymph Nodes Removed 55 1.00 .907 0.97 1.04 
Number of Positive Lymph Nodes  55 1.02 .340 0.98 1.07 
Number of Cycles (CCR ) 60 0.98 .349 0.95 1.02 
Number of Cycles (Chemo-
Induction) 33 0.97 .616 0.87 1.09 
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(b)Factors Associated with Combined Lymphedema 
Associations of possible risk factors included in this study with the occurrence of 
combined internal and external lymphedema are summarized in Table 31. Factors found 
to be significantly associated with whether or not individuals had combined lymphedema 
included dosage of radiotherapy (O.R. = 16.25, p = .010), chemo-induction therapy (O.R. 
= 3.78, p = .007), and total head and neck cancer treatment received (O.R. = 1.04, p = 
.010).  No other factors included in this study were found to be statistically significantly 
associated with the occurrence of both internal and external lymphedema. The strongest 
associations not reaching the minimal level used in this study were days of radiotherapy 
(O.R. = 1.03, p = .017) and whether or not the patient received CCR therapy (O.R. = 6.82, 
p = .015).  
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Table 31 
 
Logistic Regression of Possible Factors on Combined Lymphedema 
 
           
                
 
Factors 
Sample 
size 
(N) O.R. P-value 
95% C.I. for O.R. 
Lower Upper 
Age 81 0.99 .185 0.98 1.01 
Gender  81 1.23 .684 0.45 3.37 
Race  81 1.22 .679 0.48 3.09 
Education 81 1.00 .711 0.99 1.02 
Marital status 78 1.03 .951 0.40 2.65 
Employment Status 81 1.12 .804 0.46 2.75 
Residence Area 81 1.32 .560 0.52 3.32 
Smoking (Yes/No) 81 1.26 .642 0.48 3.33 
Drinking Alcohol (Yes/No) 81 0.87 .770 0.35 2.18 
Dietary Habit 81 1.01 .988 0.30 3.42 
Inflammatory Disease 81 1.08 .935 0.17 6.86 
Hypertension 81 0.65 .353 0.26 1.62 
Diabetes Mellitus 81 1.70 .476 0.39 7.37 
BMI 71 1.01 .428 0.99 1.03 
Stages of Tumor 77 1.02 .123 1.00 1.04 
Locations of Tumor 81 1.01 .112 1.00 1.03 
Squamous Cell Carcinoma (Yes/No) 81 -- .999 -- -- 
Radiation (Yes/No) 81 -- .999 -- -- 
Surgery (Yes/No) 81 0.68 .413 .27 1.70 
CCR (Yes/No) 81 6.82 .015 1.45 32.19 
Chemo-Induction (Yes/No) 81 3.78 .007 1.43 9.99 
Total Treatment Received 81 1.04 .010 1.01 1.07 
Total Dosage of Radiation (Low/High) 59 16.25 .010 1.96 135.01 
Days of Radiation 67 1.03 .017 1.01 1.05 
Neck Dissection (Unilateral/Bilateral) 49 1.07 .940 0.18 6.54 
Number of Lymph Nodes Removed 43 0.98 .284 0.94 1.02 
Number of Positive Lymph Nodes  49 0.99 .640 0.95 1.03 
Number of Cycles (CCR ) 51 1.00 .928 0.97 1.03 
Number of Cycles (Chemo-Induction) 26 1.00 .939 0.92 1.08 
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CHAPTER V 
 
DISCUSSION 
 
This chapter presents a summary and discussion of the study findings in the 
following five sections: (a) sample characteristics, (b) aims, (c) study strengths and 
limitations, (d) implications, and (e) recommendations for future research. 
 
Sample Characteristics 
The study recruited the head and neck cancer patients who had completed their 
cancer treatment ≥ 3 months prior to study entry. The characteristics of the sample in this 
study were similar to those of previous studies reported in the literature. The mean age of 
59.8 years in this study was very close to the 60.0 years mean age in Graeff et al.’s 
(2000) study, and similar to the 59.0 years mean age in Terrell et al.’s (2004) study and 
the 58.8 years mean age in Murphy et al.’s (2009) study. Of the 103 participants, 68.9% 
were male and 31.1% were female, which was similar to two recent studies (El-Deiry, 
Futran, McDowell, Weymuller, & Yueh, 2009; Gourin, Boyce, Vaught, Burkhead, & 
Podolsky, 2009). More males than females are diagnosed with head and neck cancer 
(Itano & Taoka, 2005; NCI, 2010), as reflected in this study. The majority of the study 
participants (64.1%) were married or living with partners, which was correspondingly the 
case in Terrell et al.’s (2004) study. The employment distribution in this study showed 
that 50.5% were employed and 49.5% described themselves as currently not employed 
(including retired, disabled, and unemployed), which was similar to Taylor et al.’s (2004) 
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study. Regarding area of residence, 63.1% (n=65) of the participants lived in 
Metropolitan areas, while the remaining lived in rural areas 36.9% (n=38), which almost 
mirrored the data of geographical statistics (U.S. Census Bureau, 2000) that 63.6% of the 
population in Tennessee live in Metropolitan areas. More than half of all participants had 
insurance through government program (including Medicare, Medicaid, TennCare, and 
TriCare), which closely matched Gourin & Podolsky’s (2006) study. The 35.0% of the 
sample with more than $50,000 income annually was lower than geographical statistics 
(U. S. Census Bureau, 2006-2008) that show 43.9% of the population in Tennessee with 
an annual income of over $50,000. Nevertheless, 32% of the sample did not care to 
respond their annual income, which may influence the actual income distributions in the 
study sample. 
Race distribution showed that 89.3% were White and only 10.7% Black, which 
was similar to several reports (Taylor et al., 2004; Terrell et al., 2004). However, this race 
ratio of minority to non-minority participants was higher than Gourin et al.’s (2009) study 
(White 73% and Black 27%), and geographical statistics (U.S. Census Bureau, 2006-
2008) (White 79.3% and Black 16.5% in Tennessee). This indicates that Black and other 
minority (e.g., Asians) patients were underrepresented in the current sample. This is of 
concern as, although Whites currently have the highest incidence rates of head and neck 
cancer, mortality is still highest in Black patients (NCI, 2010). Moreover, Black patients 
are reported to have a higher incidence of advanced head and neck cancer (Gourin & 
Podolsky, 2006). Therefore, efforts to improve Black and other minority population 
involvement in future studies are critical as improved representation will assist in 
developing a greater understanding of the impact of lymphedema on the Black and other 
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minority population after head and neck cancer treatment. In this study, 89.3% of 
participants were high school graduates or higher. This education level is higher than 
geographical statistics (U.S. Census Bureau, 2006-2008) that reveal 81.8% of the 
population in Tennessee has an equivalent education level.  
Health behaviors regarding cigarette smoking and alcohol consumption rates were 
similar to Hapner & Wise’s (2010) study. However, the cigarette smoking rate (current) 
in this study was lower than Shuman et al.’s (2010) study, but the alcohol consumption 
rate (current) was close to Shuman et al.’s (2010) study. The rates of alcohol 
consumption (current and past) were lower than the data from the Center for Disease 
Control and Prevention for the general population (CDC, 2009) raising concerns about 
the accuracy of self-report alcohol assumptions in the study sample. 
The primary characteristics for head and neck cancer disease and treatment were 
similar to those reported in the head and neck cancer treatment-related literature (Murphy 
et al., 2009; Shuman et al., 2010; Weber, Dommerich, Pau, & Kramp, 2010). That is, the 
most common primary tumor sites of the participants were oropharynx and larynx; the 
majority of the participants had advanced stage of tumors at the time of diagnosis of head 
and neck cancer; the histological type of most participants’ tumors was squamous cell 
carcinoma; and the majority of the participants received at least two modalities of cancer 
treatment.  
 
Aims  
Aim 1. To examine the prevalence of external lymphedema, internal lymphedema and 
combined lymphedema in head and neck cancer patients.  
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This is the first reported study to examine the prevalence of secondary 
lymphedema in head and neck cancer patients in the United States. The study identified 
that 75.3% of the participants had some form of lymphedema, including 9.8% with 
external lymphedema only, 39.4% with internal lymphedema only, and 50.8% with 
combined lymphedema. This rate is substantially higher than rates reported in other 
studies done in other parts of the world. Four European studies reported the prevalence of 
secondary lymphedema after head and neck cancer treatment (Buntzel et al., 2007; Dietz 
et al., 1998; Schiefke et al., 2009; Wolff et al., 2009). The first study (Dietz et al., 1998) 
reported 54% of the participants developed laryngeal lymphedema after CCR treatment 
but did not mention external lymphedema. The second study (Buntzel et al., 2007) 
reported 48.4% of participants developed submental or supraglottal lymphedema after 
head and neck cancer treatment. However, the study did not report the detailed 
occurrence rates, i.e., external lymphedema only, internal lymphedema only, and 
combined lymphedema. The third study (Schiefke et al., 2009) found that 17%-36% of 
the participants had external lymphedema after surgery treatment but they did not 
examine whether or not they developed internal lymphedema simultaneously. The last 
study (Wolff et al., 2009) reported that 12% of the patients developed subcutaneous 
lymphedema and fibrosis after head and neck cancer as identified through magnifying 
laryngoscopy examination. Use of different instruments may have contributed to the 
different findings. However, none of these studies clearly reported findings of internal 
and external lymphedema at the same time. This dissertation study is the largest study to 
date to conduct detailed assessments of both internal and external lymphedema in head 
and neck cancer patients ≥ 3 months post-treatment and to report external, internal, and 
 117 
 
combined lymphedema occurrence rates in this population.  
It is important to note that the variation in prevalence of secondary lymphedema 
in head and neck cancer patients in the literature may also reflect differences in  the 
choice of grading criteria, variations in the structures assessed for manifestations of 
lymphedema (e.g., internal vs. external), differences in the duration of follow-up (Bruns, 
Micke, & Bremer, 2003), and different cancer treatment regimens among the studies. 
Therefore, more studies, especially longitudinal studies using standardized grading 
criteria, are necessary to identify the prevalence and clinical characteristics of secondary 
lymphedema in head and neck cancer patients.  
This study found that 13.6% (n=11 of 81)of the participants had severe internal 
lymphedema and the most commonly involved sites were the pyriform sinus and 
interarytenoid space. Both are important anatomical sites in the pharynx and larynx, 
respectively. Unfortunately, no literature addressing lymphedema in these anatomical 
sites is available for review. This finding suggests that more studies are needed to 
examine the sites of internal lymphedema and the potential impact on symptoms and 
function. Additionally, clinicians need to examine these sites when they conduct 
endoscopy examinations. Findings that the most commonly involved anatomical sites for 
external lymphedema were the submental and neck areas were consistent with literature 
reports (Buntzel et al., 2007; Hammond, 2007; Zimmermann et al., 2005). In addition, the 
participants with fibrosis only (n=11) were not identified by using the NCI LE and ACS 
LE scales. This indicates that developing a standardized measurement tool for external 
lymphedema is important to future research.  
Aim 2. To examine the associations between severity of lymphedema in head and neck 
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cancer patients and (a) symptoms (physical and psychological), (b) functional status, and 
(c) quality of life. 
Associations between Severity of Lymphedema and Symptoms  
 Nutrition-related symptoms. Nutrition status is particularly important for head and 
neck cancer patients (Oates et al., 2008). Literature supports that malnutrition increases 
head and neck cancer patients’ risk of morbidity (van Bokhorst-de van der Schueren et 
al., 1997) and mortality (Jager-Wittenaar et al., 2007).  However, nutrition-related 
symptoms are not well addressed in head and neck cancer patients (Eisele, Koch, Tarazi, 
& Jones, 1991; Jager-Wittenaar et al., 2007; Oates et al., 2008). This indicates that other 
unknown factors may influence patients’ nutrition status. This study found that severity 
of external lymphedema (fibrosis) and combined lymphedema was statistically 
significantly associated with nutrition-related symptoms. This is the first study to report 
that individuals with more severe external lymphedema (fibrosis) or more severe 
combined lymphedema were more likely to have nutrition-related symptoms.  
In order to understand this association, it is critical to understand how 
lymphedema may be related to both losing weight and appetite, which were two major 
components of nutrition-related symptoms in this study. Lymphedema may contribute to 
nutrition-related symptoms through two possible mechanisms. One may be related to 
architectural factors. Lymphedema-related swelling or fibrosis may compromise key 
anatomical sites, such as external structures (e.g., facial or neck muscles) and/or internal 
structures (e.g., oral cavity or pharynx). These key anatomical sites are involved in the 
critical swallowing process (Eisele, et al., 1991; Murphy & Gilbert, 2009). Studies 
conducted in breast cancer patients with secondary lymphedema found that lymphedema 
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does cause limb skin architectural changes (Lymphoedema Framework, 2006; Rockson, 
2009). Thus, it is possible that head and neck cancer patients may have architectural 
changes in the critical anatomical sites that affect swallowing. Well designed, 
longitudinal, swallowing and symptom studies are needed to explore the possible 
relationship between lymphedema and nutrition symptoms and to examine whether head 
and neck cancer patients with lymphedema have architectural changes in these key 
anatomical sites. 
Many studies have found that lymphedema is a chronic inflammatory process 
which produces inflammatory mediators in the interstitial space such as cytokines and 
chemokines (Nakamura, Radhakrishnan, Wong, & Rockson, 2009; Tabibiazar et al., 
2006). It is possible that these inflammatory mediators may enter the bloodstream 
through the lymphatic system and be taken to the whole body through the circulation 
system. These inflammatory mediators may trigger systemic inflammatory responses and 
symptoms (e.g., decreased appetite) as well as cause digestive system dysfunction (e.g., 
influencing the process of absorption). Mechanisms regarding the possible relationships 
among lymphedema, inflammation, and nutrition status warrant future study. However, 
pending such studies, healthcare professionals still may wish to examine whether or not 
head and neck cancer patients develop lymphedema, determine its severity, and evaluate 
if patients with lymphedema have nutrition problems after their head and neck cancer 
treatment. If problems are found, referral of such patients to lymphedema therapy could 
be beneficial. 
Swallowing-related symptoms. This study found the severity of lymphedema 
(external only or combined lymphedema) was statistically significantly correlated with 
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self-reported swallowing symptoms. This finding is consistent with the reports from three 
previous studies with small sample sizes (N=11-26) (Eisbruch et al., 2004; Machtay et al., 
2004; Piso et al., 2001). Eisbruch et al. (2004) reported laryngeal lymphedema and 
fibrosis, as a side effect of radiotherapy and chemotherapy, impaired swallowing function 
based on a direct endoscopy examination. The two other studies reported that head and 
neck cancer patients with external lymphedema had subjective swallowing difficulty. 
None of them have examined whether or not patients developed combined lymphedema 
and its association with swallowing-related symptoms. This dissertation study examined 
external, as well as internal, lymphedema, and found that combined lymphedema was 
related to swallowing problems, although the exact mechanisms require investigation.  
In order to interpret the associations between severity of lymphedema and 
swallowing issues, it is important to understand the normal swallowing mechanism. The 
process of swallowing is a complex and precise coordination that involves muscles and 
structures in the oral cavity, pharynx, larynx, and esophagus (Manikantan et al., 2009; 
Murphy & Gilbert, 2009). Any compromise of these muscles and structures could cause 
swallowing dysfunction. From this standpoint, it seems logical and explicable that 
lymphedema (external and/or internal) may impede the swallowing process.  
In patients with external lymphedema, swelling or fibrosis of the soft tissues in 
the neck area may interrupt the precise coordination of the muscles and nerves that are 
involved in the swallowing process. Lymphedema-related swelling or fibrosis of soft 
tissues in the neck area may increase pressure on the pharynx and larynx anatomical 
structures that may interfere with and restrict the swallowing process. Neck soft tissue 
fibrosis may also impair laryngeal elevation and lead to poor pharyngeal clearance 
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(Eisele et al., 1991) which affects the swallowing reflex. In patients with internal 
lymphedema, swelling or fibrosis of anatomical structures in the base of tongue, pharynx, 
and larynx may affect swallowing process and swallowing reflex through the following 
several aspects: (1) the swelling or fibrosis may make it difficult for food to pass through 
these critical sites from the oral cavity to the esophagus; and (2) the swelling or fibrosis 
may interrupt the precise coordination of the swallowing reflex, such as inadequate 
closure of the larynx, limited contraction of the pharyngeal constrictors, limited laryngeal 
elevation, and delayed relaxation of the cricopharyngeus that affect  passing of the food 
bolus into the esophagus. Late-effect lymphedema may also damage neural structures that 
regulate the swallowing process (Murphy & Gilbert, 2009). Although these potential 
explanations regarding the relationship of lymphedema with swallowing were 
extrapolated from swallowing mechanisms, they need to be confirmed in future studies. 
Nevertheless, this finding indicates that it is critical for healthcare professionals to 
examine whether patients have lymphedema externally and internally, especially those 
with swallowing problems. 
Mucous/Dry mouth (xerostomia)-related symptoms. One of the notable findings in 
this study is that severity of the lymphedema (external only, internal only, or combined 
lymphedema) was statistically significantly associated with mucous and/or dry mouth-
related symptoms. In other words, head and neck cancer patients with more severe 
lymphedema had more mucous and/or dry mouth-related symptoms. This finding is 
unexpected and no literature is available for interpreting this association. 
Studies have reported that inflammation causes secretions of copious mucous 
during cancer treatment (Mallick & Waldron, 2009). However, the issue of copious 
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mucous months after head and neck cancer treatment is not fully understood (Murphy et 
al., 2009). Mucous can accumulate in the airways, which causes patients’ discomfort and 
a sensation of airway obstruction. The copious mucous causes patients’ choking, gagging, 
and sometimes influences sleeping. Some patients have to deal with self-management of 
copious secretions in their daily lives after their head and neck cancer treatment. Thus, 
addressing copious mucous is an important issue for head and neck cancer patients. This 
is the first study to report the association between severity of lymphedema and mucous-
related symptoms. Although this finding is unexpected, it may provide an insight to a 
better understanding of the mucous issue in the  head and neck cancer population. Two 
theoretical explanations are proposed. One is that lymphedema (swelling or fibrosis) 
could build up pressure on patients’ paranasal sinuses, which may obstruct the nasal 
passage, interrupt nasal discharge, lead to mucous accumulated in sinuses and later result 
in copious mucous symptoms. Second, some patients with severe internal lymphedema 
may have mucous accumulated in their oral cavity or throat due to severe swallowing 
dysfunction. In addition, lymphedema is a chronic inflammatory process and it may 
produce rich inflammatory mediators that trigger an ongoing secretion of mucous. 
However, all these possible explanations are only speculative and need to be examined in 
future longitudinal studies. 
 Studies have found that cancer treatment (especially radiotherapy) affects the 
salivary gland function, causing dry mouth symptoms (xerostomia) (Dirix, Nuyts, Vander 
Poorten, Delaere, & Van den Bogaert, 2008; Itano & Taoka, 2005; NCI, 2010). In recent 
years, intensity-modulated radiotherapy (IMRT) has rapidly been used in the 
management of head and neck cancer, which decreases dry mouth incidence (Eisbruch, 
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2007) through sparing the parotid salivary glands. However, a certain number of head 
and neck cancer patients still develop dry mouth symptoms after their cancer treatment. 
This study found that patients with more severe lymphedema have more severe dry 
mouth-related symptoms. Lymphedema, as a chronic inflammatory process, may impact 
salivary production through inflammatory mediators or facial lymphedema (swelling or 
fibrosis) may cause salivary ductal obstruction. Nonetheless, these explanations need to 
be explored in future research.    
Other symptoms. This study did not find significant associations between severity 
of lymphedema with self-reported pain or with voice-related symptoms. These findings 
are somewhat inconsistent with the current literature. Regarding self-reported pain, one 
study found that head and neck cancer patients with external lymphedema had self-
reported pain in the submandibular region, but the study only recruited 11 participants 
within 30 days after surgery (Piso et al., 2001). Furthermore, multiple studies conducted 
in breast cancer patients with secondary lymphedema have demonstrated that 
lymphedema patients may have altered sensation-related symptoms, such as tightness, 
tingling, and numbness in the affected skin area (Ridner, 2005). Additionally, in the PI’s 
previous observation study (data unpublished) similar altered sensation-related symptoms 
in head and neck cancer patients with secondary lymphedema were noted.  However, 
these symptoms were not captured in this study by the instruments used. This indicates 
that development of a lymphedema specific symptom instrument is needed. 
Voice-related symptoms were reported in one study of 16 head and neck cancer 
patients with internal pharyngeal edema who had voice dysfunction (Machtay et al., 
2004).  Assessment of the impact of lymphedema on voice in future studies is needed 
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given these mixed findings.  
The secondary analysis of the patterns in the VHNSS symptom scores revealed 
two distinct clusters of the study sample, i.e., one group with low symptom scores and a 
second group with high symptom scores. The high symptom group was likely to have 
more severe lymphedema. This finding further supported that the severity of lymphedema 
was significantly associated with symptomatology in head and neck cancer patients. This 
indicates that clinicians need to examine lymphedema and its severity in head and neck 
cancer patients to determine symptom burden. 
Body image-related symptoms. This is the first published study to examine the 
association between severity of lymphedema and body image-related symptoms in head 
and neck cancer patients. The finding of a significant relationship with primary 
contributing factor being fibrosis was not surprising as body image issues have been 
frequently reported in breast cancer patients with secondary lymphedema (Jager et al., 
2006; Morgan et al., 2005; Ridner, 2005; Speck et al., 2010). This study found that head 
and neck cancer patients developed external lymphedema in their face, neck, submental 
area, and around the eyes. All these anatomical sites are highly visible and directly 
contribute to one’s self image. It is possible that lymphedema may result in a major 
alteration in body image because of highly visible skin color and/or texture changes 
(swelling or fibrosis) in the head and neck area. External lymphedema may cause facial 
disfiguration and distress in head and neck cancer patients (Murphy et al., 2007a; Ridner, 
2008; Smith & Lewin, 2010). Body image issues related to external lymphedema are 
highly important in head and neck cancer patients, as such concerns may contribute to 
self consciousness and increase the risk of social isolation. As a result, it is essential for 
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healthcare professionals to detect external lymphedema early and refer patients to 
appropriate lymphedema management in an attempt to reduce the degree of visible 
swelling/fibrosis. 
The lack of a statistically significant correlation between severity of lymphedema 
and anxiety was unexpected. Although no studies are available for comparison regarding 
these relationships in head and neck cancer patients, studies conducted in breast cancer 
patients found that patients with more severe lymphedema had more anxiety (Heppner et 
al., 2009; Meeske et al., 2009). Another interesting finding in this study is that patients 
with more severe lymphedema did not report more depressive symptoms. This finding 
was consistent with at least one study conducted in breast cancer patients with secondary 
lymphedema (Ridner, 2009). Small sample size may have contributed to this negative 
finding. 
Associations between Severity of Lymphedema and Functional Status 
Hearing. In head and neck cancer patients, hearing impairment includes 
conductive and sensorineural hearing loss due to cancer treatment (Hitchcock, Tward, 
Szabo, Bentz, & Shrieve, 2009; Person, Meyer, Adams, & Ondrey, 2006). This is the first 
published study to evaluate the relationship between severity of lymphedema and hearing 
impairment in head and neck cancer patients with lymphedema. We assessed hearing in 
this study based on the theoretical assumptions that (1) lymphedema (swelling) in 
pharynx and larynx may lead to pressure changes in the inner ear or impact on opening of 
the Eustachian tube (Jereczek-Fossa, Zarowski, Milani, & Orecchia, 2003) or (2) fibrosis 
occurring at the pharyngeal orifice of the Eustachian tube and atrophy of its mucosal 
lining could lead to hyperpatency of the tube.  Weak associations were found between 
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severity of lymphedema (internal or combined lymphedema) and hearing loss based on 
the whispered voice test and the tuning fork test. However, given the limited sample size 
and grossness of the hearing assessment, it may be simply that the relationship between 
lymphedema and hearing impairment needs to be examined in future studies using more 
sensitive hearing measures such as a formal audiological testing. In addition, a larger 
sample is needed to clarify the association between severity of lymphedema and hearing 
impairment.  
Trismus. Trismus is a common complication of head and neck cancer treatment. 
Studies have found that cancer treatment results in damage and fibrosis of the muscles of 
mastication (i.e., the temporomandibular joints, the pterygoid muscles, or the masseter 
muscle) which is a major cause of trismus (Bensadoun et al., 2010; Dijkstra, Kalk, 
Roodenbrug, 2004; Hsiung, Huang, Ting, & Huang, 2008). An abnormal proliferation of 
fibroblasts from radiation or surgery is an important initial factor for trismus. No studies 
have examined the relationship of lymphedema with trismus. Based on a theoretical 
hypothesis, lymphedema may contribute to trismus in head and neck cancer patients if 
lymphatic fibrosis affects the muscles of mastication. However, the study finding did not 
support this hypothesis. One possible explanation for this finding is that only eight 
participants with facial lymphedema (swelling or fibrosis) were identified in this study. 
Thus, the relationship between lymphedema and trismus could not truly be assessed with 
this study. There is a need to recruit more participants with facial lymphedema and 
further examine whether or not facial lymphedema (fibrosis) is related to trismus in 
future research.  
 127 
 
CROM. Decreased neck range of motion is a common complication after head 
and neck cancer treatment (Teymoortash, Hoch, Eivazi, & Werner, 2010; van Wilgen, 
Dijkstra, van der Laan, Plukker, Roodenburg, 2004). From a theoretical hypothesis, 
individuals with more severe lymphedema (swelling or fibrosis) may be likely to 
decrease their neck range of motion. Weak associations were found between severity of 
external lymphedema with forward flexion degrees and with left rotation degrees. The 
possible associations between severity of lymphedema and CROM degrees needs to be 
examined in future studies.  
Signs (Physical Examination).  The study evaluated the signs in neck and 
shoulder area by direct physical examination of participants. Only elicited pain in the 
neck and shoulder area was statistically significantly associated with severity of external 
lymphedema or combined lymphedema. This finding was consistent with one study’s 
report (Piso et al., 2001). No statistically significant associations were identified between 
severity of external lymphedema and tenderness, postural abnormalities, and fixed 
deformity. These finding were unexpected. Whether these findings represent a sampling 
bias or an actual relationship is unknown and will need to be examined in future research.   
Associations between Severity of Lymphedema and Quality of Life 
One of the most important findings in this study was that severity of lymphedema 
(external, internal, and combined) was statistically significantly associated with head and 
neck cancer-treatment related quality of life. This is the first published study to examine 
this relationship. Although no other studies on head and neck cancer patients are 
available for review, this finding was expected and similar to the outcomes from the 
studies conducted in the breast cancer population (Morgan et al., 2005). This dissertation 
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study identified that head and neck cancer patients with more severe lymphedema tended 
to experience poorer physical well-being, functional well-being, treatment-related well-
being, and overall quality of life than patients with less or no lymphedema. This indicates 
that management of lymphedema in head and neck cancer patients may be critical to 
improving patients’ quality of life. Intervention studies are desired to identify appropriate 
strategies to manage lymphedema and improve quality of life in head and neck cancer 
patients.  
Aim 3. To examine the possible risk factors contributing to the presence of secondary 
lymphedema in head and neck cancer patients.  
This is the first published study to examine the relationships between 
demographic, health behavior, cancer disease, and treatment-related factors with the 
presence of lymphedema after head and neck cancer treatment.  
Factors Associated with Any Type of Lymphedema 
The study found that the type of treatment, including radiotherapy, CCR, and 
multi-modality head and neck cancer treatment, was statistically significantly related to 
the presence of lymphedema.  
Radiotherapy. In this study, whether or not patients received radiotherapy was 
statistically significantly associated with the presence of lymphedema. This finding was 
expected and logical, as one study reported that laryngeal lymphedema was significantly 
related to radiotherapy (Sanguineti et al., 2007). This finding was also similar to the 
studies of breast cancer patients with lymphedema (Hayes, Janda, Cornish, Battistutta, & 
Newman, 2008; Hinrichs et al., 2004; Powell et al., 2003). Several studies have found 
that radiation damages lymph nodes’ structure and lymph vessels, leads to abnormal 
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lymphatic flow as well as stimulates inflammatory response. Inflammation may be a key 
factor related to the development of lymphedema. For example, studies found that the 
chronic inflammatory response with tissue hypoxia results in fibroblast proliferation and 
eventual scarring and fibrosis (Avraham et al., 2009; Chopra & Bogart, 2010; Rockson, 
2009). Studies also reported that anti-inflammatory pharmacotherapy reduced 
experimental lymphedema in a murine model (Nakamura et al., 2009), which further 
demonstrated that lymphedema may be caused by a chronic inflammatory response. One 
recent study examined the possible mechanisms of radiation therapy leading to the 
development of lymphedema in mouse (Avraham et al., 2010). They found that radiation 
caused tissue edema that resolved in 12-24 weeks. After edema was resolved in the mice 
tail, irradiated tissue displayed continuing lymphatic dysfunction. That is, radiotherapy 
depletes lymphatic vessels and lymphatic endothelial cells (LECs), and promotes 
irradiated soft tissue fibrosis. This experimental phenomenon mirrors a clinical 
manifestation; radiation not only induces acute edema but also leads to chronic 
lymphedema.  
CCR.  Concurrent chemoradiation is frequently used in patients with locally 
advanced head and neck cancer. Due to patients receiving radiotherapy and 
chemotherapy simultaneously, CCR results in numerous treatment-related toxicities (such 
as severe mucositis) (Machtay et al., 2008). However, no studies are available for 
examining the relationship between CCR and lymphedema in head and neck cancer 
patients. This is the first study to report that CCR was statistically significantly associated 
with the presence of lymphedema. This finding was expected and logical. A plausible 
explanation is that CCR may lead to severe cutaneous toxicity (Pryor et al., 2009), such 
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as severe skin and mucosal reactions and lymphatic damage, and later chronic 
inflammation damages skin and interstitial tissues. This mechanism is still unknown at 
this time. However, this finding suggests that clinicians need to evaluate whether or not 
head and neck cancer patients have lymphedema after their CCR treatment.     
Number of treatment modalities received. The number of head and neck cancer 
treatment modalities received was statistically significantly associated with the presence 
of lymphedema. This finding was expected and logical as a larger treatment dose (more 
treatments) may lead to more severe damage than single modality cancer treatment.  This 
finding indicates that healthcare professionals need to provide the minimal amount of 
treatment need to promote a cure in order to reduce the negative impact on patients.  
Factors Associated with Combined Lymphedema 
This is the first published study to report that three factors (dosage of 
radiotherapy, chemo-induction therapy (yes/no), and number of head and neck cancer 
treatment modalities received) were statistically significantly associated with whether or 
not individuals had combined internal and external lymphedema. Studies have 
demonstrated that radiation toxicity is closely related to radiation dosage (Hinrichs et al., 
2004). Individuals treated by CCR with chemo-induction reported more severe toxicity 
than individuals treated by CCR without chemo-induction (Geller et al., 2003; Paskett et 
al., 2007). Multi-modality cancer treatment increased treatment-related toxicity more than 
single modality treatment. This finding indicates that clinicians need to routinely examine 
patients for the development of combined lymphedema if they receive high dosage 
radiotherapy, or chemo-induction therapy, or multi-modality cancer treatment.  
Many studies found that age (Hayes et al., 2008; Meeske et al., 2008), BMI (Clark 
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et al., 2005; Mclaughlin et al., 2008; Meeske et al., 2005; Ridner, 2005; Soran et al., 
2006), hypertension (Meeske et al., 2005; Soran et al., 2006), diabetes mellitus (Soran et 
al., 2006), stage of tumor (Deo et al., 2004; Herd-Smith et al., 2001; Park et al., 2008; 
Soran et al., 2006), number of lymph nodes excised, and the number of positive lymph 
nodes excised (Hayes et al., 2008; Meeske et al., 2008; Soran et al., 2006) were 
significantly related to increasing risk of developing lymphedema in breast cancer 
patients. This study did not find that these factors were associated with the presence of 
lymphedema in this sample of head and neck cancer patients. In addition, race, 
inflammatory disease (yes/no), cigarette smoking (yes/no) and drinking alcohol (yes/no) 
were also not statistically significantly associated with the presence of lymphedema in 
this study. Given the size and cross-sectional nature of this study, large longitudinal 
studies of these factors would be required to ascertain risk factors for developing 
lymphedema in head and neck cancer patients.   
 
Study Strengths and Limitations 
This dissertation research study is unique in that it is the first study to 
systematically examine secondary lymphedema in head and neck cancer patients. It is 
also unique in that it was done by a nurse researcher. The major strengths are discussed in 
terms of methodology and research content.  
Strengths  
Strengths in Methodology. The study captured the basic characteristics of 
lymphedema in head and neck cancer patients. Moreover, it was the first study to 
objectively evaluate external lymphedema in head and neck cancer patients through 
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physical examination. The study graded external lymphedema by using four national and 
international lymphedema scales and identified the similarities and differences among 
these scales. These comparisons among measures provide an empirical basis for future 
studies regarding developing lymphedema measurement tools in head and neck cancer 
patients. Furthermore, it was the first study to grade internal laryngopharyngeal 
lymphedema in head and neck cancer patients by using Patterson’s scale.  
Strengths in Research Content. This study identified that head and neck cancer 
patients not only developed external lymphedema, but also internal lymphedema and 
combined lymphedema. The findings of 75% lymphedema prevalence in the study 
sample reveal that it is likely that lymphedema is a common late-effect in head and neck 
cancer patients. There are multiple clinical manifestations (swelling and/or fibrosis) and 
multiple sites involved in lymphedema (external and/or internal lymphedema). Moreover, 
this is the first study to examine the associations between severity of lymphedema and 
symptoms, functional status, and quality of life in head and neck cancer populations. 
Some important findings were identified, such as severity of lymphedema was 
significantly associated with swallowing and mucous/dry mouth-related symptoms and 
overall quality of life in head and neck cancer patients. These findings indicate that 
secondary lymphedema is an important clinical phenomenon and needs to be managed in 
clinical settings. Nurses can play a key role in identification of external lymphedema and 
in assessment of patient symptoms. Furthermore, the study explored the possible risk 
factors associated with the presence of lymphedema in head and neck cancer populations. 
The types and dosages of head and neck cancer treatment may be related to the presence 
of secondary lymphedema in head and neck cancer patients.  
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Limitations  
There are some limitations in this study. (1) External validity (generalizability). 
The study used a convenience sampling method rather than random selection of 
participants. Study participants were recruited from a single comprehensive cancer center. 
Thus, the findings from this study may be generalized only to head and neck cancer 
populations coming to the type of clinic sampled in this study, that is, there were primary 
white and black population with little other minority representatives. (2) Internal validity. 
The main threat to the internal validity of a cross-sectional design stems from problems in 
establishing cause without a time dimension. The study investigated only possible risk 
factors associated with the presence of secondary lymphedema. Statements about 
relationships with the development or causes cannot be made. For example, the study 
could not explain the transition between swelling and fibrosis. In other words, the study 
could not explicate whether or not head and neck cancer patients had swelling first and 
later developed fibrosis or patients developed fibrosis only without a swelling process. In 
addition, the sample was too small for multivariate assessments. Given the complexity of 
disease processes, it is highly unlikely that simply univariate associations will be 
informative. Larger, longitudinal studies are needed to evaluate possible underlying 
multivariate, causative factors leading to the development of lymphedema. (3) Potential 
reliability issue. The Patterson’s Scale is the only valid instrument published in the 
current literature to evaluate anatomical sites of internal lymphedema. Although it has 
strong intra-rater reliability and moderate inter-rater reliability, it had previously been 
tested in only a small (n=25) study (Patterson et al., 2007). In this study, two trained 
oncologists collected the internal lymphedema data along with the PI. However, an inter-
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rater reliability issue may exist as, due to physician scheduling difficulties, the PI was 
unable to directly examine inter-rater reliability. This suggests that taking pictures during 
scoping and comparing findings across physicians conducting the procedures is important 
to enable us to test inter-rater reliability in future research. Additionally, in studies when 
more than one rater use external lymphedema scales, the inter-rater reliability needs to be 
carefully monitored. (4) The use of existing valid and reliable instruments that were not 
lymphedema specific to evaluate symptoms may have limited ability to assess certain 
potential lymphedema driven symptoms such as altered sensation in swollen areas. (5) 
Other possible confounding factors. The study recruited the participants three months or 
more post-treatment. The results showed the time from completion of cancer treatment 
ranged from 3.09 months to159 months in this study. Thus, unknown confounding factors 
may impact the study findings.  
 
Implications 
Lymphedema in head and neck cancer patients is an under-recognized and 
understudied clinical phenomenon. Throughout the current literature inconsistent 
measurement/staging/grading methods are noted and limited research data are available 
regarding prevalence, symptoms, functional status, quality of life and possible risk factors 
of secondary lymphedema in head and neck cancer patients. Poor understanding of this 
phenomenon has critically compromised healthcare professionals’ ability to assess, 
diagnose, and manage secondary lymphedema in head and neck cancer patients. 
Successfully guided by the Theory of Unpleasant Symptoms, this dissertation study 
focused on examining the prevalence of secondary lymphedema, the associations 
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between severity of lymphedema and symptoms, functional status, quality of life, and 
lymphedema risk factors in an effort to fill some of the many gaps related to this 
phenomenon of interest.  
 Several critical findings were generated from this study. First, the study findings 
suggest that lymphedema in head and neck cancer patients may be a very common late-
effect. The study identified that head and neck cancer patients may not only develop 
internal lymphedema (such as pharynx and larynx), but also have external lymphedema 
(such as facial and neck area) after their cancer treatment. The findings from this study 
demonstrated that the severity of lymphedema was significantly associated with 
swallowing difficulty, mucous/dry mouth-related symptoms, and impaired body image.  
Furthermore, the study found that the severity of combined lymphedema was 
significantly associated with head and neck cancer patients’ quality of life status. Finally, 
the study found that types and dosages of cancer treatment were significantly associated 
with the presence of lymphedema in this sample of head and neck cancer patients. Thus, 
the findings from this dissertation study have shed light on the clinical importance of 
secondary lymphedema in head and neck cancer patients. This study also provides an 
insight regarding the importance of addressing lymphedema in head and neck cancer 
patients.  
There are several implications from the study findings. Healthcare professionals 
need to be equipped with the knowledge related to risk factors for head and neck 
lymphedema, its clinical manifestations, its impact, and appropriate management 
strategies. Health care professionals need to be aware of lymphedema as a common late-
effect in head and neck cancer patients and inform patients about their risk. They need to 
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regularly examine head and neck cancer patients, many of whom are at risk of 
lymphedema, but they should be exceptionally vigilant in on-going monitoring of patients 
that may be of higher risk than others, e.g., those receiving multi-modality cancer 
treatment and high dosage of radiotherapy.  
Healthcare professionals, especially nurses, need to evaluate patients’ 
lymphedema-related symptomatology and conduct physical examinations to detect early 
lymphedema, such as skin examination of the face and neck to identify any swelling 
and/or fibrosis. Specifically, in patients with nutrition, swallowing, and mucous/dry 
mouth-related symptoms, healthcare professionals need to conduct internal examination 
(e.g., endoscopy) for oral cavity, pharynx, and larynx fluid as this could be a contributing 
factor to their problems. Healthcare professionals need to document lymphedema-related 
symptoms (such as swallowing-related symptoms) and evaluate their effects on quality of 
life. Given positive findings related to swallowing, nutrition, and quality of life, a 
multidisciplinary approach to lymphedema management is indicated.  
Although more research is needed, given the high prevalence of lymphedema 
found in this study, several clinical implications are noteworthy and could be 
implemented immediately in patient care environments. First, as previously noted, head 
and neck cancer patients should be told of their risks for developing lymphedema and 
patient education about how to identify developing lymphedema should be provided. 
Physicians, when discussing treatment options, can inform patients of the risk. Nurses 
can serve as key team players in discussing symptoms of developing lymphedema such 
as swelling in the submental or facial areas several months after treatment. Second, when 
conducting endoscopic examinations of head and neck cancer patients, routine 
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observation for lymphedema and any lymphedema covering vital structures should be 
documented. Third, anytime internal or external lymphedema is noted, patients should be 
referred for lymphedema treatment by certified lymphedema therapists or knowledgeable 
physical therapists. Fourth, patients with lymphedema may need to be assessed for 
swallowing problems. Fifth, patients with known lymphedema should be queried by 
nurses or physicians at every clinic/office visit regarding any potential 
problems/symptoms they may have related to the swelling. 
 
Recommendations for Future Research  
The study findings can be used to guide future research through the following 
aspects.   
In this study the majority of the study participants were White and the study data 
were collected from one comprehensive cancer center. This indicates that future studies 
should attempt to obtain a more racially diverse sample and more research sites should be 
involved in the studies. In future studies, it is a need to control for the time since end of 
head and neck cancer treatment. Studies are needed to examine the study findings 
trending toward significance (e.g., the association between severity of lymphedema and 
hearing).   
The study found that the manifestations of lymphedema varied in head and neck 
cancer patients. For example, some patients had swelling only, some had fibrosis only, 
and some had both lymphedema and fibrosis. This finding suggests that it is essential to 
conduct longitudinal studies to identify causal mechanisms for lymphedema (i.e., 
inflammation), the relationships among lymphedema manifestations, including the 
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transition between swelling and fibrosis, and the differences between lymphedema-
related fibrosis and non lymphedema-related fibrosis. Longitudinal studies are also 
needed to tease out whether or not head and neck cancer patients developed internal 
lymphedema and external lymphedema at the same time or if one leads to the other. 
Moreover, studies are needed to determine whether or not internal edema is a transitional 
or a chronic clinical phenomenon in this population.  
In addition, the study findings demonstrated that the four external lymphedema 
scales resulted in the different occurrence rates of lymphedema. None of them clearly 
captured all the characteristics of external lymphedema. The NCI lymphedema scale and 
the ACS lymphedema scale lack a fibrosis component, while the NCI fibrosis scale is 
short of a swelling component. Although Foldi’s lymphedema scale captured both 
swelling and fibrosis in this study, its pathological component is not well-defined and not 
easily understood, which may cause inconsistency in grading the severity of external 
lymphedema (an inter-rater reliability issue). These findings indicate that there is a need 
to develop a validated scale of external lymphedema to be consistently used among 
researchers and clinicians. Such a scale could have significant clinical utility as it could 
be easily used by nurses during each office/clinic visit to evaluate external lymphedema 
during the routine collection of vital signs and weight.  Also, it is important to develop an 
instrument to evaluate lymphedema specific symptoms and a tool to examine economic 
impact of secondary lymphedema in head and neck cancer populations. Further, the 
Patterson’s scale was the only one used to evaluate internal lymphedema, and its validity 
and reliability needs further testing. 
The study found that severity of lymphedema was statistically significantly 
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associated with swallowing, mucous/dry mouth, and nutrition status, as well as quality of 
life.  Studies exploring the temporal presentations of lymphedema and symptoms are 
needed to clearly elucidate the relationship between lymphedema, symptomatology, and 
quality of life. Interventional studies are needed to explore strategies regarding treatment 
of lymphedema, symptomatology, and improving quality of life in head and neck cancer 
patients with lymphedema.  
If armed with information from these proposed studies, knowledgeable healthcare 
professionals, such as nurses, could make significant contributions to improve head and 
neck cancer patients’ lymphedema related symptomatology and quality of life. 
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APPENDIX A 
 
MDS CONTACT SCRIPT  
 
Hello. My name is Jie Deng. I am a PhD (c) at Vanderbilt University School of Nursing. I am 
conducting my dissertation study and focusing on secondary lymphedema related to head and 
neck cancer treatment. I would like to tell you about my study if you have a few minutes. 
 
The study is being done to help us better understand lymphedema that happens after head and 
neck cancer treatment. This study would require participants to perform the following tasks only 
one time: (1) filling out some forms that ask them about their symptoms, ability to carry out daily 
activities, and quality of life; (2) answering questions about their demographic information (e.g., 
education, insurance) and any treatment they have had for lymphedema; and (3) their head and 
neck cancer disease & treatment information (e.g., date and type of surgery) will be collected 
from their medical records. In addition, I will evaluate them to see if they have swelling/tightness 
in their head and neck region, neck range of movement, mouth range of motion, and hearing. The 
time involved in this study is estimated to be 75-85 minutes. 
 
Would you mind telling the potential participants about my study information? Or, would you 
prefer I go talk to them? 
 
If yes (they want to talk to patients), I give them the inclusion and exclusion criteria about the 
participant recruitment in the proposed dissertation study. And then tell them my contact 
information (including phone number and email address) and thank them for their assistance.  
 
If not, thank them for their time.  
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APPENDIX B 
 
PATIENTS CONTACT SCRIPT 
 
Hello. My name is Jie Deng. I am a PhD (c) at Vanderbilt University School of Nursing. I am 
conducting my dissertation study and focusing on swelling/tightness related to head and neck 
cancer treatment. I would like to tell you about my study if you have a few minutes. 
 
The study is being done to help us better understand swelling/tightness that happens after  
head and neck cancer treatment. This study would require you to perform the following 
tasks only one time: (1) filling out some forms that ask you about your symptoms, ability 
to carry out daily activities, and quality of life; (2) answering questions about your  
demographic information (e.g., education, insurance) and any treatment you have had for  
swellings; and (3) your head and neck cancer disease & treatment information (e.g., date 
and type of surgery) will be collected from your medical records. In addition, I will  
evaluate you to see if you have swelling/tightness in your head and neck region, neck  
range of movement, mouth range of motion, and hearing. The time involved in this study  
is estimated to be 75-85 minutes. 
 
Do you think you might be interested? (If yes, then screen them using the screening form) 
 
Thank you so much. 
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APPENDIX C 
 
SCREENING FORM     
 
1. How old are you? ___ 
(Required: To be 18 and over years of age) 
Yes-Continue No-Ineligible 
2. Have you had head and neck cancer? Yes-Continue No-Ineligible 
3. Have you completed your cancer treatment for more 
than 3 months?  
(Last Treatment Date__________mm/dd/yyyy) 
Yes-Continue No-Ineligible 
4. Do you currently have cancer? No-Continue Yes-Ineligible 
5. Do you currently have any problems understanding 
what is taking place around you?  
No-Continue Yes-Ineligible 
6. Thank you for answering those questions. It seems 
that you are eligible for this research study. Do you have 
any questions for me? 
(After answering any questions and thanks participants 
again for their time). 
 
  
 
 
Note: (1) Stop asking questions when the first exclusion criterion is met.  
           
         (2) If ineligible, please tell the participants about the following content: “I am sorry that you 
would not be eligible for this study. Thank you so much for your time”.  
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APPENDIX D 
 
DEMOGRAPHIC AND BACKGROUND INFORMATION FORM 
 
1. What is your birthdate?     
____/____/_______ (month/day/year) 
 
2. Gender:  
(1) Female___(2) Male____ 
(3) Other____ (4) Do not care to respond___ 
 
3. What is your race? 
(1) American Indian/Alaskan Native____   
(2) Asian____   
(3) Native Hawaiian or Other Pacific 
Islander _____ 
(4) Black or African American_____ 
(5) White_____ 
Nation of Origin: _______________ 
 
4. What is the highest grade of education 
you completed? (Please circle) 
 1      2     3     4     5     6    7    8    9   10   11 
12 (high school) 13  14    15   16  (college)      
17  18  (master)  19  20  (doctorate) 
 
5. What is your marital status?  
(1) Single____    
(2) Single, living with partner_____          
(3) Married_____ 
(4) Widowed____    
(5) Other____ 
 
6. What is your current employment 
status? 
(1) Employed full time____      
(2) Employed part time____     
(3) Homemaker____  
(4) Retired_____                         
(5) Unemployed_____                  
(6) Other____ 
Vocation___________________________ 
 
7. What best describes your area of 
residence? 
(1) City___ (2) Country ___ (3) Other___ 
 
 
 
 
8. Do you have any special dietary habits? 
(1) No ___  
(2) Yes___ (Spicy, Sweet, Sour, etc.) 
(Please describe)____________________ 
 
9. Health Maintenance 
9.1 Smoking 
(1) No  ____ 
(2) Yes ___(Tobacco__or Marijuana__or 
_________) 
_____years _____ cigarettes per day  
(3) Quit _____ 
(4) Not Quit ______  
_____cigarettes per day (Current) 
 
9.2 Drinking Alcohol 
(1) No ____ 
(2) Yes ____ 
_____years _____ times per week 
(3) Quit ______ 
(4) Not Quit ______ 
_____ times per week (Current) 
 
10. What is your insurance coverage? 
(1) Medicare____ (2) Medicaid____  
(3) TennCare____ (4) Private Insurance____ 
(5) HMO____        (6) None_____                      
(7) Other_____ 
 
11. Do you have any medical problems?  
(1) No 
(2) Yes (e.g., HBP, DM, Obesity, Injury 
History) __________________________ 
 
12. What is your yearly household 
income? 
(1) $10,000 or less____      
(2) $10,001 to $ 20,000____    
(3) $20,001 to $ 30,000____ 
(4) $30,001 to $40,000 ____    
(5) $ 40,001 to $50,000____    
(6) $50,001 to $60,000 ____ 
(7) Over $60,000____         
(8) Do not care to respond____ 
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APPENDIX E     
 
HEAD AND NECK CANCER DISEASE & TREATMENT INFORMATION FORM 
 
Diagnosis 
Date ____/____/_____(mm/dd/year) 
 
 
Type  
(Location/Originating cancerous lesions) 
___(1) Nasal cavity   
___(2) Paranasal sinuses 
___(3) Oral cavity 
___(4) Nasopharynx 
___(5) Oropharynx 
___(6) Hypopharynx  
___(7) Larynx 
___(8) Salivary gland 
___(9) Other______________  
 
 
Stage: T____N____M____ 
___X (1)     ___0 (2)   ___I (3)       
___IIa (4)   __IIb (5)      
___IIIa (6)  __IIIb (7)  
___Iva (8)  __IVb (9) 
___IVc (10) 
 
 
Surgery: ___No (0), ____Yes (1) 
Date____/___/_____ 
Type: 
___(1) Radical neck dissection 
___(2) Modified neck dissection 
___(3) Selective neck dissection 
___(4) Total laryngectomy 
___(5) Partial laryngectomy 
___(6) Maxillectomy 
___(7) Other________________  
Number of dissected lymph nodes____ 
Number of positive lymph nodes____ 
 
 
Radiation Therapy 
___None (0) 
___Some (1) 
Site (1) ____________ Dosage______cGy 
Site (2) ____________ Dosage______cGy 
Site (3) ____________ Dosage______cGy 
Site (4) ____________ Dosage______cGy 
 
Radiation Therapy 
Begin date____/____/_____ 
End date  ____/____/_____ 
 
Chemotherapy 
Induction ___None (0) ___some (1) 
Number of cycles____ 
Begin date____/____/_____ 
End date  ____/____/_____ 
Type:  
____5-FU (1)  
____Erbitux (Cetuximab) (2) 
____Cisplation (Platinol) (3) 
____Docetaxel (Taxotere) (4) 
____Taxol+Carboplatin (5) 
Other (6):_____________________  
 
 
ChemoXRT 
___None (0) 
___Some (1) 
Number of cycles____ 
Begin date____/____/_____ 
End date  ____/____/_____ 
Type:  
____5-FU (1)  
____Erbitux (Cetuximab) (2) 
____Cisplation (Platinol) (3) 
____Docetaxel (Taxotere) (4) 
____Taxol+Carboplatin (5) 
Other (6):_____________________ 
 
 
 
Total treatment received 
___ (1) Surgery only  
___ (2) Radiotherapy only  
___ (3) Surgery+Radiotherapy 
___ (4) Surgery+ChemoXRT 
___ (5) Chemo-Induction+ChemoXRT 
___ (6) Surgery+Chemo-induction 
             + ChemoXRT 
___ (7) other_________________ 
 
Treatment-related complications_______ 
_________________________________ 
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APPENDIX F  
PATTERSON’S SCALE FOR EDEMA IN LARYNX AND PHARYNX  
Based upon your examination of the participant, please use the following scale to grade 
lymphedema/edema in the laryngopharyngeal structures. 
 
                                 Rating of Edema 
Normal Mild Moderate Severe 
Structures  
1) Base of tongue 
2) Posterior pharyngeal wall 
3) Epiglottis 
4) Pharyngoepiglottic folds 
5) Aryepiglottic folds 
6) Interarytenoid space 
7) Cricopharyngeal prominence 
8) Arytenoids 
9) False vocal folds 
10) True vocal folds 
11) Anterior commissure 
  
  
Spaces 
                      
12) Valleculae 
13) Pyriform sinus 
 
1) ___ 
2) ___ 
3) ___ 
4) ___ 
5) ___ 
6) ___ 
7) ___ 
8) ___ 
9) ___ 
10) ___ 
11) ___ 
 
Normal 
 
 
12)___ 
 
13)___ 
 
     ____ 
     ____ 
     ____ 
 
     ____ 
 
     ____ 
 
     ____ 
 
     ____ 
    
____ 
 
____ 
 
____ 
 
____ 
 
 
Mildly 
Reduced 
 
____ 
 
___ 
 
 
      ____ 
      ____ 
      ____ 
 
      ____ 
 
      ____ 
 
      ____ 
 
      ____ 
 
      ____ 
 
     ____ 
 
     ____ 
 
     ____ 
 
 
Moderately 
Reduced 
 
____ 
 
____ 
 
 
        ____ 
____ 
____ 
____ 
 
____ 
 
____ 
 
____ 
 
____ 
 
____ 
 
____ 
 
____ 
 
 
Severely 
Reduced 
 
____ 
 
____ 
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APPENDIX G 
 
LYMPHEDEMA DISEASE & TREATMENT INFORMATION FORM 
 
Do you have swelling/fibrosis? 
_____No (If met, stop collecting other data) 
_____Yes (If met, continue collecting the following data) 
 
Diagnosis 
Date:____/____/_____(mm/dd/year) 
Location: __________ 
 
Treatment history  
Initial treatment:  
______No  
______Yes  
 
Location_____________ 
Method______________ 
Effect________________ 
 
 
Current treatment: 
______No  
______Yes  
 
Location_____________ 
Method______________ 
Effect_______________ 
 
 
 
Other information (e.g., self-care, other care providers): 
___________________________________________________________________________ 
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APPENDIX H  
THE VANDERBILT HEAD AND NECK CANCER SYMPTOM SURVEY (VHNSS) 
Directions:  Please read all questions and circle the number that best describes your symptoms 
over the past week.  In general, a “0” indicates the least amount of problems with a particular 
symptom and “10” indicates the most problems. 
 
 
1. I have been losing weight 
None 0 1 2 3 4 5 6 7 8 9 10 A lot 
2. I have lost my appetite 
“Normal” 
appetite 
0 1 2 3 4 5 6 7 8 9 10 No appetite 
3. My taste is altered 
None 0 1 2 3 4 5 6 7 8 9 10 A lot 
4. I worry about having to get a 
feeding tube 
 N/A—I already have a PEG tube 
None 0 1 2 3 4 5 6 7 8 9 10 A lot 
5. I have to use liquid supplements (like Ensure® or Boost®) to maintain my weight 
None 0 1 2 3 4 5 6 7 8 9 10 All liquid 
supplements 
6. I have trouble maintaining my weight because of my swallowing problem 
None 0 1 2 3 4 5 6 7 8 9 10 A lot 
7. I have trouble eating certain solid foods (like hard to chew, crumbly, or sticky 
foods) 
None 0 1 2 3 4 5 6 7 8 9 10 A lot 
8. I have trouble drinking thin liquids (like water, tea and Ensure®) 
None 0 1 2 3 4 5 6 7 8 9 10 A lot 
9. Food gets stuck in my mouth 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
10.  Food gets stuck in my throat 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
11.  I choke or strangle on liquids 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
12.  I choke or strangle on solid foods 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
13.  I cough after I swallow 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
(Continued) 
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14.  Swallowing takes great effort 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
15.  It takes me longer to eat because of my swallowing problem 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
16.  I have problems with dry mouth  
None 0 1 2 3 4 5 6 7 8 9 10 Severe 
17.  Problems with dry mouth make chewing and swallowing difficult 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
18.  I have thick mucous / phlegm 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
19.  Mucous causes me to choke or gag 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
20.  I have difficulty chewing because of my teeth or dentures 
None 0 1 2 3 4 5 6 7 8 9 10 Severe 
21.  I have sores in my mouth or throat that cause pain 
No pain 0 1 2 3 4 5 6 7 8 9 10 Severe 
pain 
22.  My average overall pain level over the last week has been… 
No pain 0 1 2 3 4 5 6 7 8 9 10 Severe 
pain 
23.  My worst overall pain level over the last week has been… 
No pain 0 1 2 3 4 5 6 7 8 9 10 Severe 
pain 
24.  The average relief from my pain medication is… 
None 0 1 2 3 4 5 6 7 8 9 10 Total 
relief 
25.  My voice is hoarse 
Not at all 0 1 2 3 4 5 6 7 8 9 10 Very 
Hoarse 
26.  I have trouble being understood because of my hoarse voice 
Never 0 1 2 3 4 5 6 7 8 9 10 Always 
27.  I have trouble with my hearing 
None 0 1 2 3 4 5 6 7 8 9 10 Severe 
28.  The top three problems bothering me today are:  
1. _________________ 2. __________________ 3. ________________ 
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APPENDIX I 
HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS)  
This questionnaire is designed to help your healthcare professionals to know how you feel. Please 
Read each item and circle the one which comes closest to how you have been feeling in the past 
week. Don't take too long over your replies; your immediate reaction to each item will probably 
be more accurate than a long thought out response.  
     
    1. I feel tense or “wound up”:  
        A. Most of the time       
     B. A lot of the time      
     C. From time to time, occasionally      
     D. Not at all 
 
2.  I still enjoy the things I used to enjoy: 
     A. Definitely as much     
     B. Not quite so much    
     C. Only a little     
     D. Hardly at all 
 
3. I feel a sort of frightened feeling as if something awful is about to happen:  
     A. Very definitely and quite badly     
     B. Yes, but not too badly      
     C. A little, but it doesn’t worry me      
     D. Not at all 
 
4. I can laugh and see the funny side of things:  
    A. As much as I always could      
    B. Not quite so much now       
    C. Definitely not so much now      
    D. Not at all 
 
5. Worrying thoughts go through my mind:  
    A. A great deal of the time       
    B. A lot of the time      
    C. From time to time, but not too often      
    D. Only occasionally  
 
6. I feel cheerful:  
   A. Not at all      
   B. Not often      
   C. Sometimes       
   D. Most of the time 
 
7. I can sit at ease and feel relaxed:  
   A. Definitely      
   B. Usually         
   C. Not often        
   D. Not at all  
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8. I feel as if I am slowed down:  
   A. Nearly all the time     
   B. Very often     
   C. Sometimes      
   D. Not at all 
 
9. I get a sort of frightened feeling like “butterflies” in the stomach:  
    A. Not at all     
    B. Occasionally     
    C. Quite often     
    D. Very Often  
 
10. I have lost interest in my appearance:  
     A. Definitely     
     B. I don’t take as much care as I should      
     C. I may not take quite as much care      
     D. I take just as much care as ever 
 
11. I feel restless as I have to be on the move:  
     A. Very much indeed       
     B. Quite a lot      
     C. Not very much      
     D. Not at all 
 
12. I look forward with enjoyment to things:  
     A. As much as I ever did       
     B. Rather less than I used to      
     C. Definitely less than I used to    
     D. Hardly at all 
 
 13. I get sudden feelings of panic:  
     A. Very often indeed        
     B. Quite often       
     C. Not very often     
     D. Not at all 
 
14. I can enjoy a good book or radio or TV program:  
      A. Often 
      B. Sometimes  
      C. Not often 
      D. Very seldom  
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APPENDIX J 
 
BODY IMAGE SCALE (BIS)  
 
In this questionnaire you will be asked how you feel about your appearance, and about any 
changes that may have resulted from your disease or treatment. Please read each item carefully, 
and circle the one choice which comes closest to the way you have been feeling about yourself, 
during the past week.  
 
1. Have you been feeling self-conscious about your appearance?   
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
2. Have you felt less physically attractive as a result of your disease or treatment? 
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
3. Have your been dissatisfied with your appearance when dressed? 
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
4. Have you been feeling less feminine/masculine as a result of your disease or treatment? 
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
5. Did you find it difficult to look at yourself naked? 
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
6. Have you been feeling less sexually attractive as a result of your disease or treatment? 
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
7. Did you avoid people because of the way you felt about your appearance? 
     A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
8. Have you been feeling the treatment has left your body less whole? 
    A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
9. Have you felt dissatisfied with your body? 
    A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
 
10. Have you been dissatisfied with the appearance of your scar? 
    A. Not at all     B. A little     C. Quite a bit     D. Very much     E. Not Applicable 
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APPENDIX K 
 
WHISPERED VOICE TEST  
 
Whispered Voice Test Results ____________Fail (0) _____________Pass (1)                               
 
 
• The examiner stands arm’s length (0.6 m) behind the seated patient and whispers a combination 
of numbers and letters (for example, 4-K-2) and then asks the patient to repeat the sequence. 
 
• The examiner should quietly exhale before whispering to ensure as quiet a voice as possible. 
 
• If the patient responds correctly, hearing is considered normal; if the patient responds 
incorrectly, the test is repeated using a different number/letter combination. 
 
• The patient is considered to have passed the screening test if they repeat at least three out of a 
possible six numbers or letters correctly. 
 
• The examiner always stands behind the patient to prevent lip reading. 
 
• Each ear is tested individually, starting with the ear with better hearing, and during testing the 
non-test ear is masked by gently occluding the auditory canal with a finger and rubbing the tragus 
in a circular motion. 
 
• The other ear is assessed similarly with a different combination of numbers and letters. 
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APPENDIX L 
 
TRISMUS GRADING CRITERIA   
 
 
Definition of Trismus: difficulty, restriction or pain when opening mouth 
 
Please check the one that best applies based upon your knowledge of the participant.  
 
_______Grade 1-- Decreased range of motion without impaired eating 
 
_______Grade 2--Decreased range of motion requiring small bites, soft foods or purees 
 
_______Grade 3--Decreased range of motion with inability to adequately aliment or hydrate  
                             orally 
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APPENDIX M 
 
CERVICAL RANGE OF MOTION (CROM) 
 
The participant’s CROM parameters: 
 
(1) Forward flexion________degrees   
 
(2) Extension ____________degrees   
 
(3) Left lateral flexion______degrees   
 
(4) Right lateral flexion_____degrees   
 
(5) Left lateral rotation______degrees   
 
(6) Right lateral rotation_____degrees  
 
 
 
Signs in their head/neck/shoulder area: 
Elicited Pain____  
Tenderness____  
Postural abnormalities____ 
Fixed deformity ____ 
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APPENDIX N 
 
FACT- H&N (Version 4) 
 
Below is a list of statements that other people with your illness have said are important.  By 
circling one (1) number per line, please indicate how true each statement has been for you 
during the past 7 days. 
 
 
 PHYSICAL WELL-BEING  
                                                                                   
 
 I have a lack of energy………………………. …..       0          1          2          3         4 
 I have nausea……………………………………..       0          1          2          3         4  
 Because of my physical condition, I have trouble 
 meeting the needs of my family…………………..      0          1          2          3         4 
 I have pain…………………………………………      0          1          2          3         4 
 I am bothered by side effects of treatment…………     0          1          2          3         4  
 I feel ill……………………………………………       0          1          2          3         4  
 I am forced to spend time in bed………………….       0          1          2          3         4 
   
 SOCIAL/FAMILY WELL-BEING  
   
 
 I feel close to my friends……………………….     0          1          2          3         4 
 I get emotional support from my family..………    0          1          2          3         4  
 I get support from my friends………………….     0          1          2          3         4  
 My family has accepted my illness……………      0          1          2          3         4 
 I am satisfied with family communication about  
 my illness………………………………………     0          1          2          3         4  
 I feel close to my partner (or the person who is  
0 my main support)………………………………     0          1          2          3         4  
 Regardless of your current level of sexual activity, please 
  answer the following question.  If you prefer not to answer  
  it, please check this box         and go to the next section. 
 I am satisfied with my sex life…………………     0          1          2          3         4  
GP1 
GP2 
GP3 
 
 
 
GP4 
GP5 
GP6 
GP7 
GS1 
GS2 
GS3 
 
 
GS4 
GS5 
GS6 
Q1 
GS7 
Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
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By circling one (1) number per line, please indicate how true each statement has been for 
you during the past 7 days. 
 
 EMOTIONAL WELL-BEING 
    
 
 I feel sad……………………………………….      0          1          2          3         4  
                     
                    I am satisfied with how I am coping with  
                    my illness……………………………………..       0          1          2          3         4 
   
 I am losing hope in my fight against my illness.      0          1          2          3         4  
 I feel nervous………………………………….       0          1          2          3         4 
 I worry about dying………….............................     0          1          2          3         4 
 I worry my condition will get worse……………    0          1          2          3         4 
 
 
 FUNCTIONAL WELL-BEING  
   
 
 I am able to work (include work at home)………  0          1          2          3         4  
 My work (include work at home) is fulfilling….    0          1          2          3         4 
 I am able to enjoy life…………………………..    0          1          2          3         4  
 I have accepted my illness……………………..     0          1          2          3         4  
 I am sleeping well…………………..………….     0          1          2          3         4  
 I am enjoying the things I usually do for fun…..     0          1          2          3         4 
 I am content with the quality of my life  
                   right now……………………………………….     0          1          2          3         4  
 
GE1 
GE2 
GE3 
 
 
GE4 
GE5 
GE6 
GF1 
GF2 
GF3 
 
 
GF4 
GF5 
GF6 
GF7 
Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
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By circling one (1) number per line, please indicate how true each statement has been for 
you during the past 7 days. 
 
 ADDITIONAL CONCERNS 
    
 
 I am able to eat foods I like……………………… 0          1          2          3         4  
 My mouth is dry…………………………………  0          1          2          3         4  
 I have trouble breathing…………………………   0          1          2          3         4    
 My voice has its usual quality and strength……… 0          1          2          3         4  
 I am able to eat as much food as I want………….  0          1          2          3         4 
 I am unhappy with how my face and neck looks… 0          1          2          3         4 
 I can swallow naturally and easily……………….. 0          1          2          3         4  
 I smoke cigarettes and tobacco products………… 0          1          2          3         4  
 I drink alcohol (e.g. beer, wine, etc.)……………..0          1          2          3         4 
 I am able to communicate with others…………… 0          1          2          3         4  
 I can eat solid foods……………………………… 0          1          2          3         4  
 I have pain in my mouth, throat or neck…………. 0          1          2          3         4  
  
 
 
 
 
 
 
 
 
 
 
 
 
H&N  1 
 
H&N  2 
 
H&N  3 
 
H&N  4 
 
H&N  5 
 
H&N  6 
 
H&N  7 
 
H&N  8 
 
H&N  9 
 
H&N10 
 
H&N11 
 
H&N12 
 
 
Not  
at all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
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APPENDIX O 
 
QUALITY OF LIFE SCALE (LINEAR ANALOG SELF ASSESSMENT)  
 
Directions: Please circle the number (0-10) best reflecting your response to the following that 
describes your feelings during the past week, including today. 
 
 
1. How would you rate your physical well being over the past week? 
 This question refers to such things as fatigue, activity, etc. 
 
        0            1            2            3            4            5            6            7           8         9         10 
As bad as                                                                                                                       As good as it 
can be                                                                                                                             it can be 
 
 
2. How would you rate your emotional well being over the past week? 
 This question refers to such things as depression, anxiety, stress, etc. 
 
        0            1            2            3            4            5            6            7           8         9         10 
As bad as                                                                                                                       As good as it 
can be                                                                                                                             it can be 
 
 
3. How would you rate your spiritual well being over the past week? 
 This question refers to such things as a sense of meaning and purpose, relationship with God, etc. 
 
        0            1            2            3            4            5            6            7           8         9         10 
As bad as                                                                                                                       As good as it 
can be                                                                                                                             it can be 
 
 
4. How would you rate your intellectual well being over the past week? 
This question refers to such things as the ability to think clearly, to concentrate, to remember, etc. 
 
        0            1            2            3            4            5            6            7           8         9         10 
As bad as                                                                                                                       As good as it 
can be                                                                                                                             it can be 
 
 
5. How would you rate your overall well being over the past week? 
 
        0            1            2            3            4            5            6            7           8         9         10 
As bad as                                                                                                                       As good as it 
can be                                                                                                                             it can be 
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